US20040181827A1 - Plant Gntl sequences and the use thereof for the production of plants having reduced or lacking N-acetyl glucosaminyl transferase I (GnTI) activity - Google Patents
Plant Gntl sequences and the use thereof for the production of plants having reduced or lacking N-acetyl glucosaminyl transferase I (GnTI) activity Download PDFInfo
- Publication number
- US20040181827A1 US20040181827A1 US10/615,144 US61514403A US2004181827A1 US 20040181827 A1 US20040181827 A1 US 20040181827A1 US 61514403 A US61514403 A US 61514403A US 2004181827 A1 US2004181827 A1 US 2004181827A1
- Authority
- US
- United States
- Prior art keywords
- dna
- leu
- asp
- plant
- ala
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108010070113 alpha-1,3-mannosyl-glycoprotein beta-1,2-N-acetylglucosaminyltransferase I Proteins 0.000 title claims abstract description 61
- 230000000694 effects Effects 0.000 title claims abstract description 43
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 31
- 230000002829 reductive effect Effects 0.000 title claims abstract description 19
- 108090000288 Glycoproteins Proteins 0.000 claims abstract description 62
- 102000003886 Glycoproteins Human genes 0.000 claims abstract description 62
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 62
- 230000000692 anti-sense effect Effects 0.000 claims abstract description 53
- 230000009261 transgenic effect Effects 0.000 claims abstract description 51
- 244000005700 microbiome Species 0.000 claims abstract description 13
- 241000196324 Embryophyta Species 0.000 claims description 170
- 108090000623 proteins and genes Proteins 0.000 claims description 89
- 108020004414 DNA Proteins 0.000 claims description 68
- 102000004190 Enzymes Human genes 0.000 claims description 56
- 108090000790 Enzymes Proteins 0.000 claims description 56
- 244000061456 Solanum tuberosum Species 0.000 claims description 45
- 239000012634 fragment Substances 0.000 claims description 40
- 235000002595 Solanum tuberosum Nutrition 0.000 claims description 39
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 38
- 102000004169 proteins and genes Human genes 0.000 claims description 34
- 238000000034 method Methods 0.000 claims description 32
- 235000002637 Nicotiana tabacum Nutrition 0.000 claims description 31
- 244000061176 Nicotiana tabacum Species 0.000 claims description 31
- 210000004027 cell Anatomy 0.000 claims description 30
- 238000009396 hybridization Methods 0.000 claims description 29
- 230000014509 gene expression Effects 0.000 claims description 28
- 239000002773 nucleotide Substances 0.000 claims description 18
- 125000003729 nucleotide group Chemical group 0.000 claims description 18
- 230000009466 transformation Effects 0.000 claims description 18
- 241000700605 Viruses Species 0.000 claims description 17
- 241000219195 Arabidopsis thaliana Species 0.000 claims description 15
- 230000004048 modification Effects 0.000 claims description 15
- 238000012986 modification Methods 0.000 claims description 15
- 239000013598 vector Substances 0.000 claims description 13
- 150000001413 amino acids Chemical class 0.000 claims description 11
- 239000000427 antigen Substances 0.000 claims description 10
- 102000036639 antigens Human genes 0.000 claims description 10
- 108091007433 antigens Proteins 0.000 claims description 10
- 238000003780 insertion Methods 0.000 claims description 9
- 230000037431 insertion Effects 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 9
- 238000006467 substitution reaction Methods 0.000 claims description 9
- 238000013518 transcription Methods 0.000 claims description 9
- 230000035897 transcription Effects 0.000 claims description 9
- 210000004899 c-terminal region Anatomy 0.000 claims description 8
- 230000000295 complement effect Effects 0.000 claims description 8
- 230000010354 integration Effects 0.000 claims description 8
- 239000002299 complementary DNA Substances 0.000 claims description 7
- 238000012217 deletion Methods 0.000 claims description 7
- 230000037430 deletion Effects 0.000 claims description 7
- 230000002068 genetic effect Effects 0.000 claims description 7
- 230000036961 partial effect Effects 0.000 claims description 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 7
- 208000036142 Viral infection Diseases 0.000 claims description 6
- 230000009385 viral infection Effects 0.000 claims description 6
- 230000007850 degeneration Effects 0.000 claims description 5
- 239000013612 plasmid Substances 0.000 claims description 5
- 230000009467 reduction Effects 0.000 claims description 5
- 230000003053 immunization Effects 0.000 claims description 4
- 230000001105 regulatory effect Effects 0.000 claims description 4
- 108020004635 Complementary DNA Proteins 0.000 claims description 3
- 239000003816 antisense DNA Substances 0.000 claims description 3
- 238000002649 immunization Methods 0.000 claims description 3
- 108020004491 Antisense DNA Proteins 0.000 claims description 2
- 230000008105 immune reaction Effects 0.000 claims description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 4
- 102100023315 N-acetyllactosaminide beta-1,6-N-acetylglucosaminyl-transferase Human genes 0.000 claims 1
- 108010056664 N-acetyllactosaminide beta-1,6-N-acetylglucosaminyltransferase Proteins 0.000 claims 1
- 230000008030 elimination Effects 0.000 claims 1
- 238000003379 elimination reaction Methods 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 238000013519 translation Methods 0.000 abstract description 7
- 150000007523 nucleic acids Chemical group 0.000 abstract description 4
- 235000018102 proteins Nutrition 0.000 description 28
- 210000001519 tissue Anatomy 0.000 description 21
- 241000282326 Felis catus Species 0.000 description 18
- 238000010367 cloning Methods 0.000 description 15
- 230000013595 glycosylation Effects 0.000 description 15
- 238000006206 glycosylation reaction Methods 0.000 description 15
- 239000000523 sample Substances 0.000 description 15
- 230000007547 defect Effects 0.000 description 13
- 238000001514 detection method Methods 0.000 description 11
- 108010050848 glycylleucine Proteins 0.000 description 11
- 102000004547 Glucosylceramidase Human genes 0.000 description 10
- 108010017544 Glucosylceramidase Proteins 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 10
- 239000003550 marker Substances 0.000 description 10
- 238000012163 sequencing technique Methods 0.000 description 10
- 241000282414 Homo sapiens Species 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 241000219194 Arabidopsis Species 0.000 description 8
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 8
- 241000124008 Mammalia Species 0.000 description 8
- 230000004988 N-glycosylation Effects 0.000 description 8
- 108700001094 Plant Genes Proteins 0.000 description 8
- 108010029485 Protein Isoforms Proteins 0.000 description 8
- 102000001708 Protein Isoforms Human genes 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 8
- 108010063718 gamma-glutamylaspartic acid Proteins 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 238000012216 screening Methods 0.000 description 8
- 108010051110 tyrosyl-lysine Proteins 0.000 description 8
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 7
- 230000000890 antigenic effect Effects 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 238000002955 isolation Methods 0.000 description 7
- 239000011159 matrix material Substances 0.000 description 7
- 210000001938 protoplast Anatomy 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- 108091005804 Peptidases Proteins 0.000 description 6
- 239000004365 Protease Substances 0.000 description 6
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 6
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 6
- 108010008355 arginyl-glutamine Proteins 0.000 description 6
- 108010069205 aspartyl-phenylalanine Proteins 0.000 description 6
- 150000004676 glycans Chemical class 0.000 description 6
- 150000002482 oligosaccharides Polymers 0.000 description 6
- 235000019419 proteases Nutrition 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 238000003757 reverse transcription PCR Methods 0.000 description 6
- 238000012546 transfer Methods 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- CCDFBRZVTDDJNM-GUBZILKMSA-N Ala-Leu-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O CCDFBRZVTDDJNM-GUBZILKMSA-N 0.000 description 5
- 108020004705 Codon Proteins 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 5
- LUGUNEGJNDEBLU-DCAQKATOSA-N Gln-Met-Arg Chemical compound CSCC[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](CCC(=O)N)N LUGUNEGJNDEBLU-DCAQKATOSA-N 0.000 description 5
- XMYURPUVJSKTMC-KBIXCLLPSA-N Ile-Ser-Gln Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N XMYURPUVJSKTMC-KBIXCLLPSA-N 0.000 description 5
- PMGDADKJMCOXHX-UHFFFAOYSA-N L-Arginyl-L-glutamin-acetat Natural products NC(=N)NCCCC(N)C(=O)NC(CCC(N)=O)C(O)=O PMGDADKJMCOXHX-UHFFFAOYSA-N 0.000 description 5
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 5
- UCRJTSIIAYHOHE-ULQDDVLXSA-N Leu-Tyr-Arg Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N UCRJTSIIAYHOHE-ULQDDVLXSA-N 0.000 description 5
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 5
- VNGKMNPAENRGDC-JYJNAYRXSA-N Val-Phe-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)CC1=CC=CC=C1 VNGKMNPAENRGDC-JYJNAYRXSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 150000007513 acids Chemical class 0.000 description 5
- 229940024606 amino acid Drugs 0.000 description 5
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 5
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 5
- 239000013522 chelant Substances 0.000 description 5
- 230000002950 deficient Effects 0.000 description 5
- 108010049041 glutamylalanine Proteins 0.000 description 5
- 229920001542 oligosaccharide Polymers 0.000 description 5
- 230000002285 radioactive effect Effects 0.000 description 5
- 108010078580 tyrosylleucine Proteins 0.000 description 5
- 108010073969 valyllysine Proteins 0.000 description 5
- 241000589158 Agrobacterium Species 0.000 description 4
- YYSWCHMLFJLLBJ-ZLUOBGJFSA-N Ala-Ala-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YYSWCHMLFJLLBJ-ZLUOBGJFSA-N 0.000 description 4
- KVWLTGNCJYDJET-LSJOCFKGSA-N Ala-Arg-His Chemical compound C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N KVWLTGNCJYDJET-LSJOCFKGSA-N 0.000 description 4
- CKLDHDOIYBVUNP-KBIXCLLPSA-N Ala-Ile-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(O)=O CKLDHDOIYBVUNP-KBIXCLLPSA-N 0.000 description 4
- SOBIAADAMRHGKH-CIUDSAMLSA-N Ala-Leu-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O SOBIAADAMRHGKH-CIUDSAMLSA-N 0.000 description 4
- 108010011170 Ala-Trp-Arg-His-Pro-Gln-Phe-Gly-Gly Proteins 0.000 description 4
- XAXMJQUMRJAFCH-CQDKDKBSSA-N Ala-Tyr-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)C)CC1=CC=C(O)C=C1 XAXMJQUMRJAFCH-CQDKDKBSSA-N 0.000 description 4
- UZGFHWIJWPUPOH-IHRRRGAJSA-N Arg-Leu-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N UZGFHWIJWPUPOH-IHRRRGAJSA-N 0.000 description 4
- IYVSIZAXNLOKFQ-BYULHYEWSA-N Asn-Asp-Val Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O IYVSIZAXNLOKFQ-BYULHYEWSA-N 0.000 description 4
- DWOGMPWRQQWPPF-GUBZILKMSA-N Asp-Leu-Glu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O DWOGMPWRQQWPPF-GUBZILKMSA-N 0.000 description 4
- UCHSVZYJKJLPHF-BZSNNMDCSA-N Asp-Phe-Phe Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O UCHSVZYJKJLPHF-BZSNNMDCSA-N 0.000 description 4
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 4
- 240000000385 Brassica napus var. napus Species 0.000 description 4
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 4
- 239000003298 DNA probe Substances 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- SVZIKUHLRKVZIF-GUBZILKMSA-N Glu-Asn-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCC(=O)O)N SVZIKUHLRKVZIF-GUBZILKMSA-N 0.000 description 4
- GYCPQVFKCPPRQB-GUBZILKMSA-N Glu-Gln-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)O)N GYCPQVFKCPPRQB-GUBZILKMSA-N 0.000 description 4
- PJYSOYLLTJKZHC-GUBZILKMSA-N Leu-Asp-Gln Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCC(N)=O PJYSOYLLTJKZHC-GUBZILKMSA-N 0.000 description 4
- JRJLGNFWYFSJHB-HOCLYGCPSA-N Leu-Gly-Trp Chemical compound [H]N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O JRJLGNFWYFSJHB-HOCLYGCPSA-N 0.000 description 4
- ZDBMWELMUCLUPL-QEJZJMRPSA-N Leu-Phe-Ala Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](C)C(O)=O)CC1=CC=CC=C1 ZDBMWELMUCLUPL-QEJZJMRPSA-N 0.000 description 4
- MVJRBCJCRYGCKV-GVXVVHGQSA-N Leu-Val-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O MVJRBCJCRYGCKV-GVXVVHGQSA-N 0.000 description 4
- DSWOTZCVCBEPOU-IUCAKERBSA-N Met-Arg-Gly Chemical compound CSCC[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CCCNC(N)=N DSWOTZCVCBEPOU-IUCAKERBSA-N 0.000 description 4
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 4
- 108010002311 N-glycylglutamic acid Proteins 0.000 description 4
- MMJJFXWMCMJMQA-STQMWFEESA-N Phe-Pro-Gly Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(=O)NCC(O)=O)C1=CC=CC=C1 MMJJFXWMCMJMQA-STQMWFEESA-N 0.000 description 4
- WEDZFLRYSIDIRX-IHRRRGAJSA-N Phe-Ser-Arg Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CC=CC=C1 WEDZFLRYSIDIRX-IHRRRGAJSA-N 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- OLIJLNWFEQEFDM-SRVKXCTJSA-N Ser-Asp-Phe Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 OLIJLNWFEQEFDM-SRVKXCTJSA-N 0.000 description 4
- BMKNXTJLHFIAAH-CIUDSAMLSA-N Ser-Ser-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O BMKNXTJLHFIAAH-CIUDSAMLSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- LIXBDERDAGNVAV-XKBZYTNZSA-N Thr-Gln-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(O)=O LIXBDERDAGNVAV-XKBZYTNZSA-N 0.000 description 4
- FHDLKMFZKRUQCE-HJGDQZAQSA-N Thr-Glu-Arg Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O FHDLKMFZKRUQCE-HJGDQZAQSA-N 0.000 description 4
- MPKPIWFFDWVJGC-IRIUXVKKSA-N Tyr-Gln-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC1=CC=C(C=C1)O)N)O MPKPIWFFDWVJGC-IRIUXVKKSA-N 0.000 description 4
- KSCVLGXNQXKUAR-JYJNAYRXSA-N Tyr-Leu-Glu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O KSCVLGXNQXKUAR-JYJNAYRXSA-N 0.000 description 4
- VUVVMFSDLYKHPA-PMVMPFDFSA-N Tyr-Lys-Trp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC3=CC=C(C=C3)O)N VUVVMFSDLYKHPA-PMVMPFDFSA-N 0.000 description 4
- NAHUCETZGZZSEX-IHPCNDPISA-N Tyr-Trp-Asp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CC3=CC=C(C=C3)O)N NAHUCETZGZZSEX-IHPCNDPISA-N 0.000 description 4
- VHRLUTIMTDOVCG-PEDHHIEDSA-N Val-Ile-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)NC(=O)[C@H](C(C)C)N VHRLUTIMTDOVCG-PEDHHIEDSA-N 0.000 description 4
- AEMPCGRFEZTWIF-IHRRRGAJSA-N Val-Leu-Lys Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(O)=O AEMPCGRFEZTWIF-IHRRRGAJSA-N 0.000 description 4
- ODUHAIXFXFACDY-SRVKXCTJSA-N Val-Val-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)C(C)C ODUHAIXFXFACDY-SRVKXCTJSA-N 0.000 description 4
- 229960001230 asparagine Drugs 0.000 description 4
- 235000009582 asparagine Nutrition 0.000 description 4
- 108010040443 aspartyl-aspartic acid Proteins 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 210000000172 cytosol Anatomy 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 108010078144 glutaminyl-glycine Proteins 0.000 description 4
- 108010085059 glutamyl-arginyl-proline Proteins 0.000 description 4
- 108010055341 glutamyl-glutamic acid Proteins 0.000 description 4
- 210000002288 golgi apparatus Anatomy 0.000 description 4
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 4
- 108010036413 histidylglycine Proteins 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 108010064486 phenylalanyl-leucyl-valine Proteins 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- NJPMYXWVWQWCSR-ACZMJKKPSA-N Ala-Glu-Asn Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NJPMYXWVWQWCSR-ACZMJKKPSA-N 0.000 description 3
- LLZXKVAAEWBUPB-KKUMJFAQSA-N Arg-Gln-Phe Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O LLZXKVAAEWBUPB-KKUMJFAQSA-N 0.000 description 3
- HQIZDMIGUJOSNI-IUCAKERBSA-N Arg-Gly-Arg Chemical compound N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O HQIZDMIGUJOSNI-IUCAKERBSA-N 0.000 description 3
- OFQPMRDJVWLMNJ-CIUDSAMLSA-N Asn-His-Cys Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC(=O)N)N OFQPMRDJVWLMNJ-CIUDSAMLSA-N 0.000 description 3
- WXVGISRWSYGEDK-KKUMJFAQSA-N Asn-Lys-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)N)N WXVGISRWSYGEDK-KKUMJFAQSA-N 0.000 description 3
- RYKWOUUZJFSJOH-FXQIFTODSA-N Asp-Gln-Glu Chemical compound C(CC(=O)N)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CC(=O)O)N RYKWOUUZJFSJOH-FXQIFTODSA-N 0.000 description 3
- HRGGPWBIMIQANI-GUBZILKMSA-N Asp-Gln-Leu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O HRGGPWBIMIQANI-GUBZILKMSA-N 0.000 description 3
- DPNWSMBUYCLEDG-CIUDSAMLSA-N Asp-Lys-Ser Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O DPNWSMBUYCLEDG-CIUDSAMLSA-N 0.000 description 3
- 241000020089 Atacta Species 0.000 description 3
- 235000016068 Berberis vulgaris Nutrition 0.000 description 3
- 241000335053 Beta vulgaris Species 0.000 description 3
- 235000014698 Brassica juncea var multisecta Nutrition 0.000 description 3
- 235000006008 Brassica napus var napus Nutrition 0.000 description 3
- 235000006618 Brassica rapa subsp oleifera Nutrition 0.000 description 3
- 235000004977 Brassica sinapistrum Nutrition 0.000 description 3
- 235000002566 Capsicum Nutrition 0.000 description 3
- 108091035707 Consensus sequence Proteins 0.000 description 3
- PLUBXMRUUVWRLT-UHFFFAOYSA-N Ethyl methanesulfonate Chemical compound CCOS(C)(=O)=O PLUBXMRUUVWRLT-UHFFFAOYSA-N 0.000 description 3
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 3
- 208000015872 Gaucher disease Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 244000068988 Glycine max Species 0.000 description 3
- 235000010469 Glycine max Nutrition 0.000 description 3
- JRYQSFOFUFXPTB-RWRJDSDZSA-N Ile-Gln-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N JRYQSFOFUFXPTB-RWRJDSDZSA-N 0.000 description 3
- MASWXTFJVNRZPT-NAKRPEOUSA-N Ile-Met-Ala Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)O)N MASWXTFJVNRZPT-NAKRPEOUSA-N 0.000 description 3
- REXAUQBGSGDEJY-IGISWZIWSA-N Ile-Tyr-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)N REXAUQBGSGDEJY-IGISWZIWSA-N 0.000 description 3
- 240000008415 Lactuca sativa Species 0.000 description 3
- 235000003228 Lactuca sativa Nutrition 0.000 description 3
- 241000880493 Leptailurus serval Species 0.000 description 3
- YKNBJXOJTURHCU-DCAQKATOSA-N Leu-Asp-Arg Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N YKNBJXOJTURHCU-DCAQKATOSA-N 0.000 description 3
- JQSXWJXBASFONF-KKUMJFAQSA-N Leu-Asp-Phe Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O JQSXWJXBASFONF-KKUMJFAQSA-N 0.000 description 3
- KAFOIVJDVSZUMD-UHFFFAOYSA-N Leu-Gln-Gln Natural products CC(C)CC(N)C(=O)NC(CCC(N)=O)C(=O)NC(CCC(N)=O)C(O)=O KAFOIVJDVSZUMD-UHFFFAOYSA-N 0.000 description 3
- HFBCHNRFRYLZNV-GUBZILKMSA-N Leu-Glu-Asp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O HFBCHNRFRYLZNV-GUBZILKMSA-N 0.000 description 3
- FAELBUXXFQLUAX-AJNGGQMLSA-N Leu-Leu-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(C)C FAELBUXXFQLUAX-AJNGGQMLSA-N 0.000 description 3
- MVVSHHJKJRZVNY-ACRUOGEOSA-N Leu-Phe-Tyr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O MVVSHHJKJRZVNY-ACRUOGEOSA-N 0.000 description 3
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 3
- 240000004658 Medicago sativa Species 0.000 description 3
- 235000017587 Medicago sativa ssp. sativa Nutrition 0.000 description 3
- BJPQKNHZHUCQNQ-SRVKXCTJSA-N Met-Pro-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCSC)N BJPQKNHZHUCQNQ-SRVKXCTJSA-N 0.000 description 3
- SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 3
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 3
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 description 3
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 3
- 101100342977 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) leu-1 gene Proteins 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 240000007594 Oryza sativa Species 0.000 description 3
- 235000007164 Oryza sativa Nutrition 0.000 description 3
- 238000012408 PCR amplification Methods 0.000 description 3
- 238000002944 PCR assay Methods 0.000 description 3
- 239000006002 Pepper Substances 0.000 description 3
- INHMISZWLJZQGH-ULQDDVLXSA-N Phe-Leu-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CC=CC=C1 INHMISZWLJZQGH-ULQDDVLXSA-N 0.000 description 3
- 235000016761 Piper aduncum Nutrition 0.000 description 3
- 240000003889 Piper guineense Species 0.000 description 3
- 235000017804 Piper guineense Nutrition 0.000 description 3
- 235000008184 Piper nigrum Nutrition 0.000 description 3
- 108020005120 Plant DNA Proteins 0.000 description 3
- DLZBBDSPTJBOOD-BPNCWPANSA-N Pro-Tyr-Ala Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C)C(O)=O DLZBBDSPTJBOOD-BPNCWPANSA-N 0.000 description 3
- XDKKMRPRRCOELJ-GUBZILKMSA-N Pro-Val-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]1CCCN1 XDKKMRPRRCOELJ-GUBZILKMSA-N 0.000 description 3
- NLQUOHDCLSFABG-GUBZILKMSA-N Ser-Arg-Arg Chemical compound NC(N)=NCCC[C@H](NC(=O)[C@H](CO)N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O NLQUOHDCLSFABG-GUBZILKMSA-N 0.000 description 3
- OWCVUSJMEBGMOK-YUMQZZPRSA-N Ser-Lys-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)NCC(O)=O OWCVUSJMEBGMOK-YUMQZZPRSA-N 0.000 description 3
- 241000208292 Solanaceae Species 0.000 description 3
- 240000003768 Solanum lycopersicum Species 0.000 description 3
- 108010090804 Streptavidin Proteins 0.000 description 3
- LRHBBGDMBLFYGL-FHWLQOOXSA-N Tyr-Phe-Glu Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C1=CC=C(O)C=C1 LRHBBGDMBLFYGL-FHWLQOOXSA-N 0.000 description 3
- PAPWZOJOLKZEFR-AVGNSLFASA-N Val-Arg-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)O)N PAPWZOJOLKZEFR-AVGNSLFASA-N 0.000 description 3
- HJSLDXZAZGFPDK-ULQDDVLXSA-N Val-Phe-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](C(C)C)N HJSLDXZAZGFPDK-ULQDDVLXSA-N 0.000 description 3
- 240000008042 Zea mays Species 0.000 description 3
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 3
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 3
- 108010041407 alanylaspartic acid Proteins 0.000 description 3
- 108010087924 alanylproline Proteins 0.000 description 3
- 238000000137 annealing Methods 0.000 description 3
- 108010093581 aspartyl-proline Proteins 0.000 description 3
- 108010038633 aspartylglutamate Proteins 0.000 description 3
- 108010068265 aspartyltyrosine Proteins 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 150000001615 biotins Chemical class 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 235000013339 cereals Nutrition 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 235000005822 corn Nutrition 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 108010078274 isoleucylvaline Proteins 0.000 description 3
- 108010047926 leucyl-lysyl-tyrosine Proteins 0.000 description 3
- 108010003700 lysyl aspartic acid Proteins 0.000 description 3
- 108010038320 lysylphenylalanine Proteins 0.000 description 3
- 125000000311 mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 3
- 230000003228 microsomal effect Effects 0.000 description 3
- HNQXDLYBFNWFEE-VHZSLYHRSA-N n-[(2r,3r,4r,5s,6r)-2-[(2r,3r,4s,5r)-2-acetamido-5-[(2r,3s,4s,5r,6r)-5-hydroxy-6-(hydroxymethyl)-3,4-bis[[(2r,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy]oxan-2-yl]oxy-1-oxo-4-[(2s,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] Chemical compound O([C@H]([C@H](C=O)NC(=O)C)[C@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H](CO[C@@H]1[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@@H]1[C@H]([C@@H](O[C@@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O[C@@H]1[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O HNQXDLYBFNWFEE-VHZSLYHRSA-N 0.000 description 3
- 108010012581 phenylalanylglutamate Proteins 0.000 description 3
- 108010073025 phenylalanylphenylalanine Proteins 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 108010053725 prolylvaline Proteins 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 235000009566 rice Nutrition 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 125000000969 xylosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)CO1)* 0.000 description 3
- CWFMWBHMIMNZLN-NAKRPEOUSA-N (2s)-1-[(2s)-2-[[(2s,3s)-2-amino-3-methylpentanoyl]amino]propanoyl]pyrrolidine-2-carboxylic acid Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O CWFMWBHMIMNZLN-NAKRPEOUSA-N 0.000 description 2
- JLIDBLDQVAYHNE-YKALOCIXSA-N Abscisic acid Natural products OC(=O)/C=C(/C)\C=C\[C@@]1(O)C(C)=CC(=O)CC1(C)C JLIDBLDQVAYHNE-YKALOCIXSA-N 0.000 description 2
- QDRGPQWIVZNJQD-CIUDSAMLSA-N Ala-Arg-Gln Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(O)=O QDRGPQWIVZNJQD-CIUDSAMLSA-N 0.000 description 2
- CSAHOYQKNHGDHX-ACZMJKKPSA-N Ala-Gln-Asn Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O CSAHOYQKNHGDHX-ACZMJKKPSA-N 0.000 description 2
- CHFFHQUVXHEGBY-GARJFASQSA-N Ala-Lys-Pro Chemical compound C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@@H]1C(=O)O)N CHFFHQUVXHEGBY-GARJFASQSA-N 0.000 description 2
- CJQAEJMHBAOQHA-DLOVCJGASA-N Ala-Phe-Asn Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(=O)N)C(=O)O)N CJQAEJMHBAOQHA-DLOVCJGASA-N 0.000 description 2
- MMLHRUJLOUSRJX-CIUDSAMLSA-N Ala-Ser-Lys Chemical compound C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCCN MMLHRUJLOUSRJX-CIUDSAMLSA-N 0.000 description 2
- IOFVWPYSRSCWHI-JXUBOQSCSA-N Ala-Thr-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C)N IOFVWPYSRSCWHI-JXUBOQSCSA-N 0.000 description 2
- MUGAESARFRGOTQ-IGNZVWTISA-N Ala-Tyr-Tyr Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O)N MUGAESARFRGOTQ-IGNZVWTISA-N 0.000 description 2
- 108010002020 Alpha-1,3-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase Proteins 0.000 description 2
- MCYJBCKCAPERSE-FXQIFTODSA-N Arg-Ala-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCN=C(N)N MCYJBCKCAPERSE-FXQIFTODSA-N 0.000 description 2
- SQKPKIJVWHAWNF-DCAQKATOSA-N Arg-Asp-Lys Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(O)=O SQKPKIJVWHAWNF-DCAQKATOSA-N 0.000 description 2
- VNFWDYWTSHFRRG-SRVKXCTJSA-N Arg-Gln-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O VNFWDYWTSHFRRG-SRVKXCTJSA-N 0.000 description 2
- ITHMWNNUDPJJER-ULQDDVLXSA-N Arg-His-Tyr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O ITHMWNNUDPJJER-ULQDDVLXSA-N 0.000 description 2
- YQGZIRIYGHNSQO-ZPFDUUQYSA-N Arg-Ile-Gln Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N YQGZIRIYGHNSQO-ZPFDUUQYSA-N 0.000 description 2
- LLUGJARLJCGLAR-CYDGBPFRSA-N Arg-Ile-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N LLUGJARLJCGLAR-CYDGBPFRSA-N 0.000 description 2
- XSPKAHFVDKRGRL-DCAQKATOSA-N Arg-Pro-Glu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O XSPKAHFVDKRGRL-DCAQKATOSA-N 0.000 description 2
- HGKHPCFTRQDHCU-IUCAKERBSA-N Arg-Pro-Gly Chemical compound NC(N)=NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O HGKHPCFTRQDHCU-IUCAKERBSA-N 0.000 description 2
- OGZBJJLRKQZRHL-KJEVXHAQSA-N Arg-Thr-Tyr Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 OGZBJJLRKQZRHL-KJEVXHAQSA-N 0.000 description 2
- PIWWUBYJNONVTJ-ZLUOBGJFSA-N Asn-Asp-Asn Chemical compound C([C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)N)C(=O)N PIWWUBYJNONVTJ-ZLUOBGJFSA-N 0.000 description 2
- WONGRTVAMHFGBE-WDSKDSINSA-N Asn-Gly-Gln Chemical compound C(CC(=O)N)[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CC(=O)N)N WONGRTVAMHFGBE-WDSKDSINSA-N 0.000 description 2
- PPCORQFLAZWUNO-QWRGUYRKSA-N Asn-Phe-Gly Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CC(=O)N)N PPCORQFLAZWUNO-QWRGUYRKSA-N 0.000 description 2
- DPSUVAPLRQDWAO-YDHLFZDLSA-N Asn-Tyr-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CC(=O)N)N DPSUVAPLRQDWAO-YDHLFZDLSA-N 0.000 description 2
- RGKKALNPOYURGE-ZKWXMUAHSA-N Asp-Ala-Val Chemical compound N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)O RGKKALNPOYURGE-ZKWXMUAHSA-N 0.000 description 2
- IXIWEFWRKIUMQX-DCAQKATOSA-N Asp-Arg-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O IXIWEFWRKIUMQX-DCAQKATOSA-N 0.000 description 2
- GWTLRDMPMJCNMH-WHFBIAKZSA-N Asp-Asn-Gly Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O GWTLRDMPMJCNMH-WHFBIAKZSA-N 0.000 description 2
- JGDBHIVECJGXJA-FXQIFTODSA-N Asp-Asp-Arg Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O JGDBHIVECJGXJA-FXQIFTODSA-N 0.000 description 2
- VHWNKSJHQFZJTH-FXQIFTODSA-N Asp-Asp-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)N VHWNKSJHQFZJTH-FXQIFTODSA-N 0.000 description 2
- KGAJCJXBEWLQDZ-UBHSHLNASA-N Asp-Asp-Trp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)N KGAJCJXBEWLQDZ-UBHSHLNASA-N 0.000 description 2
- PDECQIHABNQRHN-GUBZILKMSA-N Asp-Glu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC(O)=O PDECQIHABNQRHN-GUBZILKMSA-N 0.000 description 2
- WBDWQKRLTVCDSY-WHFBIAKZSA-N Asp-Gly-Asp Chemical compound OC(=O)C[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O WBDWQKRLTVCDSY-WHFBIAKZSA-N 0.000 description 2
- SNDBKTFJWVEVPO-WHFBIAKZSA-N Asp-Gly-Ser Chemical compound [H]N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(O)=O SNDBKTFJWVEVPO-WHFBIAKZSA-N 0.000 description 2
- WSGVTKZFVJSJOG-RCOVLWMOSA-N Asp-Gly-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O WSGVTKZFVJSJOG-RCOVLWMOSA-N 0.000 description 2
- JXGJJQJHXHXJQF-CIUDSAMLSA-N Asp-Met-Glu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(O)=O JXGJJQJHXHXJQF-CIUDSAMLSA-N 0.000 description 2
- GWIJZUVQVDJHDI-AVGNSLFASA-N Asp-Phe-Glu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O GWIJZUVQVDJHDI-AVGNSLFASA-N 0.000 description 2
- QSFHZPQUAAQHAQ-CIUDSAMLSA-N Asp-Ser-Leu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O QSFHZPQUAAQHAQ-CIUDSAMLSA-N 0.000 description 2
- YUELDQUPTAYEGM-XIRDDKMYSA-N Asp-Trp-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CC(=O)O)N YUELDQUPTAYEGM-XIRDDKMYSA-N 0.000 description 2
- FIRWLDUOFOULCA-XIRDDKMYSA-N Asp-Trp-Lys Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)O)N FIRWLDUOFOULCA-XIRDDKMYSA-N 0.000 description 2
- NWAHPBGBDIFUFD-KKUMJFAQSA-N Asp-Tyr-Leu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(O)=O NWAHPBGBDIFUFD-KKUMJFAQSA-N 0.000 description 2
- GFYOIYJJMSHLSN-QXEWZRGKSA-N Asp-Val-Arg Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O GFYOIYJJMSHLSN-QXEWZRGKSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000244203 Caenorhabditis elegans Species 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- BUIYOWKUSCTBRE-CIUDSAMLSA-N Cys-Arg-Gln Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(O)=O BUIYOWKUSCTBRE-CIUDSAMLSA-N 0.000 description 2
- BYALSSDCQYHKMY-XGEHTFHBSA-N Cys-Arg-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CS)N)O BYALSSDCQYHKMY-XGEHTFHBSA-N 0.000 description 2
- GGIHYKLJUIZYGH-ZLUOBGJFSA-N Cys-Cys-Asp Chemical compound C([C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CS)N)C(=O)O GGIHYKLJUIZYGH-ZLUOBGJFSA-N 0.000 description 2
- BCFXQBXXDSEHRS-FXQIFTODSA-N Cys-Ser-Arg Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O BCFXQBXXDSEHRS-FXQIFTODSA-N 0.000 description 2
- WTXCNOPZMQRTNN-BWBBJGPYSA-N Cys-Thr-Ser Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CS)N)O WTXCNOPZMQRTNN-BWBBJGPYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- WQWMZOIPXWSZNE-WDSKDSINSA-N Gln-Asp-Gly Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O WQWMZOIPXWSZNE-WDSKDSINSA-N 0.000 description 2
- JFSNBQJNDMXMQF-XHNCKOQMSA-N Gln-Asp-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)N)N)C(=O)O JFSNBQJNDMXMQF-XHNCKOQMSA-N 0.000 description 2
- NVEASDQHBRZPSU-BQBZGAKWSA-N Gln-Gln-Gly Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O NVEASDQHBRZPSU-BQBZGAKWSA-N 0.000 description 2
- IWUFOVSLWADEJC-AVGNSLFASA-N Gln-His-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(O)=O IWUFOVSLWADEJC-AVGNSLFASA-N 0.000 description 2
- ITZWDGBYBPUZRG-KBIXCLLPSA-N Gln-Ile-Ser Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O ITZWDGBYBPUZRG-KBIXCLLPSA-N 0.000 description 2
- QBLMTCRYYTVUQY-GUBZILKMSA-N Gln-Leu-Asp Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O QBLMTCRYYTVUQY-GUBZILKMSA-N 0.000 description 2
- CAXXTYYGFYTBPV-IUCAKERBSA-N Gln-Leu-Gly Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O CAXXTYYGFYTBPV-IUCAKERBSA-N 0.000 description 2
- MLSKFHLRFVGNLL-WDCWCFNPSA-N Gln-Leu-Thr Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O MLSKFHLRFVGNLL-WDCWCFNPSA-N 0.000 description 2
- WHVLABLIJYGVEK-QEWYBTABSA-N Gln-Phe-Ile Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O WHVLABLIJYGVEK-QEWYBTABSA-N 0.000 description 2
- FTTHLXOMDMLKKW-FHWLQOOXSA-N Gln-Phe-Phe Chemical compound C([C@H](NC(=O)[C@H](CCC(N)=O)N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 FTTHLXOMDMLKKW-FHWLQOOXSA-N 0.000 description 2
- QFXNFFZTMFHPST-DZKIICNBSA-N Gln-Phe-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CCC(=O)N)N QFXNFFZTMFHPST-DZKIICNBSA-N 0.000 description 2
- DYVMTEWCGAVKSE-HJGDQZAQSA-N Gln-Thr-Arg Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](CCC(=O)N)N)O DYVMTEWCGAVKSE-HJGDQZAQSA-N 0.000 description 2
- ARYKRXHBIPLULY-XKBZYTNZSA-N Gln-Thr-Ser Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O ARYKRXHBIPLULY-XKBZYTNZSA-N 0.000 description 2
- JKDBRTNMYXYLHO-JYJNAYRXSA-N Gln-Tyr-Leu Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 JKDBRTNMYXYLHO-JYJNAYRXSA-N 0.000 description 2
- UTKUTMJSWKKHEM-WDSKDSINSA-N Glu-Ala-Gly Chemical compound OC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(O)=O UTKUTMJSWKKHEM-WDSKDSINSA-N 0.000 description 2
- NTBDVNJIWCKURJ-ACZMJKKPSA-N Glu-Asp-Asn Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NTBDVNJIWCKURJ-ACZMJKKPSA-N 0.000 description 2
- JPHYJQHPILOKHC-ACZMJKKPSA-N Glu-Asp-Asp Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O JPHYJQHPILOKHC-ACZMJKKPSA-N 0.000 description 2
- MUSGDMDGNGXULI-DCAQKATOSA-N Glu-Glu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCC(O)=O MUSGDMDGNGXULI-DCAQKATOSA-N 0.000 description 2
- QYPKJXSMLMREKF-BPUTZDHNSA-N Glu-Glu-Trp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)N QYPKJXSMLMREKF-BPUTZDHNSA-N 0.000 description 2
- UHVIQGKBMXEVGN-WDSKDSINSA-N Glu-Gly-Asn Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O UHVIQGKBMXEVGN-WDSKDSINSA-N 0.000 description 2
- XIKYNVKEUINBGL-IUCAKERBSA-N Glu-His-Gly Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)NCC(O)=O XIKYNVKEUINBGL-IUCAKERBSA-N 0.000 description 2
- ZWABFSSWTSAMQN-KBIXCLLPSA-N Glu-Ile-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O ZWABFSSWTSAMQN-KBIXCLLPSA-N 0.000 description 2
- FBEJIDRSQCGFJI-GUBZILKMSA-N Glu-Leu-Ser Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O FBEJIDRSQCGFJI-GUBZILKMSA-N 0.000 description 2
- JYXKPJVDCAWMDG-ZPFDUUQYSA-N Glu-Pro-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(=O)O)N JYXKPJVDCAWMDG-ZPFDUUQYSA-N 0.000 description 2
- NNQDRRUXFJYCCJ-NHCYSSNCSA-N Glu-Pro-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(O)=O NNQDRRUXFJYCCJ-NHCYSSNCSA-N 0.000 description 2
- YOTHMZZSJKKEHZ-SZMVWBNQSA-N Glu-Trp-Lys Chemical compound C1=CC=C2C(C[C@@H](C(=O)N[C@@H](CCCCN)C(O)=O)NC(=O)[C@@H](N)CCC(O)=O)=CNC2=C1 YOTHMZZSJKKEHZ-SZMVWBNQSA-N 0.000 description 2
- KCCNSVHJSMMGFS-NRPADANISA-N Glu-Val-Cys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CCC(=O)O)N KCCNSVHJSMMGFS-NRPADANISA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- RQZGFWKQLPJOEQ-YUMQZZPRSA-N Gly-Arg-Gln Chemical compound C(C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)CN)CN=C(N)N RQZGFWKQLPJOEQ-YUMQZZPRSA-N 0.000 description 2
- FZQLXNIMCPJVJE-YUMQZZPRSA-N Gly-Asp-Leu Chemical compound [H]NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O FZQLXNIMCPJVJE-YUMQZZPRSA-N 0.000 description 2
- JUGQPPOVWXSPKJ-RYUDHWBXSA-N Gly-Gln-Phe Chemical compound [H]NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O JUGQPPOVWXSPKJ-RYUDHWBXSA-N 0.000 description 2
- JUBDONGMHASUCN-IUCAKERBSA-N Gly-Glu-His Chemical compound NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1cnc[nH]1)C(O)=O JUBDONGMHASUCN-IUCAKERBSA-N 0.000 description 2
- YYPFZVIXAVDHIK-IUCAKERBSA-N Gly-Glu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CN YYPFZVIXAVDHIK-IUCAKERBSA-N 0.000 description 2
- LHRXAHLCRMQBGJ-RYUDHWBXSA-N Gly-Glu-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)CN LHRXAHLCRMQBGJ-RYUDHWBXSA-N 0.000 description 2
- QPTNELDXWKRIFX-YFKPBYRVSA-N Gly-Gly-Gln Chemical compound NCC(=O)NCC(=O)N[C@H](C(O)=O)CCC(N)=O QPTNELDXWKRIFX-YFKPBYRVSA-N 0.000 description 2
- SWQALSGKVLYKDT-ZKWXMUAHSA-N Gly-Ile-Ala Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O SWQALSGKVLYKDT-ZKWXMUAHSA-N 0.000 description 2
- SWQALSGKVLYKDT-UHFFFAOYSA-N Gly-Ile-Ala Natural products NCC(=O)NC(C(C)CC)C(=O)NC(C)C(O)=O SWQALSGKVLYKDT-UHFFFAOYSA-N 0.000 description 2
- FCKPEGOCSVZPNC-WHOFXGATSA-N Gly-Ile-Phe Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 FCKPEGOCSVZPNC-WHOFXGATSA-N 0.000 description 2
- OHUKZZYSJBKFRR-WHFBIAKZSA-N Gly-Ser-Asp Chemical compound [H]NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O OHUKZZYSJBKFRR-WHFBIAKZSA-N 0.000 description 2
- RJVZMGQMJOQIAX-GJZGRUSLSA-N Gly-Trp-Met Chemical compound [H]NCC(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCSC)C(O)=O RJVZMGQMJOQIAX-GJZGRUSLSA-N 0.000 description 2
- YGHSQRJSHKYUJY-SCZZXKLOSA-N Gly-Val-Pro Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)CN YGHSQRJSHKYUJY-SCZZXKLOSA-N 0.000 description 2
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 2
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 2
- 108700023372 Glycosyltransferases Proteins 0.000 description 2
- RVKIPWVMZANZLI-UHFFFAOYSA-N H-Lys-Trp-OH Natural products C1=CC=C2C(CC(NC(=O)C(N)CCCCN)C(O)=O)=CNC2=C1 RVKIPWVMZANZLI-UHFFFAOYSA-N 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- XJQDHFMUUBRCGA-KKUMJFAQSA-N His-Asn-Phe Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O XJQDHFMUUBRCGA-KKUMJFAQSA-N 0.000 description 2
- YADRBUZBKHHDAO-XPUUQOCRSA-N His-Gly-Ala Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)NCC(=O)N[C@@H](C)C(O)=O YADRBUZBKHHDAO-XPUUQOCRSA-N 0.000 description 2
- FYTCLUIYTYFGPT-YUMQZZPRSA-N His-Gly-Ser Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)NCC(=O)N[C@@H](CO)C(O)=O FYTCLUIYTYFGPT-YUMQZZPRSA-N 0.000 description 2
- VFBZWZXKCVBTJR-SRVKXCTJSA-N His-Leu-Asp Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CC1=CN=CN1)N VFBZWZXKCVBTJR-SRVKXCTJSA-N 0.000 description 2
- 206010020649 Hyperkeratosis Diseases 0.000 description 2
- DMHGKBGOUAJRHU-UHFFFAOYSA-N Ile-Arg-Pro Natural products CCC(C)C(N)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(O)=O DMHGKBGOUAJRHU-UHFFFAOYSA-N 0.000 description 2
- NKRJALPCDNXULF-BYULHYEWSA-N Ile-Asp-Gly Chemical compound [H]N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O NKRJALPCDNXULF-BYULHYEWSA-N 0.000 description 2
- HUORUFRRJHELPD-MNXVOIDGSA-N Ile-Leu-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N HUORUFRRJHELPD-MNXVOIDGSA-N 0.000 description 2
- RMNMUUCYTMLWNA-ZPFDUUQYSA-N Ile-Lys-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)O)C(=O)O)N RMNMUUCYTMLWNA-ZPFDUUQYSA-N 0.000 description 2
- YSGBJIQXTIVBHZ-AJNGGQMLSA-N Ile-Lys-Leu Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O YSGBJIQXTIVBHZ-AJNGGQMLSA-N 0.000 description 2
- AKOYRLRUFBZOSP-BJDJZHNGSA-N Ile-Lys-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)O)N AKOYRLRUFBZOSP-BJDJZHNGSA-N 0.000 description 2
- SAVXZJYTTQQQDD-QEWYBTABSA-N Ile-Phe-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N SAVXZJYTTQQQDD-QEWYBTABSA-N 0.000 description 2
- FBGXMKUWQFPHFB-JBDRJPRFSA-N Ile-Ser-Cys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N FBGXMKUWQFPHFB-JBDRJPRFSA-N 0.000 description 2
- NGKPIPCGMLWHBX-WZLNRYEVSA-N Ile-Tyr-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N NGKPIPCGMLWHBX-WZLNRYEVSA-N 0.000 description 2
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 2
- XIRYQRLFHWWWTC-QEJZJMRPSA-N Leu-Ala-Phe Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 XIRYQRLFHWWWTC-QEJZJMRPSA-N 0.000 description 2
- VKOAHIRLIUESLU-ULQDDVLXSA-N Leu-Arg-Phe Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O VKOAHIRLIUESLU-ULQDDVLXSA-N 0.000 description 2
- CUXRXAIAVYLVFD-ULQDDVLXSA-N Leu-Arg-Tyr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 CUXRXAIAVYLVFD-ULQDDVLXSA-N 0.000 description 2
- RVVBWTWPNFDYBE-SRVKXCTJSA-N Leu-Glu-Arg Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O RVVBWTWPNFDYBE-SRVKXCTJSA-N 0.000 description 2
- OGUUKPXUTHOIAV-SDDRHHMPSA-N Leu-Glu-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N1CCC[C@@H]1C(=O)O)N OGUUKPXUTHOIAV-SDDRHHMPSA-N 0.000 description 2
- FIYMBBHGYNQFOP-IUCAKERBSA-N Leu-Gly-Gln Chemical compound CC(C)C[C@@H](C(=O)NCC(=O)N[C@@H](CCC(=O)N)C(=O)O)N FIYMBBHGYNQFOP-IUCAKERBSA-N 0.000 description 2
- KOSWSHVQIVTVQF-ZPFDUUQYSA-N Leu-Ile-Asp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(O)=O KOSWSHVQIVTVQF-ZPFDUUQYSA-N 0.000 description 2
- QNBVTHNJGCOVFA-AVGNSLFASA-N Leu-Leu-Glu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCC(O)=O QNBVTHNJGCOVFA-AVGNSLFASA-N 0.000 description 2
- ZRHDPZAAWLXXIR-SRVKXCTJSA-N Leu-Lys-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O ZRHDPZAAWLXXIR-SRVKXCTJSA-N 0.000 description 2
- JLWZLIQRYCTYBD-IHRRRGAJSA-N Leu-Lys-Arg Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O JLWZLIQRYCTYBD-IHRRRGAJSA-N 0.000 description 2
- HVHRPWQEQHIQJF-AVGNSLFASA-N Leu-Lys-Glu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O HVHRPWQEQHIQJF-AVGNSLFASA-N 0.000 description 2
- ONPJGOIVICHWBW-BZSNNMDCSA-N Leu-Lys-Tyr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 ONPJGOIVICHWBW-BZSNNMDCSA-N 0.000 description 2
- WXZOHBVPVKABQN-DCAQKATOSA-N Leu-Met-Asp Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)O)C(=O)O)N WXZOHBVPVKABQN-DCAQKATOSA-N 0.000 description 2
- KQFZKDITNUEVFJ-JYJNAYRXSA-N Leu-Phe-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(C)C)CC1=CC=CC=C1 KQFZKDITNUEVFJ-JYJNAYRXSA-N 0.000 description 2
- SYRTUBLKWNDSDK-DKIMLUQUSA-N Leu-Phe-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O SYRTUBLKWNDSDK-DKIMLUQUSA-N 0.000 description 2
- AMSSKPUHBUQBOQ-SRVKXCTJSA-N Leu-Ser-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)O)N AMSSKPUHBUQBOQ-SRVKXCTJSA-N 0.000 description 2
- SBANPBVRHYIMRR-GARJFASQSA-N Leu-Ser-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N1CCC[C@@H]1C(=O)O)N SBANPBVRHYIMRR-GARJFASQSA-N 0.000 description 2
- SQUFDMCWMFOEBA-KKUMJFAQSA-N Leu-Ser-Tyr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 SQUFDMCWMFOEBA-KKUMJFAQSA-N 0.000 description 2
- HGLKOTPFWOMPOB-MEYUZBJRSA-N Leu-Thr-Tyr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 HGLKOTPFWOMPOB-MEYUZBJRSA-N 0.000 description 2
- FBNPMTNBFFAMMH-UHFFFAOYSA-N Leu-Val-Arg Natural products CC(C)CC(N)C(=O)NC(C(C)C)C(=O)NC(C(O)=O)CCCN=C(N)N FBNPMTNBFFAMMH-UHFFFAOYSA-N 0.000 description 2
- WSXTWLJHTLRFLW-SRVKXCTJSA-N Lys-Ala-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(O)=O WSXTWLJHTLRFLW-SRVKXCTJSA-N 0.000 description 2
- VHXMZJGOKIMETG-CQDKDKBSSA-N Lys-Ala-Tyr Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)NC(=O)[C@H](CCCCN)N VHXMZJGOKIMETG-CQDKDKBSSA-N 0.000 description 2
- NTEVEUCLFMWSND-SRVKXCTJSA-N Lys-Arg-Gln Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(O)=O NTEVEUCLFMWSND-SRVKXCTJSA-N 0.000 description 2
- AAORVPFVUIHEAB-YUMQZZPRSA-N Lys-Asp-Gly Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O AAORVPFVUIHEAB-YUMQZZPRSA-N 0.000 description 2
- IWWMPCPLFXFBAF-SRVKXCTJSA-N Lys-Asp-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O IWWMPCPLFXFBAF-SRVKXCTJSA-N 0.000 description 2
- NNCDAORZCMPZPX-GUBZILKMSA-N Lys-Gln-Ser Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CO)C(=O)O)N NNCDAORZCMPZPX-GUBZILKMSA-N 0.000 description 2
- DTUZCYRNEJDKSR-NHCYSSNCSA-N Lys-Gly-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN DTUZCYRNEJDKSR-NHCYSSNCSA-N 0.000 description 2
- SQJSXOQXJYAVRV-SRVKXCTJSA-N Lys-His-Asn Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCCCN)N SQJSXOQXJYAVRV-SRVKXCTJSA-N 0.000 description 2
- GTAXSKOXPIISBW-AVGNSLFASA-N Lys-His-Gln Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CCCCN)N GTAXSKOXPIISBW-AVGNSLFASA-N 0.000 description 2
- FGMHXLULNHTPID-KKUMJFAQSA-N Lys-His-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(O)=O)CC1=CN=CN1 FGMHXLULNHTPID-KKUMJFAQSA-N 0.000 description 2
- ZMMDPRTXLAEMOD-BZSNNMDCSA-N Lys-His-Phe Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O ZMMDPRTXLAEMOD-BZSNNMDCSA-N 0.000 description 2
- SLQJJFAVWSZLBL-BJDJZHNGSA-N Lys-Ile-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CCCCN SLQJJFAVWSZLBL-BJDJZHNGSA-N 0.000 description 2
- NJNRBRKHOWSGMN-SRVKXCTJSA-N Lys-Leu-Asn Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O NJNRBRKHOWSGMN-SRVKXCTJSA-N 0.000 description 2
- HVAUKHLDSDDROB-KKUMJFAQSA-N Lys-Lys-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O HVAUKHLDSDDROB-KKUMJFAQSA-N 0.000 description 2
- MIFFFXHMAHFACR-KATARQTJSA-N Lys-Ser-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CCCCN MIFFFXHMAHFACR-KATARQTJSA-N 0.000 description 2
- AWMMBHDKERMOID-YTQUADARSA-N Lys-Trp-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)[C@H](CCCCN)N)C(=O)O AWMMBHDKERMOID-YTQUADARSA-N 0.000 description 2
- IEIHKHYMBIYQTH-YESZJQIVSA-N Lys-Tyr-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CCCCN)N)C(=O)O IEIHKHYMBIYQTH-YESZJQIVSA-N 0.000 description 2
- MVQGZYIOMXAFQG-GUBZILKMSA-N Met-Ala-Arg Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCCNC(N)=N MVQGZYIOMXAFQG-GUBZILKMSA-N 0.000 description 2
- QRHWTCJBCLGYRB-FXQIFTODSA-N Met-Ala-Cys Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CS)C(O)=O QRHWTCJBCLGYRB-FXQIFTODSA-N 0.000 description 2
- GXYYFDKJHLRNSI-SRVKXCTJSA-N Met-Gln-His Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CNC=N1)C(O)=O GXYYFDKJHLRNSI-SRVKXCTJSA-N 0.000 description 2
- CHQWUYSNAOABIP-ZPFDUUQYSA-N Met-Glu-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)N CHQWUYSNAOABIP-ZPFDUUQYSA-N 0.000 description 2
- DBXMFHGGHMXYHY-DCAQKATOSA-N Met-Leu-Ser Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O DBXMFHGGHMXYHY-DCAQKATOSA-N 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 240000005561 Musa balbisiana Species 0.000 description 2
- 235000018290 Musa x paradisiaca Nutrition 0.000 description 2
- WYBVBIHNJWOLCJ-UHFFFAOYSA-N N-L-arginyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCCN=C(N)N WYBVBIHNJWOLCJ-UHFFFAOYSA-N 0.000 description 2
- AUEJLPRZGVVDNU-UHFFFAOYSA-N N-L-tyrosyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CC1=CC=C(O)C=C1 AUEJLPRZGVVDNU-UHFFFAOYSA-N 0.000 description 2
- 108010079364 N-glycylalanine Proteins 0.000 description 2
- 108010087066 N2-tryptophyllysine Proteins 0.000 description 2
- 101710091688 Patatin Proteins 0.000 description 2
- 244000046052 Phaseolus vulgaris Species 0.000 description 2
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 2
- IWRZUGHCHFZYQZ-UFYCRDLUSA-N Phe-Arg-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=CC=C1 IWRZUGHCHFZYQZ-UFYCRDLUSA-N 0.000 description 2
- KIEPQOIQHFKQLK-PCBIJLKTSA-N Phe-Asn-Ile Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O KIEPQOIQHFKQLK-PCBIJLKTSA-N 0.000 description 2
- KYYMILWEGJYPQZ-IHRRRGAJSA-N Phe-Glu-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 KYYMILWEGJYPQZ-IHRRRGAJSA-N 0.000 description 2
- ZLGQEBCCANLYRA-RYUDHWBXSA-N Phe-Gly-Glu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(O)=O ZLGQEBCCANLYRA-RYUDHWBXSA-N 0.000 description 2
- HGNGAMWHGGANAU-WHOFXGATSA-N Phe-Gly-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC1=CC=CC=C1 HGNGAMWHGGANAU-WHOFXGATSA-N 0.000 description 2
- VZFPYFRVHMSSNA-JURCDPSOSA-N Phe-Ile-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CC1=CC=CC=C1 VZFPYFRVHMSSNA-JURCDPSOSA-N 0.000 description 2
- FXPZZKBHNOMLGA-HJWJTTGWSA-N Phe-Ile-Arg Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)N FXPZZKBHNOMLGA-HJWJTTGWSA-N 0.000 description 2
- KAJLHCWRWDSROH-BZSNNMDCSA-N Phe-Phe-Asp Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(O)=O)C(O)=O)C1=CC=CC=C1 KAJLHCWRWDSROH-BZSNNMDCSA-N 0.000 description 2
- RBRNEFJTEHPDSL-ACRUOGEOSA-N Phe-Phe-Lys Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(O)=O)NC(=O)[C@@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 RBRNEFJTEHPDSL-ACRUOGEOSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 108010064851 Plant Proteins Proteins 0.000 description 2
- ZCXQTRXYZOSGJR-FXQIFTODSA-N Pro-Asp-Ser Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O ZCXQTRXYZOSGJR-FXQIFTODSA-N 0.000 description 2
- VPEVBAUSTBWQHN-NHCYSSNCSA-N Pro-Glu-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O VPEVBAUSTBWQHN-NHCYSSNCSA-N 0.000 description 2
- VYWNORHENYEQDW-YUMQZZPRSA-N Pro-Gly-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H]1CCCN1 VYWNORHENYEQDW-YUMQZZPRSA-N 0.000 description 2
- FKLSMYYLJHYPHH-UWVGGRQHSA-N Pro-Gly-Leu Chemical compound [H]N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CC(C)C)C(O)=O FKLSMYYLJHYPHH-UWVGGRQHSA-N 0.000 description 2
- BWCZJGJKOFUUCN-ZPFDUUQYSA-N Pro-Ile-Gln Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(O)=O BWCZJGJKOFUUCN-ZPFDUUQYSA-N 0.000 description 2
- FJLODLCIOJUDRG-PYJNHQTQSA-N Pro-Ile-His Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@@H]2CCCN2 FJLODLCIOJUDRG-PYJNHQTQSA-N 0.000 description 2
- LXLFEIHKWGHJJB-XUXIUFHCSA-N Pro-Ile-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@@H]1CCCN1 LXLFEIHKWGHJJB-XUXIUFHCSA-N 0.000 description 2
- DRKAXLDECUGLFE-ULQDDVLXSA-N Pro-Leu-Phe Chemical compound CC(C)C[C@H](NC(=O)[C@@H]1CCCN1)C(=O)N[C@@H](Cc1ccccc1)C(O)=O DRKAXLDECUGLFE-ULQDDVLXSA-N 0.000 description 2
- OFGUOWQVEGTVNU-DCAQKATOSA-N Pro-Lys-Ala Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O OFGUOWQVEGTVNU-DCAQKATOSA-N 0.000 description 2
- IQAGKQWXVHTPOT-FHWLQOOXSA-N Pro-Lys-Trp Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)O IQAGKQWXVHTPOT-FHWLQOOXSA-N 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- HBOABDXGTMMDSE-GUBZILKMSA-N Ser-Arg-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(O)=O HBOABDXGTMMDSE-GUBZILKMSA-N 0.000 description 2
- WBINSDOPZHQPPM-AVGNSLFASA-N Ser-Glu-Tyr Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)N)O WBINSDOPZHQPPM-AVGNSLFASA-N 0.000 description 2
- RIAKPZVSNBBNRE-BJDJZHNGSA-N Ser-Ile-Leu Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O RIAKPZVSNBBNRE-BJDJZHNGSA-N 0.000 description 2
- GJFYFGOEWLDQGW-GUBZILKMSA-N Ser-Leu-Gln Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CO)N GJFYFGOEWLDQGW-GUBZILKMSA-N 0.000 description 2
- QJKPECIAWNNKIT-KKUMJFAQSA-N Ser-Lys-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O QJKPECIAWNNKIT-KKUMJFAQSA-N 0.000 description 2
- KJKQUQXDEKMPDK-FXQIFTODSA-N Ser-Met-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(O)=O KJKQUQXDEKMPDK-FXQIFTODSA-N 0.000 description 2
- NMZXJDSKEGFDLJ-DCAQKATOSA-N Ser-Pro-Lys Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CO)N)C(=O)N[C@@H](CCCCN)C(=O)O NMZXJDSKEGFDLJ-DCAQKATOSA-N 0.000 description 2
- DKGRNFUXVTYRAS-UBHSHLNASA-N Ser-Ser-Trp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O DKGRNFUXVTYRAS-UBHSHLNASA-N 0.000 description 2
- OJFFAQFRCVPHNN-JYBASQMISA-N Ser-Thr-Trp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O OJFFAQFRCVPHNN-JYBASQMISA-N 0.000 description 2
- AXKJPUBALUNJEO-UBHSHLNASA-N Ser-Trp-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(N)=O)C(O)=O AXKJPUBALUNJEO-UBHSHLNASA-N 0.000 description 2
- YEDSOSIKVUMIJE-DCAQKATOSA-N Ser-Val-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O YEDSOSIKVUMIJE-DCAQKATOSA-N 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- XYEXCEPTALHNEV-RCWTZXSCSA-N Thr-Arg-Arg Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O XYEXCEPTALHNEV-RCWTZXSCSA-N 0.000 description 2
- LCCSEJSPBWKBNT-OSUNSFLBSA-N Thr-Ile-Met Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)O)NC(=O)[C@H]([C@@H](C)O)N LCCSEJSPBWKBNT-OSUNSFLBSA-N 0.000 description 2
- DOBIBIXIHJKVJF-XKBZYTNZSA-N Thr-Ser-Gln Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(N)=O DOBIBIXIHJKVJF-XKBZYTNZSA-N 0.000 description 2
- NJGMALCNYAMYCB-JRQIVUDYSA-N Thr-Tyr-Asn Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(N)=O)C(O)=O NJGMALCNYAMYCB-JRQIVUDYSA-N 0.000 description 2
- VMSSYINFMOFLJM-KJEVXHAQSA-N Thr-Tyr-Met Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCSC)C(=O)O)N)O VMSSYINFMOFLJM-KJEVXHAQSA-N 0.000 description 2
- 241000723873 Tobacco mosaic virus Species 0.000 description 2
- NMCBVGFGWSIGSB-NUTKFTJISA-N Trp-Ala-Leu Chemical compound C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)N NMCBVGFGWSIGSB-NUTKFTJISA-N 0.000 description 2
- DXDMNBJJEXYMLA-UBHSHLNASA-N Trp-Asn-Asp Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O)=CNC2=C1 DXDMNBJJEXYMLA-UBHSHLNASA-N 0.000 description 2
- AIISTODACBDQLW-WDSOQIARSA-N Trp-Leu-Arg Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)=CNC2=C1 AIISTODACBDQLW-WDSOQIARSA-N 0.000 description 2
- KRCPXGSWDOGHAM-XIRDDKMYSA-N Trp-Lys-Asp Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(O)=O KRCPXGSWDOGHAM-XIRDDKMYSA-N 0.000 description 2
- XDQGKIMTRSVSBC-WDSOQIARSA-N Trp-Pro-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CC1=CNC2=CC=CC=C12 XDQGKIMTRSVSBC-WDSOQIARSA-N 0.000 description 2
- MICSYKFECRFCTJ-IHRRRGAJSA-N Tyr-Arg-Asp Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(=O)O)C(=O)O)N)O MICSYKFECRFCTJ-IHRRRGAJSA-N 0.000 description 2
- IIJWXEUNETVJPV-IHRRRGAJSA-N Tyr-Arg-Ser Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CO)C(=O)O)N)O IIJWXEUNETVJPV-IHRRRGAJSA-N 0.000 description 2
- MBFJIHUHHCJBSN-AVGNSLFASA-N Tyr-Asn-Gln Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O MBFJIHUHHCJBSN-AVGNSLFASA-N 0.000 description 2
- XMNDQSYABVWZRK-BZSNNMDCSA-N Tyr-Asn-Phe Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O XMNDQSYABVWZRK-BZSNNMDCSA-N 0.000 description 2
- GYKDRHDMGQUZPU-MGHWNKPDSA-N Tyr-Lys-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC1=CC=C(C=C1)O)N GYKDRHDMGQUZPU-MGHWNKPDSA-N 0.000 description 2
- QPBJXNYYQTUTDD-KKUMJFAQSA-N Tyr-Met-Gln Chemical compound CSCC[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N QPBJXNYYQTUTDD-KKUMJFAQSA-N 0.000 description 2
- BIWVVOHTKDLRMP-ULQDDVLXSA-N Tyr-Pro-Leu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(O)=O BIWVVOHTKDLRMP-ULQDDVLXSA-N 0.000 description 2
- QVYFTFIBKCDHIE-ACRUOGEOSA-N Tyr-Tyr-Lys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CCCCN)C(=O)O)N)O QVYFTFIBKCDHIE-ACRUOGEOSA-N 0.000 description 2
- JFAWZADYPRMRCO-UBHSHLNASA-N Val-Ala-Phe Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 JFAWZADYPRMRCO-UBHSHLNASA-N 0.000 description 2
- AZSHAZJLOZQYAY-FXQIFTODSA-N Val-Ala-Ser Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O AZSHAZJLOZQYAY-FXQIFTODSA-N 0.000 description 2
- LABUITCFCAABSV-UHFFFAOYSA-N Val-Ala-Tyr Natural products CC(C)C(N)C(=O)NC(C)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 LABUITCFCAABSV-UHFFFAOYSA-N 0.000 description 2
- XKVXSCHXGJOQND-ZOBUZTSGSA-N Val-Asp-Trp Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)N XKVXSCHXGJOQND-ZOBUZTSGSA-N 0.000 description 2
- FRUYSSRPJXNRRB-GUBZILKMSA-N Val-Cys-Arg Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N FRUYSSRPJXNRRB-GUBZILKMSA-N 0.000 description 2
- YCMXFKWYJFZFKS-LAEOZQHASA-N Val-Gln-Asp Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)O)N YCMXFKWYJFZFKS-LAEOZQHASA-N 0.000 description 2
- PGBJAZDAEWPDAA-NHCYSSNCSA-N Val-Gln-Met Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCSC)C(=O)O)N PGBJAZDAEWPDAA-NHCYSSNCSA-N 0.000 description 2
- UZDHNIJRRTUKKC-DLOVCJGASA-N Val-Gln-Val Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](C(C)C)C(=O)O)N UZDHNIJRRTUKKC-DLOVCJGASA-N 0.000 description 2
- ZIGZPYJXIWLQFC-QTKMDUPCSA-N Val-His-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](C(C)C)N)O ZIGZPYJXIWLQFC-QTKMDUPCSA-N 0.000 description 2
- YMTOEGGOCHVGEH-IHRRRGAJSA-N Val-Lys-Lys Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O YMTOEGGOCHVGEH-IHRRRGAJSA-N 0.000 description 2
- YTNGABPUXFEOGU-SRVKXCTJSA-N Val-Pro-Arg Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(O)=O YTNGABPUXFEOGU-SRVKXCTJSA-N 0.000 description 2
- MXGLYEVGJRXBTP-QOLULZROSA-N [(6z,10e,14e)-3,7,11,15,19-pentamethylicosa-6,10,14,18-tetraenyl] phosphono hydrogen phosphate Chemical compound OP(=O)(O)OP(O)(=O)OCCC(C)CC\C=C(\C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C MXGLYEVGJRXBTP-QOLULZROSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 108010070783 alanyltyrosine Proteins 0.000 description 2
- 108010050025 alpha-glutamyltryptophan Proteins 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- -1 and thus Proteins 0.000 description 2
- 108010036533 arginylvaline Proteins 0.000 description 2
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 2
- 108010073219 beta-1,3-galactosyl-0-glycosyl-glycoprotein beta-1,3-N-acetylglucosaminyltransferase Proteins 0.000 description 2
- 108010051210 beta-Fructofuranosidase Proteins 0.000 description 2
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 2
- 239000013599 cloning vector Substances 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000022811 deglycosylation Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000001627 detrimental effect Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000030279 gene silencing Effects 0.000 description 2
- 238000012226 gene silencing method Methods 0.000 description 2
- 102000045442 glycosyltransferase activity proteins Human genes 0.000 description 2
- 108700014210 glycosyltransferase activity proteins Proteins 0.000 description 2
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 2
- 108010010147 glycylglutamine Proteins 0.000 description 2
- 108010037850 glycylvaline Proteins 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 108010025306 histidylleucine Proteins 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 235000011073 invertase Nutrition 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- ZNJFBWYDHIGLCU-HWKXXFMVSA-N jasmonic acid Chemical compound CC\C=C/C[C@@H]1[C@@H](CC(O)=O)CCC1=O ZNJFBWYDHIGLCU-HWKXXFMVSA-N 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- 108010076756 leucyl-alanyl-phenylalanine Proteins 0.000 description 2
- 108010034529 leucyl-lysine Proteins 0.000 description 2
- 108010054155 lysyllysine Proteins 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 108010056582 methionylglutamic acid Proteins 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 108010058731 nopaline synthase Proteins 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 108010072637 phenylalanyl-arginyl-phenylalanine Proteins 0.000 description 2
- 108010073101 phenylalanylleucine Proteins 0.000 description 2
- 108010051242 phenylalanylserine Proteins 0.000 description 2
- 235000021118 plant-derived protein Nutrition 0.000 description 2
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 108010004914 prolylarginine Proteins 0.000 description 2
- 108010015796 prolylisoleucine Proteins 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 108010026333 seryl-proline Proteins 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 108010033670 threonyl-aspartyl-tyrosine Proteins 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- 230000010474 transient expression Effects 0.000 description 2
- 108010080629 tryptophan-leucine Proteins 0.000 description 2
- 108010020532 tyrosyl-proline Proteins 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- PENWAFASUFITRC-UHFFFAOYSA-N 2-(4-chlorophenyl)imidazo[2,1-a]isoquinoline Chemical group C1=CC(Cl)=CC=C1C1=CN(C=CC=2C3=CC=CC=2)C3=N1 PENWAFASUFITRC-UHFFFAOYSA-N 0.000 description 1
- 102100031126 6-phosphogluconolactonase Human genes 0.000 description 1
- 108010029731 6-phosphogluconolactonase Proteins 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- DKJPOZOEBONHFS-ZLUOBGJFSA-N Ala-Ala-Asp Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC(O)=O DKJPOZOEBONHFS-ZLUOBGJFSA-N 0.000 description 1
- NHCPCLJZRSIDHS-ZLUOBGJFSA-N Ala-Asp-Ala Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(O)=O NHCPCLJZRSIDHS-ZLUOBGJFSA-N 0.000 description 1
- PBAMJJXWDQXOJA-FXQIFTODSA-N Ala-Asp-Arg Chemical compound C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N PBAMJJXWDQXOJA-FXQIFTODSA-N 0.000 description 1
- MKZCBYZBCINNJN-DLOVCJGASA-N Ala-Asp-Phe Chemical compound C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MKZCBYZBCINNJN-DLOVCJGASA-N 0.000 description 1
- KUDREHRZRIVKHS-UWJYBYFXSA-N Ala-Asp-Tyr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O KUDREHRZRIVKHS-UWJYBYFXSA-N 0.000 description 1
- HFBFSOAKPUZCCO-ZLUOBGJFSA-N Ala-Cys-Asn Chemical compound C[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(=O)N)C(=O)O)N HFBFSOAKPUZCCO-ZLUOBGJFSA-N 0.000 description 1
- OILNWMNBLIHXQK-ZLUOBGJFSA-N Ala-Cys-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(O)=O OILNWMNBLIHXQK-ZLUOBGJFSA-N 0.000 description 1
- ZVFVBBGVOILKPO-WHFBIAKZSA-N Ala-Gly-Ala Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(O)=O ZVFVBBGVOILKPO-WHFBIAKZSA-N 0.000 description 1
- VNYMOTCMNHJGTG-JBDRJPRFSA-N Ala-Ile-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O VNYMOTCMNHJGTG-JBDRJPRFSA-N 0.000 description 1
- RNHKOQHGYMTHFR-UBHSHLNASA-N Ala-Phe-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](C)N)CC1=CC=CC=C1 RNHKOQHGYMTHFR-UBHSHLNASA-N 0.000 description 1
- FQNILRVJOJBFFC-FXQIFTODSA-N Ala-Pro-Asp Chemical compound C[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(=O)O)C(=O)O)N FQNILRVJOJBFFC-FXQIFTODSA-N 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- WOPFJPHVBWKZJH-SRVKXCTJSA-N Arg-Arg-Val Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(O)=O WOPFJPHVBWKZJH-SRVKXCTJSA-N 0.000 description 1
- IIABBYGHLYWVOS-FXQIFTODSA-N Arg-Asn-Ser Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O IIABBYGHLYWVOS-FXQIFTODSA-N 0.000 description 1
- DXQIQUIQYAGRCC-CIUDSAMLSA-N Arg-Asp-Gln Chemical compound C(C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N)CN=C(N)N DXQIQUIQYAGRCC-CIUDSAMLSA-N 0.000 description 1
- FEZJJKXNPSEYEV-CIUDSAMLSA-N Arg-Gln-Ala Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(O)=O FEZJJKXNPSEYEV-CIUDSAMLSA-N 0.000 description 1
- PTVGLOCPAVYPFG-CIUDSAMLSA-N Arg-Gln-Asp Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O PTVGLOCPAVYPFG-CIUDSAMLSA-N 0.000 description 1
- OQCWXQJLCDPRHV-UWVGGRQHSA-N Arg-Gly-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC(C)C)C(O)=O OQCWXQJLCDPRHV-UWVGGRQHSA-N 0.000 description 1
- UBCPNBUIQNMDNH-NAKRPEOUSA-N Arg-Ile-Ala Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O UBCPNBUIQNMDNH-NAKRPEOUSA-N 0.000 description 1
- JEXPNDORFYHJTM-IHRRRGAJSA-N Arg-Leu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCCN=C(N)N JEXPNDORFYHJTM-IHRRRGAJSA-N 0.000 description 1
- COXMUHNBYCVVRG-DCAQKATOSA-N Arg-Leu-Ser Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O COXMUHNBYCVVRG-DCAQKATOSA-N 0.000 description 1
- CLICCYPMVFGUOF-IHRRRGAJSA-N Arg-Lys-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O CLICCYPMVFGUOF-IHRRRGAJSA-N 0.000 description 1
- XRNXPIGJPQHCPC-RCWTZXSCSA-N Arg-Thr-Val Chemical compound CC(C)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)O)C(O)=O XRNXPIGJPQHCPC-RCWTZXSCSA-N 0.000 description 1
- NMTANZXPDAHUKU-ULQDDVLXSA-N Arg-Tyr-Lys Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(O)=O)CC1=CC=C(O)C=C1 NMTANZXPDAHUKU-ULQDDVLXSA-N 0.000 description 1
- VDCIPFYVCICPEC-FXQIFTODSA-N Asn-Arg-Ala Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(O)=O VDCIPFYVCICPEC-FXQIFTODSA-N 0.000 description 1
- CIBWFJFMOBIFTE-CIUDSAMLSA-N Asn-Arg-Gln Chemical compound C(C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)N)N)CN=C(N)N CIBWFJFMOBIFTE-CIUDSAMLSA-N 0.000 description 1
- ZKDGORKGHPCZOV-DCAQKATOSA-N Asn-His-Arg Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](CC(=O)N)N ZKDGORKGHPCZOV-DCAQKATOSA-N 0.000 description 1
- QUAWOKPCAKCHQL-SRVKXCTJSA-N Asn-His-Lys Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)N)N QUAWOKPCAKCHQL-SRVKXCTJSA-N 0.000 description 1
- ZLGKHJHFYSRUBH-FXQIFTODSA-N Asp-Arg-Asp Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(O)=O ZLGKHJHFYSRUBH-FXQIFTODSA-N 0.000 description 1
- NYQHSUGFEWDWPD-ACZMJKKPSA-N Asp-Gln-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)O)N NYQHSUGFEWDWPD-ACZMJKKPSA-N 0.000 description 1
- PMEHKVHZQKJACS-PEFMBERDSA-N Asp-Gln-Ile Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O PMEHKVHZQKJACS-PEFMBERDSA-N 0.000 description 1
- ZSJFGGSPCCHMNE-LAEOZQHASA-N Asp-Gln-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)O)N ZSJFGGSPCCHMNE-LAEOZQHASA-N 0.000 description 1
- KTTCQQNRRLCIBC-GHCJXIJMSA-N Asp-Ile-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O KTTCQQNRRLCIBC-GHCJXIJMSA-N 0.000 description 1
- AYFVRYXNDHBECD-YUMQZZPRSA-N Asp-Leu-Gly Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O AYFVRYXNDHBECD-YUMQZZPRSA-N 0.000 description 1
- RQHLMGCXCZUOGT-ZPFDUUQYSA-N Asp-Leu-Ile Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O RQHLMGCXCZUOGT-ZPFDUUQYSA-N 0.000 description 1
- UMHUHHJMEXNSIV-CIUDSAMLSA-N Asp-Leu-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(O)=O UMHUHHJMEXNSIV-CIUDSAMLSA-N 0.000 description 1
- QNMKWNONJGKJJC-NHCYSSNCSA-N Asp-Leu-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O QNMKWNONJGKJJC-NHCYSSNCSA-N 0.000 description 1
- HJCGDIGVVWETRO-ZPFDUUQYSA-N Asp-Lys-Ile Chemical compound CC[C@H](C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC(O)=O)C(O)=O HJCGDIGVVWETRO-ZPFDUUQYSA-N 0.000 description 1
- BPTFNDRZKBFMTH-DCAQKATOSA-N Asp-Met-Lys Chemical compound CSCC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)O)N BPTFNDRZKBFMTH-DCAQKATOSA-N 0.000 description 1
- KNDCWFXCFKSEBM-AVGNSLFASA-N Asp-Tyr-Glu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O KNDCWFXCFKSEBM-AVGNSLFASA-N 0.000 description 1
- MFDPBZAFCRKYEY-LAEOZQHASA-N Asp-Val-Gln Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O MFDPBZAFCRKYEY-LAEOZQHASA-N 0.000 description 1
- 239000002028 Biomass Substances 0.000 description 1
- 241000219193 Brassicaceae Species 0.000 description 1
- 241000701489 Cauliflower mosaic virus Species 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- LHJDLVVQRJIURS-SRVKXCTJSA-N Cys-Phe-Asp Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CS)N LHJDLVVQRJIURS-SRVKXCTJSA-N 0.000 description 1
- IMXSCCDUAFEIOE-UHFFFAOYSA-N D-Octopin Natural products OC(=O)C(C)NC(C(O)=O)CCCN=C(N)N IMXSCCDUAFEIOE-UHFFFAOYSA-N 0.000 description 1
- IMXSCCDUAFEIOE-RITPCOANSA-N D-octopine Chemical compound [O-]C(=O)[C@@H](C)[NH2+][C@H](C([O-])=O)CCCNC(N)=[NH2+] IMXSCCDUAFEIOE-RITPCOANSA-N 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- 108010019236 Fucosyltransferases Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- KUYCTNQKTFGPMI-SXHURMOUSA-N Glc(a1-2)Glc(a1-3)Glc(a1-3)Man(a1-2)Man(a1-2)Man(a1-3)[Man(a1-2)Man(a1-3)[Man(a1-2)Man(a1-6)]Man(a1-6)]Man(b1-4)GlcNAc(b1-4)GlcNAc Chemical group O[C@@H]1[C@@H](NC(=O)C)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@@H]3[C@H]([C@@H](O[C@@H]4[C@@H]([C@@H](O[C@@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO[C@@H]3[C@H]([C@@H](O[C@@H]4[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O[C@@H]4[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO[C@@H]4[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O[C@@H]4[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)O3)O)O2)O)[C@@H](CO)O1 KUYCTNQKTFGPMI-SXHURMOUSA-N 0.000 description 1
- INKFLNZBTSNFON-CIUDSAMLSA-N Gln-Ala-Arg Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O INKFLNZBTSNFON-CIUDSAMLSA-N 0.000 description 1
- JSYULGSPLTZDHM-NRPADANISA-N Gln-Ala-Val Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O JSYULGSPLTZDHM-NRPADANISA-N 0.000 description 1
- KVXVVDFOZNYYKZ-DCAQKATOSA-N Gln-Gln-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O KVXVVDFOZNYYKZ-DCAQKATOSA-N 0.000 description 1
- DDNIZQDYXDENIT-FXQIFTODSA-N Gln-Glu-Cys Chemical compound C(CC(=O)N)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CS)C(=O)O)N DDNIZQDYXDENIT-FXQIFTODSA-N 0.000 description 1
- HWEINOMSWQSJDC-SRVKXCTJSA-N Gln-Leu-Arg Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O HWEINOMSWQSJDC-SRVKXCTJSA-N 0.000 description 1
- IULKWYSYZSURJK-AVGNSLFASA-N Gln-Leu-Lys Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(O)=O IULKWYSYZSURJK-AVGNSLFASA-N 0.000 description 1
- UWKPRVKWEKEMSY-DCAQKATOSA-N Gln-Lys-Gln Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(O)=O UWKPRVKWEKEMSY-DCAQKATOSA-N 0.000 description 1
- NMYFPKCIGUJMIK-GUBZILKMSA-N Gln-Met-Gln Chemical compound CSCC[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CCC(=O)N)N NMYFPKCIGUJMIK-GUBZILKMSA-N 0.000 description 1
- LVRKAFPPFJRIOF-GARJFASQSA-N Gln-Met-Pro Chemical compound CSCC[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCC(=O)N)N LVRKAFPPFJRIOF-GARJFASQSA-N 0.000 description 1
- VHLZDSUANXBJHW-QWRGUYRKSA-N Gln-Phe Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 VHLZDSUANXBJHW-QWRGUYRKSA-N 0.000 description 1
- RONJIBWTGKVKFY-HTUGSXCWSA-N Gln-Thr-Phe Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@H](CCC(=O)N)N)O RONJIBWTGKVKFY-HTUGSXCWSA-N 0.000 description 1
- WTJIWXMJESRHMM-XDTLVQLUSA-N Gln-Tyr-Ala Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C)C(O)=O WTJIWXMJESRHMM-XDTLVQLUSA-N 0.000 description 1
- GTBXHETZPUURJE-KKUMJFAQSA-N Gln-Tyr-Arg Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O GTBXHETZPUURJE-KKUMJFAQSA-N 0.000 description 1
- VDMABHYXBULDGN-LAEOZQHASA-N Gln-Val-Asp Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O VDMABHYXBULDGN-LAEOZQHASA-N 0.000 description 1
- VTTSANCGJWLPNC-ZPFDUUQYSA-N Glu-Arg-Ile Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O VTTSANCGJWLPNC-ZPFDUUQYSA-N 0.000 description 1
- SRZLHYPAOXBBSB-HJGDQZAQSA-N Glu-Arg-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SRZLHYPAOXBBSB-HJGDQZAQSA-N 0.000 description 1
- AFODTOLGSZQDSL-PEFMBERDSA-N Glu-Asn-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCC(=O)O)N AFODTOLGSZQDSL-PEFMBERDSA-N 0.000 description 1
- SBCYJMOOHUDWDA-NUMRIWBASA-N Glu-Asp-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SBCYJMOOHUDWDA-NUMRIWBASA-N 0.000 description 1
- VGBSZQSKQRMLHD-MNXVOIDGSA-N Glu-Leu-Ile Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O VGBSZQSKQRMLHD-MNXVOIDGSA-N 0.000 description 1
- GJBUAAAIZSRCDC-GVXVVHGQSA-N Glu-Leu-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O GJBUAAAIZSRCDC-GVXVVHGQSA-N 0.000 description 1
- HRBYTAIBKPNZKQ-AVGNSLFASA-N Glu-Lys-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCC(O)=O HRBYTAIBKPNZKQ-AVGNSLFASA-N 0.000 description 1
- QDMVXRNLOPTPIE-WDCWCFNPSA-N Glu-Lys-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O QDMVXRNLOPTPIE-WDCWCFNPSA-N 0.000 description 1
- JDUKCSSHWNIQQZ-IHRRRGAJSA-N Glu-Phe-Glu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O JDUKCSSHWNIQQZ-IHRRRGAJSA-N 0.000 description 1
- GMVCSRBOSIUTFC-FXQIFTODSA-N Glu-Ser-Glu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(O)=O GMVCSRBOSIUTFC-FXQIFTODSA-N 0.000 description 1
- HVKAAUOFFTUSAA-XDTLVQLUSA-N Glu-Tyr-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C)C(O)=O HVKAAUOFFTUSAA-XDTLVQLUSA-N 0.000 description 1
- QXUPRMQJDWJDFR-NRPADANISA-N Glu-Val-Ser Chemical compound CC(C)[C@H](NC(=O)[C@@H](N)CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O QXUPRMQJDWJDFR-NRPADANISA-N 0.000 description 1
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 1
- RLFSBAPJTYKSLG-WHFBIAKZSA-N Gly-Ala-Asp Chemical compound NCC(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(O)=O RLFSBAPJTYKSLG-WHFBIAKZSA-N 0.000 description 1
- QSDKBRMVXSWAQE-BFHQHQDPSA-N Gly-Ala-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)CN QSDKBRMVXSWAQE-BFHQHQDPSA-N 0.000 description 1
- OCQUNKSFDYDXBG-QXEWZRGKSA-N Gly-Arg-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CCCN=C(N)N OCQUNKSFDYDXBG-QXEWZRGKSA-N 0.000 description 1
- WKJKBELXHCTHIJ-WPRPVWTQSA-N Gly-Arg-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CCCN=C(N)N WKJKBELXHCTHIJ-WPRPVWTQSA-N 0.000 description 1
- OCDLPQDYTJPWNG-YUMQZZPRSA-N Gly-Asn-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)CN OCDLPQDYTJPWNG-YUMQZZPRSA-N 0.000 description 1
- GRIRDMVMJJDZKV-RCOVLWMOSA-N Gly-Asn-Val Chemical compound [H]NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O GRIRDMVMJJDZKV-RCOVLWMOSA-N 0.000 description 1
- DTRUBYPMMVPQPD-YUMQZZPRSA-N Gly-Gln-Arg Chemical compound [H]NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O DTRUBYPMMVPQPD-YUMQZZPRSA-N 0.000 description 1
- YZPVGIVFMZLQMM-YUMQZZPRSA-N Gly-Gln-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)CN YZPVGIVFMZLQMM-YUMQZZPRSA-N 0.000 description 1
- VAXIVIPMCTYSHI-YUMQZZPRSA-N Gly-His-Asp Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)CN VAXIVIPMCTYSHI-YUMQZZPRSA-N 0.000 description 1
- HKSNHPVETYYJBK-LAEOZQHASA-N Gly-Ile-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)CN HKSNHPVETYYJBK-LAEOZQHASA-N 0.000 description 1
- ITZOBNKQDZEOCE-NHCYSSNCSA-N Gly-Ile-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)CN ITZOBNKQDZEOCE-NHCYSSNCSA-N 0.000 description 1
- COVXELOAORHTND-LSJOCFKGSA-N Gly-Ile-Val Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(O)=O COVXELOAORHTND-LSJOCFKGSA-N 0.000 description 1
- MIIVFRCYJABHTQ-ONGXEEELSA-N Gly-Leu-Val Chemical compound [H]NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O MIIVFRCYJABHTQ-ONGXEEELSA-N 0.000 description 1
- WDXLKVQATNEAJQ-BQBZGAKWSA-N Gly-Pro-Asp Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(O)=O WDXLKVQATNEAJQ-BQBZGAKWSA-N 0.000 description 1
- IALQAMYQJBZNSK-WHFBIAKZSA-N Gly-Ser-Asn Chemical compound [H]NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O IALQAMYQJBZNSK-WHFBIAKZSA-N 0.000 description 1
- RIYIFUFFFBIOEU-KBPBESRZSA-N Gly-Tyr-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CC=C(O)C=C1 RIYIFUFFFBIOEU-KBPBESRZSA-N 0.000 description 1
- SYOJVRNQCXYEOV-XVKPBYJWSA-N Gly-Val-Glu Chemical compound [H]NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O SYOJVRNQCXYEOV-XVKPBYJWSA-N 0.000 description 1
- KSOBNUBCYHGUKH-UWVGGRQHSA-N Gly-Val-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)CN KSOBNUBCYHGUKH-UWVGGRQHSA-N 0.000 description 1
- UJWYPUUXIAKEES-CUJWVEQBSA-N His-Cys-Thr Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)O)C(O)=O UJWYPUUXIAKEES-CUJWVEQBSA-N 0.000 description 1
- BSVLMPMIXPQNKC-KBPBESRZSA-N His-Phe-Gly Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)NCC(O)=O BSVLMPMIXPQNKC-KBPBESRZSA-N 0.000 description 1
- BZAQOPHNBFOOJS-DCAQKATOSA-N His-Pro-Asp Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(O)=O BZAQOPHNBFOOJS-DCAQKATOSA-N 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- BOTVMTSMOUSDRW-GMOBBJLQSA-N Ile-Arg-Asn Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(N)=O)C(O)=O BOTVMTSMOUSDRW-GMOBBJLQSA-N 0.000 description 1
- CWJQMCPYXNVMBS-STECZYCISA-N Ile-Arg-Tyr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N CWJQMCPYXNVMBS-STECZYCISA-N 0.000 description 1
- IDAHFEPYTJJZFD-PEFMBERDSA-N Ile-Asp-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N IDAHFEPYTJJZFD-PEFMBERDSA-N 0.000 description 1
- QSPLUJGYOPZINY-ZPFDUUQYSA-N Ile-Asp-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)O)N QSPLUJGYOPZINY-ZPFDUUQYSA-N 0.000 description 1
- WNQKUUQIVDDAFA-ZPFDUUQYSA-N Ile-Gln-Met Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCSC)C(=O)O)N WNQKUUQIVDDAFA-ZPFDUUQYSA-N 0.000 description 1
- HTDRTKMNJRRYOJ-SIUGBPQLSA-N Ile-Gln-Tyr Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 HTDRTKMNJRRYOJ-SIUGBPQLSA-N 0.000 description 1
- KIMHKBDJQQYLHU-PEFMBERDSA-N Ile-Glu-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)O)N KIMHKBDJQQYLHU-PEFMBERDSA-N 0.000 description 1
- SPQWWEZBHXHUJN-KBIXCLLPSA-N Ile-Glu-Ser Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O SPQWWEZBHXHUJN-KBIXCLLPSA-N 0.000 description 1
- SLQVFYWBGNNOTK-BYULHYEWSA-N Ile-Gly-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)NCC(=O)N[C@@H](CC(=O)N)C(=O)O)N SLQVFYWBGNNOTK-BYULHYEWSA-N 0.000 description 1
- KFVUBLZRFSVDGO-BYULHYEWSA-N Ile-Gly-Asp Chemical compound CC[C@H](C)[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC(O)=O KFVUBLZRFSVDGO-BYULHYEWSA-N 0.000 description 1
- GVNNAHIRSDRIII-AJNGGQMLSA-N Ile-Lys-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)O)N GVNNAHIRSDRIII-AJNGGQMLSA-N 0.000 description 1
- IITVUURPOYGCTD-NAKRPEOUSA-N Ile-Pro-Ala Chemical compound CC[C@H](C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O IITVUURPOYGCTD-NAKRPEOUSA-N 0.000 description 1
- PXKACEXYLPBMAD-JBDRJPRFSA-N Ile-Ser-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O)N PXKACEXYLPBMAD-JBDRJPRFSA-N 0.000 description 1
- HXIDVIFHRYRXLZ-NAKRPEOUSA-N Ile-Ser-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)O)N HXIDVIFHRYRXLZ-NAKRPEOUSA-N 0.000 description 1
- YJRSIJZUIUANHO-NAKRPEOUSA-N Ile-Val-Ala Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)O)N YJRSIJZUIUANHO-NAKRPEOUSA-N 0.000 description 1
- YHFPHRUWZMEOIX-CYDGBPFRSA-N Ile-Val-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)O)N YHFPHRUWZMEOIX-CYDGBPFRSA-N 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010065920 Insulin Lispro Proteins 0.000 description 1
- 108010025815 Kanamycin Kinase Proteins 0.000 description 1
- HGCNKOLVKRAVHD-UHFFFAOYSA-N L-Met-L-Phe Natural products CSCCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 HGCNKOLVKRAVHD-UHFFFAOYSA-N 0.000 description 1
- FADYJNXDPBKVCA-UHFFFAOYSA-N L-Phenylalanyl-L-lysin Natural products NCCCCC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FADYJNXDPBKVCA-UHFFFAOYSA-N 0.000 description 1
- KFKWRHQBZQICHA-STQMWFEESA-N L-leucyl-L-phenylalanine Natural products CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 KFKWRHQBZQICHA-STQMWFEESA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- GRZSCTXVCDUIPO-SRVKXCTJSA-N Leu-Arg-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(O)=O GRZSCTXVCDUIPO-SRVKXCTJSA-N 0.000 description 1
- CCQLQKZTXZBXTN-NHCYSSNCSA-N Leu-Gly-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(O)=O CCQLQKZTXZBXTN-NHCYSSNCSA-N 0.000 description 1
- POZULHZYLPGXMR-ONGXEEELSA-N Leu-Gly-Val Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O POZULHZYLPGXMR-ONGXEEELSA-N 0.000 description 1
- DBSLVQBXKVKDKJ-BJDJZHNGSA-N Leu-Ile-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O DBSLVQBXKVKDKJ-BJDJZHNGSA-N 0.000 description 1
- QJXHMYMRGDOHRU-NHCYSSNCSA-N Leu-Ile-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(O)=O QJXHMYMRGDOHRU-NHCYSSNCSA-N 0.000 description 1
- OMHLATXVNQSALM-FQUUOJAGSA-N Leu-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC(C)C)N OMHLATXVNQSALM-FQUUOJAGSA-N 0.000 description 1
- KTOIECMYZZGVSI-BZSNNMDCSA-N Leu-Phe-His Chemical compound C([C@H](NC(=O)[C@@H](N)CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(O)=O)C1=CC=CC=C1 KTOIECMYZZGVSI-BZSNNMDCSA-N 0.000 description 1
- ZJZNLRVCZWUONM-JXUBOQSCSA-N Leu-Thr-Ala Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O ZJZNLRVCZWUONM-JXUBOQSCSA-N 0.000 description 1
- LCNASHSOFMRYFO-WDCWCFNPSA-N Leu-Thr-Gln Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCC(N)=O LCNASHSOFMRYFO-WDCWCFNPSA-N 0.000 description 1
- FBNPMTNBFFAMMH-AVGNSLFASA-N Leu-Val-Arg Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N FBNPMTNBFFAMMH-AVGNSLFASA-N 0.000 description 1
- YQFZRHYZLARWDY-IHRRRGAJSA-N Leu-Val-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCCN YQFZRHYZLARWDY-IHRRRGAJSA-N 0.000 description 1
- HIIZIQUUHIXUJY-GUBZILKMSA-N Lys-Asp-Gln Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O HIIZIQUUHIXUJY-GUBZILKMSA-N 0.000 description 1
- PGBPWPTUOSCNLE-JYJNAYRXSA-N Lys-Gln-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCCN)N PGBPWPTUOSCNLE-JYJNAYRXSA-N 0.000 description 1
- IRRZDAIFYHNIIN-JYJNAYRXSA-N Lys-Gln-Tyr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O IRRZDAIFYHNIIN-JYJNAYRXSA-N 0.000 description 1
- GQZMPWBZQALKJO-UWVGGRQHSA-N Lys-Gly-Arg Chemical compound [H]N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O GQZMPWBZQALKJO-UWVGGRQHSA-N 0.000 description 1
- WVJNGSFKBKOKRV-AJNGGQMLSA-N Lys-Leu-Ile Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O WVJNGSFKBKOKRV-AJNGGQMLSA-N 0.000 description 1
- OIQSIMFSVLLWBX-VOAKCMCISA-N Lys-Leu-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OIQSIMFSVLLWBX-VOAKCMCISA-N 0.000 description 1
- XOQMURBBIXRRCR-SRVKXCTJSA-N Lys-Lys-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCCN XOQMURBBIXRRCR-SRVKXCTJSA-N 0.000 description 1
- JOSAKOKSPXROGQ-BJDJZHNGSA-N Lys-Ser-Ile Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O JOSAKOKSPXROGQ-BJDJZHNGSA-N 0.000 description 1
- IOQWIOPSKJOEKI-SRVKXCTJSA-N Lys-Ser-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O IOQWIOPSKJOEKI-SRVKXCTJSA-N 0.000 description 1
- ZUGVARDEGWMMLK-SRVKXCTJSA-N Lys-Ser-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCCN ZUGVARDEGWMMLK-SRVKXCTJSA-N 0.000 description 1
- DYJOORGDQIGZAS-DCAQKATOSA-N Lys-Ser-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)N DYJOORGDQIGZAS-DCAQKATOSA-N 0.000 description 1
- DLCAXBGXGOVUCD-PPCPHDFISA-N Lys-Thr-Ile Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O DLCAXBGXGOVUCD-PPCPHDFISA-N 0.000 description 1
- XATKLFSXFINPSB-JYJNAYRXSA-N Lys-Tyr-Gln Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(N)=O)C(O)=O XATKLFSXFINPSB-JYJNAYRXSA-N 0.000 description 1
- 101710124594 Malate dehydrogenase [NADP], chloroplastic Proteins 0.000 description 1
- OSOLWRWQADPDIQ-DCAQKATOSA-N Met-Asp-Leu Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O OSOLWRWQADPDIQ-DCAQKATOSA-N 0.000 description 1
- JCMMNFZUKMMECJ-DCAQKATOSA-N Met-Lys-Asn Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O JCMMNFZUKMMECJ-DCAQKATOSA-N 0.000 description 1
- 108010093077 N-Acetylglucosaminyltransferases Proteins 0.000 description 1
- PIJXCSUPSNFXNE-QRZOAFCBSA-N N-acetyl-4-(N-acetylglucosaminyl)muramoyl-L-alanyl-D-isoglutamine Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@@H]1[C@@H](NC(C)=O)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 PIJXCSUPSNFXNE-QRZOAFCBSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108010067902 Peptide Library Proteins 0.000 description 1
- GNUCSNWOCQFMMC-UFYCRDLUSA-N Phe-Arg-Phe Chemical compound C([C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 GNUCSNWOCQFMMC-UFYCRDLUSA-N 0.000 description 1
- DJPXNKUDJKGQEE-BZSNNMDCSA-N Phe-Asp-Phe Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O DJPXNKUDJKGQEE-BZSNNMDCSA-N 0.000 description 1
- CUMXHKAOHNWRFQ-BZSNNMDCSA-N Phe-Asp-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=CC=C1 CUMXHKAOHNWRFQ-BZSNNMDCSA-N 0.000 description 1
- HPECNYCQLSVCHH-BZSNNMDCSA-N Phe-Cys-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)O)N HPECNYCQLSVCHH-BZSNNMDCSA-N 0.000 description 1
- NKLDZIPTGKBDBB-HTUGSXCWSA-N Phe-Gln-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC1=CC=CC=C1)N)O NKLDZIPTGKBDBB-HTUGSXCWSA-N 0.000 description 1
- FMMIYCMOVGXZIP-AVGNSLFASA-N Phe-Glu-Asn Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O FMMIYCMOVGXZIP-AVGNSLFASA-N 0.000 description 1
- MPFGIYLYWUCSJG-AVGNSLFASA-N Phe-Glu-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 MPFGIYLYWUCSJG-AVGNSLFASA-N 0.000 description 1
- PSKRILMFHNIUAO-JYJNAYRXSA-N Phe-Glu-Lys Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)O)N PSKRILMFHNIUAO-JYJNAYRXSA-N 0.000 description 1
- CSDMCMITJLKBAH-SOUVJXGZSA-N Phe-Glu-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC2=CC=CC=C2)N)C(=O)O CSDMCMITJLKBAH-SOUVJXGZSA-N 0.000 description 1
- JEBWZLWTRPZQRX-QWRGUYRKSA-N Phe-Gly-Asp Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O JEBWZLWTRPZQRX-QWRGUYRKSA-N 0.000 description 1
- YZJKNDCEPDDIDA-BZSNNMDCSA-N Phe-His-Lys Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(O)=O)NC(=O)[C@@H](N)CC=1C=CC=CC=1)C1=CN=CN1 YZJKNDCEPDDIDA-BZSNNMDCSA-N 0.000 description 1
- JQLQUPIYYJXZLJ-ZEWNOJEFSA-N Phe-Ile-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=CC=C1 JQLQUPIYYJXZLJ-ZEWNOJEFSA-N 0.000 description 1
- MJAYDXWQQUOURZ-JYJNAYRXSA-N Phe-Lys-Gln Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(O)=O MJAYDXWQQUOURZ-JYJNAYRXSA-N 0.000 description 1
- OHIYMVFLQXTZAW-UFYCRDLUSA-N Phe-Met-Phe Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O OHIYMVFLQXTZAW-UFYCRDLUSA-N 0.000 description 1
- RYQWALWYQWBUKN-FHWLQOOXSA-N Phe-Phe-Glu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O RYQWALWYQWBUKN-FHWLQOOXSA-N 0.000 description 1
- HBXAOEBRGLCLIW-AVGNSLFASA-N Phe-Ser-Gln Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N HBXAOEBRGLCLIW-AVGNSLFASA-N 0.000 description 1
- BPCLGWHVPVTTFM-QWRGUYRKSA-N Phe-Ser-Gly Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)NCC(O)=O BPCLGWHVPVTTFM-QWRGUYRKSA-N 0.000 description 1
- DBNGDEAQXGFGRA-ACRUOGEOSA-N Phe-Tyr-Lys Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CCCCN)C(=O)O)N DBNGDEAQXGFGRA-ACRUOGEOSA-N 0.000 description 1
- KUSYCSMTTHSZOA-DZKIICNBSA-N Phe-Val-Gln Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)N KUSYCSMTTHSZOA-DZKIICNBSA-N 0.000 description 1
- FXEKNHAJIMHRFJ-ULQDDVLXSA-N Phe-Val-His Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CC2=CC=CC=C2)N FXEKNHAJIMHRFJ-ULQDDVLXSA-N 0.000 description 1
- 108010047620 Phytohemagglutinins Proteins 0.000 description 1
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
- 241000709992 Potato virus X Species 0.000 description 1
- NHDVNAKDACFHPX-GUBZILKMSA-N Pro-Arg-Ala Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(O)=O NHDVNAKDACFHPX-GUBZILKMSA-N 0.000 description 1
- ZSKJPKFTPQCPIH-RCWTZXSCSA-N Pro-Arg-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O ZSKJPKFTPQCPIH-RCWTZXSCSA-N 0.000 description 1
- UTAUEDINXUMHLG-FXQIFTODSA-N Pro-Asp-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H]1CCCN1 UTAUEDINXUMHLG-FXQIFTODSA-N 0.000 description 1
- HXOLCSYHGRNXJJ-IHRRRGAJSA-N Pro-Asp-Phe Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O HXOLCSYHGRNXJJ-IHRRRGAJSA-N 0.000 description 1
- XUSDDSLCRPUKLP-QXEWZRGKSA-N Pro-Asp-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]1CCCN1 XUSDDSLCRPUKLP-QXEWZRGKSA-N 0.000 description 1
- DGDCSVGVWWAJRS-AVGNSLFASA-N Pro-Val-His Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@@H]2CCCN2 DGDCSVGVWWAJRS-AVGNSLFASA-N 0.000 description 1
- FHJQROWZEJFZPO-SRVKXCTJSA-N Pro-Val-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]1CCCN1 FHJQROWZEJFZPO-SRVKXCTJSA-N 0.000 description 1
- 101100209986 Rattus norvegicus Slc18a1 gene Proteins 0.000 description 1
- 108091058545 Secretory proteins Proteins 0.000 description 1
- 102000040739 Secretory proteins Human genes 0.000 description 1
- 101710196768 Seed lectin Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- WTWGOQRNRFHFQD-JBDRJPRFSA-N Ser-Ala-Ile Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O WTWGOQRNRFHFQD-JBDRJPRFSA-N 0.000 description 1
- OYEDZGNMSBZCIM-XGEHTFHBSA-N Ser-Arg-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OYEDZGNMSBZCIM-XGEHTFHBSA-N 0.000 description 1
- DKKGAAJTDKHWOD-BIIVOSGPSA-N Ser-Asn-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)N)NC(=O)[C@H](CO)N)C(=O)O DKKGAAJTDKHWOD-BIIVOSGPSA-N 0.000 description 1
- BGOWRLSWJCVYAQ-CIUDSAMLSA-N Ser-Asp-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O BGOWRLSWJCVYAQ-CIUDSAMLSA-N 0.000 description 1
- IXUGADGDCQDLSA-FXQIFTODSA-N Ser-Gln-Gln Chemical compound C(CC(=O)N)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CO)N IXUGADGDCQDLSA-FXQIFTODSA-N 0.000 description 1
- YMAWDPHQVABADW-CIUDSAMLSA-N Ser-Gln-Met Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(O)=O YMAWDPHQVABADW-CIUDSAMLSA-N 0.000 description 1
- KJMOINFQVCCSDX-XKBZYTNZSA-N Ser-Gln-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O KJMOINFQVCCSDX-XKBZYTNZSA-N 0.000 description 1
- VDVYTKZBMFADQH-AVGNSLFASA-N Ser-Gln-Tyr Chemical compound OC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 VDVYTKZBMFADQH-AVGNSLFASA-N 0.000 description 1
- MLSQXWSRHURDMF-GARJFASQSA-N Ser-His-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](CO)N)C(=O)O MLSQXWSRHURDMF-GARJFASQSA-N 0.000 description 1
- YUJLIIRMIAGMCQ-CIUDSAMLSA-N Ser-Leu-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YUJLIIRMIAGMCQ-CIUDSAMLSA-N 0.000 description 1
- HHJFMHQYEAAOBM-ZLUOBGJFSA-N Ser-Ser-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O HHJFMHQYEAAOBM-ZLUOBGJFSA-N 0.000 description 1
- PLQWGQUNUPMNOD-KKUMJFAQSA-N Ser-Tyr-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(O)=O PLQWGQUNUPMNOD-KKUMJFAQSA-N 0.000 description 1
- PMTWIUBUQRGCSB-FXQIFTODSA-N Ser-Val-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(O)=O PMTWIUBUQRGCSB-FXQIFTODSA-N 0.000 description 1
- RCOUFINCYASMDN-GUBZILKMSA-N Ser-Val-Met Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCSC)C(O)=O RCOUFINCYASMDN-GUBZILKMSA-N 0.000 description 1
- 101001116809 Solanum tuberosum Patatin group M-1 Proteins 0.000 description 1
- 101001059701 Spodoptera frugiperda Alpha-mannosidase 2 Proteins 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- DGDCHPCRMWEOJR-FQPOAREZSA-N Thr-Ala-Tyr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 DGDCHPCRMWEOJR-FQPOAREZSA-N 0.000 description 1
- VFEHSAJCWWHDBH-RHYQMDGZSA-N Thr-Arg-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(O)=O VFEHSAJCWWHDBH-RHYQMDGZSA-N 0.000 description 1
- DCLBXIWHLVEPMQ-JRQIVUDYSA-N Thr-Asp-Tyr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 DCLBXIWHLVEPMQ-JRQIVUDYSA-N 0.000 description 1
- AHOLTQCAVBSUDP-PPCPHDFISA-N Thr-Ile-Lys Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](N)[C@@H](C)O)C(=O)N[C@@H](CCCCN)C(O)=O AHOLTQCAVBSUDP-PPCPHDFISA-N 0.000 description 1
- MEJHFIOYJHTWMK-VOAKCMCISA-N Thr-Leu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)[C@@H](C)O MEJHFIOYJHTWMK-VOAKCMCISA-N 0.000 description 1
- KKPOGALELPLJTL-MEYUZBJRSA-N Thr-Lys-Tyr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 KKPOGALELPLJTL-MEYUZBJRSA-N 0.000 description 1
- YGCDFAJJCRVQKU-RCWTZXSCSA-N Thr-Pro-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)[C@@H](C)O YGCDFAJJCRVQKU-RCWTZXSCSA-N 0.000 description 1
- KHTIUAKJRUIEMA-HOUAVDHOSA-N Thr-Trp-Asp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](N)[C@H](O)C)C(=O)N[C@@H](CC(O)=O)C(O)=O)=CNC2=C1 KHTIUAKJRUIEMA-HOUAVDHOSA-N 0.000 description 1
- IJKNKFJZOJCKRR-GBALPHGKSA-N Thr-Trp-Ser Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](N)[C@H](O)C)C(=O)N[C@@H](CO)C(O)=O)=CNC2=C1 IJKNKFJZOJCKRR-GBALPHGKSA-N 0.000 description 1
- KAJRRNHOVMZYBL-IRIUXVKKSA-N Thr-Tyr-Gln Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(N)=O)C(O)=O KAJRRNHOVMZYBL-IRIUXVKKSA-N 0.000 description 1
- FYBFTPLPAXZBOY-KKHAAJSZSA-N Thr-Val-Asp Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O FYBFTPLPAXZBOY-KKHAAJSZSA-N 0.000 description 1
- PWONLXBUSVIZPH-RHYQMDGZSA-N Thr-Val-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)O)N)O PWONLXBUSVIZPH-RHYQMDGZSA-N 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- FKAPNDWDLDWZNF-QEJZJMRPSA-N Trp-Asp-Glu Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N FKAPNDWDLDWZNF-QEJZJMRPSA-N 0.000 description 1
- NLLARHRWSFNEMH-NUTKFTJISA-N Trp-Lys-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)N NLLARHRWSFNEMH-NUTKFTJISA-N 0.000 description 1
- ULHASJWZGUEUNN-XIRDDKMYSA-N Trp-Lys-Ser Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O ULHASJWZGUEUNN-XIRDDKMYSA-N 0.000 description 1
- UIRPULWLRODAEQ-QEJZJMRPSA-N Trp-Ser-Glu Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(O)=O)=CNC2=C1 UIRPULWLRODAEQ-QEJZJMRPSA-N 0.000 description 1
- YJQCOFNZVFGCAF-UHFFFAOYSA-N Tunicamycin II Natural products O1C(CC(O)C2C(C(O)C(O2)N2C(NC(=O)C=C2)=O)O)C(O)C(O)C(NC(=O)C=CCCCCCCCCC(C)C)C1OC1OC(CO)C(O)C(O)C1NC(C)=O YJQCOFNZVFGCAF-UHFFFAOYSA-N 0.000 description 1
- BURPTJBFWIOHEY-UWJYBYFXSA-N Tyr-Ala-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 BURPTJBFWIOHEY-UWJYBYFXSA-N 0.000 description 1
- IXTQGBGHWQEEDE-AVGNSLFASA-N Tyr-Asp-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 IXTQGBGHWQEEDE-AVGNSLFASA-N 0.000 description 1
- LHTGRUZSZOIAKM-SOUVJXGZSA-N Tyr-Glu-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)N)C(=O)O LHTGRUZSZOIAKM-SOUVJXGZSA-N 0.000 description 1
- JWGXUKHIKXZWNG-RYUDHWBXSA-N Tyr-Gly-Gln Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)NCC(=O)N[C@@H](CCC(=O)N)C(=O)O)N)O JWGXUKHIKXZWNG-RYUDHWBXSA-N 0.000 description 1
- KHCSOLAHNLOXJR-BZSNNMDCSA-N Tyr-Leu-Leu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O KHCSOLAHNLOXJR-BZSNNMDCSA-N 0.000 description 1
- DMWNPLOERDAHSY-MEYUZBJRSA-N Tyr-Leu-Thr Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O DMWNPLOERDAHSY-MEYUZBJRSA-N 0.000 description 1
- NVZVJIUDICCMHZ-BZSNNMDCSA-N Tyr-Phe-Ser Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(O)=O NVZVJIUDICCMHZ-BZSNNMDCSA-N 0.000 description 1
- CLEGSEJVGBYZBJ-MEYUZBJRSA-N Tyr-Thr-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H]([C@H](O)C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 CLEGSEJVGBYZBJ-MEYUZBJRSA-N 0.000 description 1
- SQUMHUZLJDUROQ-YDHLFZDLSA-N Tyr-Val-Asp Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O SQUMHUZLJDUROQ-YDHLFZDLSA-N 0.000 description 1
- GOPQNCQSXBJAII-ULQDDVLXSA-N Tyr-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N GOPQNCQSXBJAII-ULQDDVLXSA-N 0.000 description 1
- LABUITCFCAABSV-BPNCWPANSA-N Val-Ala-Tyr Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 LABUITCFCAABSV-BPNCWPANSA-N 0.000 description 1
- XQVRMLRMTAGSFJ-QXEWZRGKSA-N Val-Asp-Arg Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N XQVRMLRMTAGSFJ-QXEWZRGKSA-N 0.000 description 1
- VFOHXOLPLACADK-GVXVVHGQSA-N Val-Gln-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C(C)C)N VFOHXOLPLACADK-GVXVVHGQSA-N 0.000 description 1
- FOADDSDHGRFUOC-DZKIICNBSA-N Val-Glu-Phe Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N FOADDSDHGRFUOC-DZKIICNBSA-N 0.000 description 1
- GMOLURHJBLOBFW-ONGXEEELSA-N Val-Gly-His Chemical compound CC(C)[C@@H](C(=O)NCC(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N GMOLURHJBLOBFW-ONGXEEELSA-N 0.000 description 1
- WJVLTYSHNXRCLT-NHCYSSNCSA-N Val-His-Asp Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CC(=O)O)C(=O)O)N WJVLTYSHNXRCLT-NHCYSSNCSA-N 0.000 description 1
- MLADEWAIYAPAAU-IHRRRGAJSA-N Val-Lys-His Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N MLADEWAIYAPAAU-IHRRRGAJSA-N 0.000 description 1
- JAKHAONCJJZVHT-DCAQKATOSA-N Val-Lys-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)O)N JAKHAONCJJZVHT-DCAQKATOSA-N 0.000 description 1
- OFQGGTGZTOTLGH-NHCYSSNCSA-N Val-Met-Gln Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N OFQGGTGZTOTLGH-NHCYSSNCSA-N 0.000 description 1
- PGQUDQYHWICSAB-NAKRPEOUSA-N Val-Ser-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)N PGQUDQYHWICSAB-NAKRPEOUSA-N 0.000 description 1
- GBIUHAYJGWVNLN-AEJSXWLSSA-N Val-Ser-Pro Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N1CCC[C@@H]1C(=O)O)N GBIUHAYJGWVNLN-AEJSXWLSSA-N 0.000 description 1
- GBIUHAYJGWVNLN-UHFFFAOYSA-N Val-Ser-Pro Natural products CC(C)C(N)C(=O)NC(CO)C(=O)N1CCCC1C(O)=O GBIUHAYJGWVNLN-UHFFFAOYSA-N 0.000 description 1
- 240000004922 Vigna radiata Species 0.000 description 1
- 235000010721 Vigna radiata var radiata Nutrition 0.000 description 1
- 235000011469 Vigna radiata var sublobata Nutrition 0.000 description 1
- 108050001741 Xylosyltransferases Proteins 0.000 description 1
- 102000010199 Xylosyltransferases Human genes 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 108010047495 alanylglycine Proteins 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 108010060035 arginylproline Proteins 0.000 description 1
- 108010077245 asparaginyl-proline Proteins 0.000 description 1
- 108010092854 aspartyllysine Proteins 0.000 description 1
- 210000003578 bacterial chromosome Anatomy 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- AZZMGZXNTDTSME-JUZDKLSSSA-M cefotaxime sodium Chemical compound [Na+].N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 AZZMGZXNTDTSME-JUZDKLSSSA-M 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000033383 cell-cell recognition Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 210000003763 chloroplast Anatomy 0.000 description 1
- 229940088530 claforan Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000009264 composting Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003297 denaturating effect Effects 0.000 description 1
- FCRACOPGPMPSHN-UHFFFAOYSA-N desoxyabscisic acid Natural products OC(=O)C=C(C)C=CC1C(C)=CC(=O)CC1(C)C FCRACOPGPMPSHN-UHFFFAOYSA-N 0.000 description 1
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 230000009144 enzymatic modification Effects 0.000 description 1
- 230000002449 erythroblastic effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 238000010363 gene targeting Methods 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- XBGGUPMXALFZOT-UHFFFAOYSA-N glycyl-L-tyrosine hemihydrate Natural products NCC(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 XBGGUPMXALFZOT-UHFFFAOYSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 108010092114 histidylphenylalanine Proteins 0.000 description 1
- 108010023260 immunoglobulin Fv Proteins 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000029225 intracellular protein transport Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000001573 invertase Substances 0.000 description 1
- ZNJFBWYDHIGLCU-UHFFFAOYSA-N jasmonic acid Natural products CCC=CCC1C(CC(O)=O)CCC1=O ZNJFBWYDHIGLCU-UHFFFAOYSA-N 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 108010053037 kyotorphin Proteins 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 108010044056 leucyl-phenylalanine Proteins 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 108010064235 lysylglycine Proteins 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 108010083819 mannosyl-oligosaccharide 1,3 - 1,6-alpha-mannosidase Proteins 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 108010068488 methionylphenylalanine Proteins 0.000 description 1
- 210000001589 microsome Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 239000002357 osmotic agent Substances 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000029553 photosynthesis Effects 0.000 description 1
- 238000010672 photosynthesis Methods 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 230000008635 plant growth Effects 0.000 description 1
- 210000002706 plastid Anatomy 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 230000032361 posttranscriptional gene silencing Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 210000003660 reticulum Anatomy 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 108010048818 seryl-histidine Proteins 0.000 description 1
- 108010071207 serylmethionine Proteins 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 230000009131 signaling function Effects 0.000 description 1
- 238000009331 sowing Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 230000004960 subcellular localization Effects 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 238000009966 trimming Methods 0.000 description 1
- ZHSGGJXRNHWHRS-VIDYELAYSA-N tunicamycin Chemical compound O([C@H]1[C@@H]([C@H]([C@@H](O)[C@@H](CC(O)[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C(NC(=O)C=C2)=O)O)O1)O)NC(=O)/C=C/CC(C)C)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O ZHSGGJXRNHWHRS-VIDYELAYSA-N 0.000 description 1
- MEYZYGMYMLNUHJ-UHFFFAOYSA-N tunicamycin Natural products CC(C)CCCCCCCCCC=CC(=O)NC1C(O)C(O)C(CC(O)C2OC(C(O)C2O)N3C=CC(=O)NC3=O)OC1OC4OC(CO)C(O)C(O)C4NC(=O)C MEYZYGMYMLNUHJ-UHFFFAOYSA-N 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
- C12N9/1051—Hexosyltransferases (2.4.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
- C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
- C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
- C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
Definitions
- the present invention relates to plant GnTI sequences, in particular, plant nucleic acid sequences encoding the enzyme N-acetyl glucosaminyl transferase I (GnTI), as well as GntI antisense or sense constructs, deduced therefrom, and their translation products, antibodies directed against said translation products as well as the use of the sequence information for the production of transformed microorganisms and of transgenic plants, including those with reduced or lacking N-acetyl glucosaminyl transferase I activity.
- GnTI N-acetyl glucosaminyl transferase I
- Such plants with reduced or lacking N-acetyl glucosaminyl transferase I activity are of great importance for the production of glycoproteins of specific constitution with respect to their sugar residues.
- glycoproteins are cotranslationally assembled in the endoplasmatic reticulum (ER) (i.e. during import into the ER lumen) by the attachment of initially membrane bound glycans (via dolichol pyrophosphate) to specific asparagine residues in the growing polypeptide chain (N-glycosylation).
- ER endoplasmatic reticulum
- sugar units located at the surface of the folded polypeptide chain are subjected to further trimming and modification reactions (ref. 1) in the Golgi cisternae.
- typical basic Glc 3 Man 9 GlcNAc 2 units of the high-mannose type are formed by means of different glycosidases and glycosyl transferases in the ER, which during the passage through the different Golgi cisternae are subsequently converted to so-called complex glycans.
- the latter are characterized by less mannose units and the presence of additional sugar residues, such as fucose, galactose and/or xylose in plants and sialic acid (N-acetyl neuraminic acid, NeuNAc) in mammals (ref. 1,2,3).
- the extent of the modifications can differ between glycoproteins.
- Single polypetide chains may carry heterogeneous sugar chains.
- glycosylation pattern may vary for a specific polypeptide (tissue specific differences), and does not always have to be uniform with respect to a specific glycosylation site, which is referred to as microheterogeneity (ref. 4,5).
- microheterogeneity a specific glycosylation site
- asparagine bound glycans is barely understood, which i.a. results from the fact, that said glycans may serve several functions (ref. 6).
- glycans of a more simple oligomannosyl type e.g. protection of a polypeptide chain from proteolytic degradation can also be achieved by glycans of a more simple oligomannosyl type (ref.7).
- glycoproteins are highly important in medicine and research.
- large scale isolation of glycoproteins is time-consuming and expensive.
- the direct use of glycoproteins isolated conventionally often raises problems, since upon administration as a therapeutic, single residues of the glycan components may cause undesired side effects.
- the glycan component predominantly contributes to the physico-chemical properties (such as folding, stability and solubility) of the glycoproteins.
- isolated glycoproteins as already mentioned above, rarely carry uniform sugar residues, which is referred to as microheterogeneity.
- glycoproteins for medicine and research, yeasts prove to be unsuitable, since they are only able to perform glycosylations of the so-called high-mannose type. While insects and higher plants exhibit complex glycoprotein modifications, these, however, differ from those of animals. Therefore, glycoproteins isolated from plants have a strong antigenic effect in mammals. In most cases, animal organisms with glycosylation defects are not viable, since terminal glycan residues (e.g. of membraneous glycoproteins) mostly possess biological signal function and are indispensable for cell-cell-recognition during the course of embryogenesis. Mammalian cell lines with defined glycosylation defects already exist, the cultivation of which, however, is labour-intensive and expensive.
- glycosylation mutants are very rare. These defects, summarized under HEMPAS (Hereditary Erythroblastic Multinuclearity with a Positive Acidified Serum lysis test) (ref. 10,11), are based either on a deficiency in mannosidase II and/or low levels of the enzyme N-acetyl glucosaminyl transferase II (GnTII), and have strongly limiting effects on the viability of the mutated organism. GntI knock-out mice, in which the gene for GnTI has been destroyed, already die in utero of multiple developmental defects (personal communication, H. Schachter, Toronto).
- HEMPAS Hereditary Erythroblastic Multinuclearity with a Positive Acidified Serum lysis test
- glycoproteins mainly carried glycans of the Man 5 GlcNAc 2 type, indicating a defect in N-acetyl glucosaminyl transferase I (GnTI) (ref. 8).
- GnTI N-acetyl glucosaminyl transferase I
- the Arabidopsis cgl mutants lacked GnTI activity (ref. 13), which normally catalyzes the first reaction in the synthetic pathway to complex modified sugar chains (ref. 1).
- GnTI activity normally catalyzes the first reaction in the synthetic pathway to complex modified sugar chains
- the viability of the mutated plants is not affected.
- plants are suggested as a putative source for the production of pharmaceutically relevant glycoproteins or vaccines (ref. 14,15).
- glycoproteins isolated from plants may cause severe immune reactions in mammals, which up to now obstructed the production of heterologous glycoproteins in cultivated plants.
- FIG. 3 demonstrates, the homology of the first determined plant GntI sequence from potato ( Solanum tuberosum L., St) is extraordinary low in comparison to the corresponding known sequences of animal organisms (only 30-40% identity at the protein level, cf. FIG. 3A). Therefore, by the use of heterologous GntI gene sequences an efficient reduction of endogenous complex glycoprotein modification in plants by means of antisense or sense suppression, respectively, (ref. 21), probably cannot be achieved.
- the present invention comprises different N-acetyl glucosaminyl transferase I enzymes (EC 2.4.1.101) from plants, e.g. potato ( Solanum tuberosum L.), tobacco ( Nicotiana tabacum L.) and Arabidopsis thaliana (L.).
- the present invention relates to enzymes, which exhibit or contain the amino acid sequences given in FIGS. 2 and 3B as well as in the accompanying sequence protocol.
- the invention comprises enzymes, which are derived from amino acid sequences of the above mentioned enzymes by amino acid substitution, deletion, insertion, modification or by C-terminal and/or N-terminal truncation and/or extension, and which—if showing enzymatic activity—exhibit a specificity comparable to that of the starting enzyme,. i.e. N-acetyl glucosaminyl transferase I activity, and optionally a comparable activity.
- an activity is understood, which is in the range of up to 100% above or below that of the starting enzyme.
- derived enzymes or proteins with very low or completely lacking enzymatic activity which is detectable by means of one or more of the tests mentioned as follows.
- the enzyme activity is determined by a standard assay, which is performed with microsomal fractions either under radioactive conditions, e.g. using UDP-[6- 3 H]GlcNAc as a substrate (ref. 13) or non-radioactive conditions (HPLC method; ref 20).
- Plant GnTI activity can be detected on the subcellular level in Golgi fractions (ref. 21). On account of low yields, however, it is almost impossible to enrich the enzyme from plants.
- an enzyme derived according to the present invention may optionally be defined as an enzyme, for which a DNA sequence encoding the enzyme can be determined or derived, which hybridizes to a DNA sequence encoding the starting enzyme or to a complementary sequence under stringent conditions, as defined as follows.
- an enzyme derived in such a manner represents an isoform, which comprises the amino acids 74 to 446 of the amino acid sequence illustrated in FIG. 2 and in SEQ ID No:1 and 2.
- This isoform i.a. lacks the membrane anchor formed by amino acids 10 to 29.
- this enzyme isoform may be located in the plant cytosol.
- fusion proteins can be mentioned, comprising in addition to an amino acid sequence according to the invention a further protein, which e.g. exhibits a different enzymatic activity or which may be easily detected in another manner, such as by means of fluorescence or phosphorescence or on account of a reactivity with specific antibodies or by binding to suitable affinity matrices.
- the invention comprises fragments of said enzymes, which optionally no longer exhibit any enzymatic activity.
- these fragments show an antigenic effect in a host immunized with said fragments, and may accordingly be employed as an antigen for the production of monoclonal or polyclonal antibodies by immunization of a host with those fragments.
- this invention also relates to N-acetyl glucosaminyl transferase I enzymes from other varieties and plant species, which are obtainable on account of hybridization of their genes or one or more regions of their genes:
- suitable hybridization probes according to the invention which may be prepared on the basis of the amino acid sequences mentioned in the sequence protocol considering the degeneration of the genetic code.
- Another aspect of the present invention relates to the use of the amino acid sequences mentioned above and of fragments thereof having antigenic effects, respectively, for the production of monoclonal or polyclonal antibodies or antisera by immunizing hosts with said amino acid sequences or fragments, respectively, as well as of antibodies or antisera, respectively, per se, which specifically recognize and bind to the enzymes and/or antigens described above.
- the general procedure and the corresponding techniques for the generation of polyclonal and monoclonal antibodies are all well-known to the persons skilled in the art.
- One possible use of the antibodies of the invention resides in the screening of plants for the presence of N-acetyl glucosaminyl transferase I.
- Binding of the antibody according to the present invention to plant protein(s) indicates the presence of N-acetyl glucosaminyl transferase I enzyme detectable with said antibody.
- this antibody may then be covalently bound to a carrier in a later step, and optionally be employed for the enrichment or purification of the enzyme by means of column chromatography.
- a negative binding result using the antibody of the present invention i.e. lack of binding to the plant proteins, may suggest, that N-acetyl glucosaminyl transferase I enzyme is absent (or highly modified by mutation), and thus, that N-acetyl glucosaminyl transferase I activity of a plant investigated is missing or highly reduced.
- the present invention further comprises DNA sequences encoding the amino acid sequences of the invention, including amino acid sequences derived therefrom according to the above provisions.
- the invention relates to the respective gene, which is the basis of the amino acid sequences described in the FIGS. 2 and- 3 B and the sequence protocol, and especially, to the cDNA sequences described in FIG. 2 and the sequence protocol, as well as to DNA sequences derived from these genes and DNA sequences.
- derived DNA sequences are meant sequences, which are obtained by substitution, deletion and/or insertion of one or more and/or smaller groups of nucleotides of the sequences mentioned above and/or by truncation or extension at the 5′ and/or 3′ terminus. Modifications within the DNA sequence may lead to derived DNA sequences, which encode amino acid sequences being identical to the amino acid sequence encoded by the starting DNA sequence, or to such sequences, in which, compared to the amino acid sequence, which is encoded by the starting DNA sequence, single or a few amino acids are altered, i.e. substituted, deleted and/or inserted, as well as to such sequences, which—optionally in addition—are truncated and/or extended at the C-terminus and/or N-terminus.
- the present invention also extends to the complementary sequences of the genes and DNA sequences according to the invention, as well as the RNA transcription products thereof.
- sequences derived according to the above provisions which over their entire length or only with one or more partial regions hybridize under stringent conditions to the starting sequences mentioned above or to the sequences complementary thereto or to parts thereof, as well as DNA sequences comprising such sequences.
- hybridization under stringent conditions in the sense of the present invention is understood a hybridization procedure according to one or more of the methods described below.
- Hybridizing up to 20 h in PEG buffer according to Church and Gilbert (0.25 M Na 2 HPO 4 , 1 mM EDTA, 1% (w/v) BSA, 7% (w/v) SDS, pH 7.5 with phosphoric acid; ref. 22) at 42° C. or in standard hybridization buffers with formamide at 42° C. or without formamide at 68° C. (ref. 23). Washing: 3 times at 65° C. for 30 min in 3 ⁇ SSC buffer (ref. 23), 0.1% SDS.
- hybridization always means hybridization under stringent conditions, as mentioned above, even if this is not explicitely indicated in the individual case.
- the invention relates to fragments of the DNA sequences mentioned above, including the DNA sequences derived in accordance with the above provisions, to fragments derived from such fragments by nucleic acid substitution, insertion and/or deletion as well as the corresponding fragments with sequences complementary thereto.
- Such fragments are i.a. suitable as sequencing or PCR primers, screening probes and/or for uses as discussed below.
- the DNA fragments according to the present invention are frequently employed as radio-labelled fragments.
- Fragments carrying sequences which are derived from the starting sequences defined above by substitution, deletion and/or insertion of one or more nucleotides, and the sequences complementary thereto, respectively, are comprised by the invention to that extent, as said fragments hybridize under the above mentioned stringent conditions to the starting sequences, or to the sequences complementary thereto, respectively.
- DNA fragments according to the invention may for example be obtained starting from plant DNA by means of restriction endonucleases using appropriate restriction sites or by employment of PCR by means of primers appropriately synthesized, or may, as an alternative, also be chemically synthesized. Such techniques are well-known to those skilled in the art.
- the invention relates to any DNA sequences, which represent a gene or are a part of a gene encoding the enzyme N-acetyl glucosaminyl transferase I and, which in their entirety or in a partial region thereof hybridize under stringent conditions
- hybridization or screening probes are used as DNA fragments, which generally comprise at least 15 nucleotides, typically between 15 and 30 nucleotides, and, if necessary, substantially more nucleotides.
- the primers employed in Example 1 may be used.
- DNA sequences of appropriate length, derived from the DNA sequences mentioned in the sequence protocol may be used.
- appropriate hybridization probes according to the invention may be developed starting from the amino acid sequences mentioned in the sequence protocol considering the degeneration of the genetic code.
- a subject-matter of the present invention are also genes encoding N-acetyl glucosaminyl transferase I, which may be detected from other varieties or plant species on account of the hybridization thereof to above mentioned hybridization probes, as well as DNA sequences, DNA fragments and constructs, which are derived therefrom in accordance with the above provisions.
- constructs which may optionally comprise besides additional 5′ and/or 3′ sequences, e.g. linkers and/or regulatory DNA sequences or other modifications, the DNA sequences of the invention, including the DNA sequences derived as detailed above.
- hybridization or screening probes which in addition to a DNA sequence of the invention also comprise a detection agent for the verification of hybridization products, which in this case typically is non-radioactive, e.g. fluorescent or phosphorescent molecules, biotin, biotin derivatives, digoxigenin and digoxigenin derivatives.
- a detection agent for the verification of hybridization products typically is non-radioactive, e.g. fluorescent or phosphorescent molecules, biotin, biotin derivatives, digoxigenin and digoxigenin derivatives.
- radioactive or non-radioactive detection agents may be considered, which may be attached to the DNA sequence according to the present invention e.g. by means of end labelling.
- a subject-matter of the invention are also antisense and sense constructs with respect to the DNA sequences and fragments according to the present invention, i.e. with respect to
- DNA sequences especially from other varieties or plant species, which represent a gene or are a part of a gene, encoding the enzyme N-acetyl glucosaminyl transferase I; and which hybridize under stringent conditions
- the present invention extends to any DNA-transfer systems such as vectors, plasmids, viral and phage genomes or cosmids, which contain the DNA sequences according to the present invention, e.g. the GntI gene, cDNA and DNA regions according to the invention, as mentioned in the sequence protocol, fragments thereof, in particular antisense or sense constructs and/or cDNA sequences derived therefrom according to the above provisions.
- vectors e.g. the GntI gene, cDNA and DNA regions according to the invention, as mentioned in the sequence protocol, fragments thereof, in particular antisense or sense constructs and/or cDNA sequences derived therefrom according to the above provisions.
- One possibility of application of the DNA hybridization probes according to the invention is the detection of N-acetyl glucosaminyl transferase I genes in plants other than those, from which the DNA sequences mentioned in the sequence protocol were obtained, or the detection of potential (other) isoforms of the N-acetyl glucosaminyl transferase I gene in the starting plants Solanum tuberosum, Nicotiana tabacum and Arabidopsis thaliana.
- a positive hybridization result of such screening of each library may indicate a clone or a few clones, which contain the desired sequence completely or in part, i.e. the N-acetyl glucosaminyl transferase I gene, combined with only a limited amount of other DNA from the genome of the target plant, which appropriately facilitates cloning and sequencing of the target gene.
- a PCR amplification of the gene or parts thereof may also be carried out starting from plant DNA and suitable constructs, so-called PCR primers, to facilitate cloning and sequencing.
- sequencing primers of the invention which are synthesized starting from suitable regions of the sequences according to the invention, e.g. enables genomic sequencing starting from the entire target plant-genomic DNA cleaved by restriction endonucleases, by means of the Church-Gilbert technique, as well as sequencing at the cDNA level following RT-PCR amplification of the total RNA of the target plant (cf. Expl. 1).
- the hybridization experiment serves to detect the N-acetyl glucosaminyl transferase I (GntI) gene by which it may be concluded, e.g. owing to a negative hybridization result under stringent conditions, that the GntI gene, and thus, N-acetyl glucosaminyl transferase I activity in a plant investigated is lacking.
- GntI N-acetyl glucosaminyl transferase I
- DNA hybridization probes comprise at least 15 nucleotides of a sequence, which for example is derived from the cDNA sequences mentioned in FIG. 2 and the sequence protocol or from the corresponding GntI genes.
- the invention relates to microorganisms, such as bacteria, bacteriophages, viruses, unicellular eukaryotic organisms, such as fungi, yeasts, protozoa, algae, and human, animal and plant cells, which have been transformed by one or more of the DNA sequences of the invention or one or more of the constructs of the invention, as illustrated above.
- microorganisms such as bacteria, bacteriophages, viruses, unicellular eukaryotic organisms, such as fungi, yeasts, protozoa, algae, and human, animal and plant cells, which have been transformed by one or more of the DNA sequences of the invention or one or more of the constructs of the invention, as illustrated above.
- Transformed microorganisms according to the present invention are used e.g. as expression systems for the transforming foreign DNA to obtain the corresponding expression products.
- typical microorganisms are bacteria, e.g. such as E. coli.
- transformed microorganisms according to the invention in particular agrobacteria, may be employed e.g. for the transformation of plants by transmission of the transforming foreign DNA.
- constructs referred to as expression vectors which contain the DNA sequence of the invention under control of a constitutive or inducible promoter, which, if necessary, is additionally tissue specific, so as to enable the expression of the introduced DNA in the target or host cell.
- a further aspect of the invention is a method for the production of the enzymes and proteins of the invention by using one or more of the transformed microorganisms of the present invention.
- the method comprises cultivating at least one microorganism transformed by the DNA of the invention, in particular by one of the cDNAs mentioned in the sequence protocol, under the control of an active promoter, as defined above, and isolating the enzyme of the invention from the microorganisms, and, if applicable, also from the culture medium. It is understood, that this method also relates to the production of enzymes and proteins, respectively, which are derived from the enzymes according to the present invention from Solanum tuberosum, Nicotiana tabacum and Arabidopsis thaliana, as defined under i) above.
- Methods for the cultivation of transformed microorganisms are well-known to those skilled in the art.
- the isolation of the expressed enzyme may be employed according to the method described in Example 5 by means of metal-chelate chromatography or, alternatively, by chromatography via columns, which contain the antibodies against the enzyme bound to the packing material.
- the invention comprises transgenic plants, which are transformed by means of a DNA sequence according to the invention or a corresponding construct, respectively. Accordingly, there may be obtained e.g. transgenic plants, in which a GnTI deficiency, for example on account of a missing or defectice GntI gene or due to defects in the regulatory regions of this gene, has been removed by complementation using a construct derived from the cDNA sequences mentioned in the sequence protocol, wherein the expression of said construct is under the control of an active constitutive or inducible promoter, which may be additionally tissue specific.
- the GnTI enzyme or protein expressed on account of the DNA of the invention contained in the construct and having GnTI activity complements the GnTI activity missing in the starting plant.
- transgenic plants in which the GnTI activity already present in the starting plant is increased by additional expression of the GntI transgene introduced by means of a construct according to the present invention.
- the extremely low expression of the GntI gene in vivo accompanied by extremely low enzyme activity which correspondingly was very difficult to detect, has been a main problem in the investigation of the enzyme N-acetyl glucosaminyl transferase I in plants.
- the problem of a too low GnTI enzyme activity in plants may be overcome by the coexpression of a DNA according to the present invention.
- DNA according to the invention additionally comprising a sequence region, which following expression enables a facilitated detection and/or enrichment and purification, respectively, of the protein product having GnTI activity.
- This is for example accomplished by the use of a specific DNA sequence for the expression of a recombinant GnTI enzyme, said sequence carrying a N-terminal or C-terminal sequence extension encoding an affinity marker.
- cleavage of the N-terminal or C-terminal sequence extension from the GnTI enzyme may be achieved by the subsequent use of this specific protease, and the GnTI enzyme thereby obtained in isolated form.
- DNA sequence according to the present invention which codes for the recombinant GnTI enzyme with a C-terminal sequence extension, encoding the affinity marker AWRHPQFGG (strep-tag; ref. 39), and an intervening protease recognition site IEGR.
- the expression of the DNA according to the present invention provides GnTI enzymes with the C-terminal sequence extension mentioned, by means of which the expressed protein molecules specifically bind to a streptavidin derivatized matrix, and may thus be isolated. Then, by means of the protease factor Xa specifically recognizing the amino acid sequence IEGR, the GnTI portion of the protein molecules may be released.
- the complete protein may be removed from the streptavidin derivatized matrix by means of biotin or biotin derivatives.
- a further example is represented by DNA sequences of the invention, encoding a protein which comprises multiple, e.g. 10, N-terminally added histidine residues (His-tag) in addition to a GnTI enzyme. Due to the N-terminal histidine residues, isolation or purification, respectively, of the proteins expressed may be easily conducted by metal-chelate affinity chromatography (e.g. Ni sepharose) (cf. also Example 5).
- His-tag N-terminally added histidine residues
- the invention comprises portions of such transgenic plants, adequately transformed plant cells, transgenic seeds and transgenic reproduction material.
- a further important aspect of the invention is the use of the sequence information discussed above for the production of plants having reduced or lacking N-acetyl glucosaminyl transferase I activity.
- antisense or sense constructs are derived from the DNA sequence of a plant GntI gene, for the production of transgenic plants with reduced or lacking N-acetyl glucosaminyl transferase I activity by means of homology-dependent gene silencing (cf. ref. 16,17).
- the DNA sequence used as a starting sequence for the generation of the constructs may be derived from the starting plant to be transformed itself but also from a different plant variety or species.
- antisense or sense constructs as discussed under items iii) and iv) above are of use.
- the constructs employed comprise at least 50 to 200 and more base pairs.
- constructs employed for this purpose comprise at least 50 to 200 and more base pairs, with a sequence, which is derived on the basis of
- DNA sequences in particular from other varieties and plant species,.which encode N-acetyl glucosaminyl transferase I and which may be identified due to a hybridization under stringent conditions to hybridization or screening probes, as defined under items iii) and iv) above.
- the constructs contain a strong constitutive or inducible promoter, which additionally may be tissue specific, by means of which the antisense or sense DNA sequence regions are controlled.
- transgenic plants by integration of antisense construct(s) into the plant genome or by viral infection of starting plants or plant cells by means of virus containing antisense construct(s) for an extrachomosomal propagation and transcription of the antisense construct or the antisense constructs in infected plant tissue, it is intended to achieve a hybridization of GntI-gene transcripts to transcripts of the antisense DNA region at the RNA level, which prevents translation of the GntI mRNA.
- the result is a transgenic plant with strongly decreased contents of N-acetyl glucosaminyl transferase I, and thus, a strongly decreased corresponding enzyme activity.
- constructs which hybridize to one of the complete cDNAs, mentioned in FIG. 2 and in the sequence protocol, or to corresponding regions thereof, generally comprising at least 50 to more than 200 base-pairs.
- antisense constructs may be used according to the present invention, which themselves or the transcripts of which, respectively, hybridize to a DNA or RNA region of the GntI gene or the GntI mRNA, comprising a part of the 5′ untranslated region and the coding region including the membrane anchor.
- the extension of the region of hybridization up to position 266 of the cDNA in FIG. 2 and SEQ ID NO: 1 is considered harmless for the purpose mentioned above.
- transgenic plants by integration of sense constructs into the plant genome or by viral infection of starting plants or plant cells by means of virus containing sense construct(s) for extrachromosomal propagation and expression of the construct or constructs in infected plant tissue, there are assumed hybridization phenomena in tobacco according to the work of Faske et al. (ref. 17), of said constructs to the endogenous GntI gene at a posttranscriptional or DNA level, respectively, which finally affect or prevent the translation of the GntI gene. Also in this case, the result are transgenic plants having reduced or-even lacking N-acetyl glucosaminyl transferase I activity.
- TMV tobacco mosaic virus
- potato virus X potato virus X
- Representative plants which are suitable for such integration, comprise dicotyledonous as well as monocotyledonous cultivated plants, in particular Solanaceae such as potato, tobacco, tomato and pepper. Additionally, banana, alfalfa, canola, beets, soybean, lettuce, corn, rice and grain, would be suitable target plants for the use of homologous antisense constructs.
- Solanaceae such as potato, tobacco, tomato and pepper.
- banana, alfalfa, canola, beets, soybean, lettuce, corn, rice and grain would be suitable target plants for the use of homologous antisense constructs.
- the sequence from Arabidopsis thaliana mentioned in the sequence protocol appears to be particularly suitable as a starting sequence for the transformation according to the invention of Brassicaceae, such as canola plants, by means of sense or antisense constructs.
- Further plants of interest are any plants, which express glycoproteins of interest for medicine and research.
- the transformation according to the invention of plants which in the corresponding region of the GntI gene exhibit a homology of ⁇ 70% at the nucleotide level to the employed antisense or sense constructs according to the present invention, typically results in transgenic plants of the invention, which show the desired reduction of N-acetyl glucosaminyl transferase I activity.
- the present invention comprises transgenic plants, which have been transformed by the antisense or sense constructs mentioned above or the viruses containing the same, respectively, as well as parts of such transgenic plants, correspondingly transformed plant cells, transgenic seeds and transgenic reproduction material.
- the plants of the invention and the plants obtained according to the invention, respectively, with reduced or lacking N-acetyl glucosaminyl transferase I activity, may be used according to the invention for the production of glycoproteins with minimal and uniform, i.e. defined, sugar residues.
- glycoproteins are of great importance for medicine and research.
- plants per se represent ideal bioreactors.
- biotechnologically or pharmaceutically relevant glycoproteins e.g. therapeutics of low antigenic potential for mammals
- the invention also comprises a method for the production of glycoproteins with minimal uniform and defined sugar residues, comprising cultivating a transgenic plant according to the invention, of parts of such plants or of plant cells transformed according to the invention, each expressing the desired glycoprotein, as well as isolating the desired glycoprotein from the cultivated material.
- representative cultivated plants are Solanaceae, in particular potato, tobacco, tomato and pepper. Furthermore possible are banana, alfalfa, canola, beets, soybean, lettuce, corn, rice and grain.
- FIG. 1 The sequence of the enzymatically controlled and plant specific N-glycan modifications, which secretory glycoproteins are subjected to during passage through the Golgi apparatus of higher plants, is schematically shown in FIG. 1.
- the biosynthesis block due to lacking or insufficient N-acetyl glucosaminyl transferase I (GlcNAc transferase I) activity in a plant leads, instead of complex glycans, to the predominant formation of glycans of the Man 5 GlcNAc 2 type, i.e. glycoproteins with uniform and well-defined sugar residues, which are of extremely high importance for medicine and research.
- GlcNAc transferase I N-acetyl glucosaminyl transferase I
- the genes encoding the desired glycoproteins may be expressed in their natural producing plants, which have been transformed according to the present invention e.g. by means of antisense or sense constructs to yield transgenic plants with reduced or missing N-acetyl glucosaminyl transferase I activity.
- transgenic plants of the invention displaying reduced or lacking N-acetyl glucosaminyl transferase I activity, which additionally have been transformed by the gene encoding the desired glycoprotein.
- constructs may be employed, which contain the gene encoding the desired glycoprotein under the control of a strong constitutive or inducible promoter, which is optionally tissue specific as well, and lead to the integration of the gene into the plant genome.
- the transformation may also be conducted by viral infection by means of a virus containing the gene for the desired glycoprotein for extrachromosomal propagation and expression of the gene. The glycoprotein may then be expressed in the respective host plant and obtained therefrom.
- the procedure may be such, that initially a transformation using an expression construct or virus containing the DNA encoding the glycoprotein is performed, and subsequently, another transformation with one or more of the antisense or sense constructs of the invention or with one or more viruses, containing the corresponding DNA, is performed. It is also possible to perform a simultaneous transformation using both constructs or using one virus containing the antisense or sense construct as well as the gene encoding the desired glycoprotein (piggyback version).
- tissue specific promoters are available, which drive expression of foreign genes specifically only-in these tissues.
- tuber specific promoters such as patatin class I (ref. 26) and proteinase inhibitor II promoters (ref. 27) may be mentioned.
- both promoters exhibit expression also in leaf tissue, i.e. they can be induced by high metabolite contents (for example sucrose) and in the case of the proteinase inhibitor II promoter also by mechanical lesion or by spraying with abscisic or jasmonic acid, respectively.
- tissue specific promoters may also be indicated in cases, where the DNA sequence or the transcription products or translation products thereof according to the invention, respectively, which are employed for the transformation, turn out to be detrimental to certain plant parts, e.g. due to a negative influence on the metabolism of the corresponding plant cells.
- human glucocerebrosidase may be used for the therapy of the hereditary Gaucher's disease (ref. 25).
- human glucocerebrosidase (GC) with uniform and defined sugar residues e.g. plants of the present invention which are transformed by means of-antisense DNA, may be transformed with the gene encoding human glucocerebrosidase.
- the human glucocerebrosidase cDNA sequence (ref. 38) is modified at the 3′ terminus by means of PCR using gene specific primers in a manner, that the recombinant enzyme carries a C-terminal sequence extension encoding an affinity marker (e.g.
- the GC-cDNA sequence thus altered is expressed in GntI antisense plants of the present invention by using a strong and optionally tissue specific promoter (e.g. for potato under the control of the tuber specific B33 patatin promoter), so that the enzyme synthesized in these plants exclusively carries well defined N-glycans.
- the affinity marker is intended to facilitate-the enrichment of the recombinant enzyme from the transgenic plants.
- the expressed protein molecules bind to a streptavidin derivatized matrix via the affinity marker sequence and can be released therefrom by means of biotin or biotin derivatives.
- the removal from the strepatavidin derivatized matrix may also be carried out by means of catalytic amounts of a protease, which exhibits a specificity for the protease recognition site located between the GnTI enzyme region and the affinity marker. In this case, only the GnTI enzyme region is released from the matrix. This could be advantageous especially in that case, if the affinity marker sequence has a detrimental effect on the GnTI activity.
- the Man 5 GlcNAc 2 -glycans of the glucocerebrosidase obtained, from the plants of the present invention will be recognized by macrophages as an uptake signal, and can thus directly be employed for the therapy of hereditary Gaucher's disease.
- a therapy is only possible upon expensive isolation and deglycosylation of native glucocerebrosidase (ref. 25).
- glycoproteins may be highly facilitated by the use of plant GntI sequences compared to conventional methods, e.g. the chemical deglycosylation of purified glycoproteins, which is technically demanding (ref. 25), or a difficult and expensive production in GnTI deficient animal cell lines (ref. 7,10).
- FIG. 1 Sequence of plant specific N-glycan modifications, which secretory glycoproteins are subject to during passage through the Golgi apparatus of higher plants (ref. 28).
- the biosythesis block to complex modified glycans is based on a deficiency in GnTI activity (which is either caused by a defective or missing GnTI enzyme or by effective reduction of the GntI gene expression) and is indicated by a cross. Meaning of the symbols: (F) fucose residues, (X) xylose residues, dues, ( ⁇ ) GlcNAc residues, ( ⁇ ) mannose residues.
- FIG. 2 Full length cDNA sequence of a plant GnTI from potato ( Solanum tuberosum L.) and amino acid sequence deduced therefrom.
- the complete cDNA of the membrane anchor containing GntI isoform from potato leaf tissue (A1) is illustrated.
- the EcoRI/NotI linkers at the 5′ and 3′ ends of the cDNA are highlighted by bold letters, the binding sites of the degenerate oligonucleotides used for obtaining the RT-PCR probe are underlined.
- the protein sequence derived from the potato cDNA clones contains a potential N-glycosylation site: Asn-X(without Pro)-Ser/Thr, which is indicated by an asterisk.
- the region of the membrane anchor is highlighted in italics (aa 10 to 29).
- the start of the isoform (A8), which is potentially located in the cytosol, is indicated by an arrow.
- FIG. 3 A, Degree of identity or similarity, respectively, of the amino acid sequence deduced from a complete GntI cDNA sequence from potato (A1) in comparison to other GnTI sequences of animal organisms, which have been selected from data bases. Identical amino acid positions (in %) are printed in bold letters, similar amino acid positions are given in brackets underneath. Meaning of the abbreviations: Hu, human; Ra, rat; Mo, mouse; Ce, Caenorhabditis elegans (round-worm); St, Solanum tuberosum (potato) B, Comparison of the derived amino acid sequences of different plant GntI-cDNA clones.
- FIG. 5 Extent of suppression of complex glycoprotein modification in transgenic potato plants transformed with the long GntI antisense construct (cf. FIG. 4).
- A Coomassie-stained SDS gel from leaf extracts;
- B Western-blot analysis (Ref. 13,33) of parallel samples developed with a complex-glycan antiserum (Ref. 12,13).
- the lanes contain 30 ⁇ g each of total protein: cgl (Ara), Arabidopsis cgl mutant (Ref. 13); WT(Desi), wild-type potato; the numerals refer to individual transgenic potato plants; the arrows represent molecular weight standards of 66, 45, 36 and 29 kDa, respectively.
- FIG. 6 Detection of specificity of the generated GnTI antiserum following cell fractionation (Ref. 40) of tobacco callus material.
- Ref. 40 cell fractionation
- Western-blot analysis (Ref. 13,33) 30 ⁇ g of protein were applied per lane. The antiserum was used in 1:1000 dilution.
- Aa amino acid(s); bp, base pair(s); EMS, Ethyl methane sulfonate (mutagenic agent); F2, second filial generation; Fuc, fucose; Glc, glucose; GlcNAc, N-acetyl glucosamine; GnTI, N-acetyl glucosaminyl transferase I (EC 2.4.1.101); GntI, gene for GnTI (nuclear encoded); kDa, kilodalton; Man, mannose; PCR, polymerase chain reaction; PAGE, polyacrylamide gel electrophoresis; ref., reference; RT-PCR, reverse transcription coupled polymerase chain reaction; SDS, sodium dodecyl sulfate; var., variety; Xyl, xylose.
- radio-labelled probes were synthesized by means of PCR (standard PCR assay using degenerate primers as above, nucleotide mixture without dCTP, but instead with 50 ⁇ Ci ⁇ - 32 P-dCTP [>3000 Ci/mMol]), and different cDNA libraries were screened for GntI containing clones using the corresponding homologous potato or tobacco probes, respectively (procedure analogous to ref. 31; the stringent hybridization conditions have already been described in the text above).
- the cDNA libraries were prepared from mRNA of young and still growing plant parts (sink tissues).
- EcoRI compatible lambda arms were ligated, those packaged and used to transfect E. coli XL1 Blue cells (Lambda ZAPII cloning and packaging system, Stratagene).
- EcoRI compatible lambda arms were ligated, those packaged and used to transfect E. coli XL1 Blue cells (Lambda ZAPII cloning and packaging system, Stratagene).
- one full-length GntI clone each was isolated from a potato leaf sink library (Al according to FIG. 2 and SEQ ID NO: 1) and a tobacco leaf sink library (A9 according to SEQ ID NO: 3), as well as two additional clones from a tuber sink library (A6, A8).
- the deduced GnTI amino-acid sequences contain a potential N-glycosylation site, Asn-X(without Pro)-Ser/Thr, in contrast to those of animals.
- One of the tuber GntI cDNA sequences carries stop codons in all three reading frames in front of the first methionine (A8).
- the coding region shows high homology to the longer tuber clone (A6) (only 2 aa substitutions), but displays a completely different 5′ non-translated region.
- the membrane anchor characteristic for the Golgi enzyme is missing, so that this GnTI isoform might be located in the cytosol.
- the missing 5′-terminus was amplified from another library (via an unique SpeI restriction site in the 5′ region) and assembled to yield a full-length cDNA sequence.
- the nucleic acid sequence determined by means of sequencing is listed in SEQ ID NO: 5.
- protoplasts were isolated from leaves of cgl mutants cultivated under sterile conditions (nonstainer plants following 5 backcrosses, ref. 13), transformed with expression constructs of the complete GntI cDNA sequences (NotI cDNA fragments, cf. FIG. 4) in sense (pA35N-A1s or pA35N-A9s, respectively) or antisense orientation (pA35N-Alas or pA35N-A9as, respectively), and cultivated for 96 h at room temperature in the dark (50 ⁇ g of plasmid DNA each per 1 million protoplasts, PEG method according to ref. 32).
- the EcoRI restriction site of the vector is restored by fusion with the equally filled-in NcoI restriction site of the fragment.
- the binary antisense GntI constructs (pBin-35-Alas and pBin-35-A1-short) were transformed into the Agrobacterium strain GV2260 (ref. 34, 35).
- GV2260 sterile leaf discs of potato plants var. Désirée and of tobacco plants var. Wisconsin 38 were infected with the recombinant agrobacterial lines (50 ⁇ l of a fresh overnight culture in 10 ml liquid 2MS medium: 2% sucrose in Murashige & Skoog salt/vitamin standard mediums pH 5.6; small pieces of leaf without midrip; co-cultivation for 2 days in the dark in phytotrons).
- transgenic plants were regenerated from said pieces in tissue culture under kanamycin selection (potato protocol ref. 26; tobacco protocol ref. 36) and analyzed for reduced GnTI activity (exemplary shown in FIG. 5 for transgenic potato plants).
- antisense suppression of complex glycoprotein modifiaction was successful in transgenic potato plant #439.
- the determined reduction of complex glycoprotein modification was stable in this transformant over the entire investigation period of several months and has been verified in three tests which were performed in an interval of about l month each. For the respective transgenic tobacco plants, analogous results were obtained.
- Recombinant GnTI carrying 10 additional N-terminal histidine residues was produced in E. coli by means of the pET system (Novagen) and purified by metal-chelate affinity chromatography.
- a cDNA fragment comprising nucleotides 275-1395 of the potato GntI cDNA was amplified by standard PCR (annealing temperature of 50° C., 30 cycles, ref.
- coli XL1-Blue (Stratagene) the construct was stored as a glycerol culture. Competent E. coli BL21(DE3) pLysS cells (Novagen) were transformed with pET-His-A1 for overexpression. Addtition of IPTG (Isopropyl-1-thio- ⁇ -D-galactopyranoside, at 0.5-2 mM) to a BL21 culture in logarithmic growth phase, initially induces the expression of T7 RNA polymerase (from the bacterial chromosome), and thus, also the expression of the recombinant fusion protein under control of the T7 promoter in pET vectors (Novagen).
- IPTG Isopropyl-1-thio- ⁇ -D-galactopyranoside
- recombinant potato GnTI was purified from induced BL21:pET-His-A1 cells under denaturating conditions via its His-tag (manufacturer's protocol, Novagen), and the preparation was verified with respect to homogeneity by means of SDS-PAGE.
- Recombinant potato GnTI (from Expl. 5) was used as an antigen. Following the harvest of some milliliters of pre-immune serum, the rabbits were subcutaneously injected with 300-500 ⁇ g of affinity-purified protein together with 25 ⁇ g of GMDP adjuvant (Gerbu) in intervals of three weeks. Subsequent to three basis injections, the- animals were bled from the ear vein 12 to 14 days after the respective successive injection (boost), the serum harvested (ref. 37) and tested for recognition of recombinant GnTI by Western-blot analyses (dilution 1:200 to 1:2000).
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Pharmacology & Pharmacy (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
This invention relates to plant GntI sequences, in particular to plant nucleic acid sequences encoding the enzyme N-acetyl glucosaminyl transferase I (GnTI), DNA sequences derived therefrom, including GntI antisense and sense constructs, and the translation products thereof, antibodies directed against said translation products, as well as the use of the sequence information for the production of transformed microorganisms and transgenic plants, including those having reduced or missing N-acetyl glucosaminyl transferase I activity. Such plants displaying reduced or lacking N-acetyl glucosaminyl transferase I activity are of great importance for the production of glycoproteins of specific constitution with respect to their sugar residues.
Description
- The present invention relates to plant GnTI sequences, in particular, plant nucleic acid sequences encoding the enzyme N-acetyl glucosaminyl transferase I (GnTI), as well as GntI antisense or sense constructs, deduced therefrom, and their translation products, antibodies directed against said translation products as well as the use of the sequence information for the production of transformed microorganisms and of transgenic plants, including those with reduced or lacking N-acetyl glucosaminyl transferase I activity. Such plants with reduced or lacking N-acetyl glucosaminyl transferase I activity are of great importance for the production of glycoproteins of specific constitution with respect to their sugar residues.
- In eukaryotes, glycoproteins are cotranslationally assembled in the endoplasmatic reticulum (ER) (i.e. during import into the ER lumen) by the attachment of initially membrane bound glycans (via dolichol pyrophosphate) to specific asparagine residues in the growing polypeptide chain (N-glycosylation). In higher organisms, sugar units located at the surface of the folded polypeptide chain are subjected to further trimming and modification reactions (ref. 1) in the Golgi cisternae. Initially, typical basic Glc3Man9GlcNAc2 units of the high-mannose type are formed by means of different glycosidases and glycosyl transferases in the ER, which during the passage through the different Golgi cisternae are subsequently converted to so-called complex glycans. The latter are characterized by less mannose units and the presence of additional sugar residues, such as fucose, galactose and/or xylose in plants and sialic acid (N-acetyl neuraminic acid, NeuNAc) in mammals (ref. 1,2,3). The extent of the modifications can differ between glycoproteins. Single polypetide chains may carry heterogeneous sugar chains. Furthermore, the glycosylation pattern may vary for a specific polypeptide (tissue specific differences), and does not always have to be uniform with respect to a specific glycosylation site, which is referred to as microheterogeneity (ref. 4,5). Up to now, the role of asparagine bound glycans is barely understood, which i.a. results from the fact, that said glycans may serve several functions (ref. 6). However, it can be assumed, that e.g. protection of a polypeptide chain from proteolytic degradation can also be achieved by glycans of a more simple oligomannosyl type (ref.7).
- Glycoproteins are highly important in medicine and research. However, large scale isolation of glycoproteins is time-consuming and expensive. The direct use of glycoproteins isolated conventionally often raises problems, since upon administration as a therapeutic, single residues of the glycan components may cause undesired side effects. In this context, the glycan component predominantly contributes to the physico-chemical properties (such as folding, stability and solubility) of the glycoproteins. Furthermore, isolated glycoproteins, as already mentioned above, rarely carry uniform sugar residues, which is referred to as microheterogeneity.
- For the production of glycoproteins for medicine and research, yeasts prove to be unsuitable, since they are only able to perform glycosylations of the so-called high-mannose type. While insects and higher plants exhibit complex glycoprotein modifications, these, however, differ from those of animals. Therefore, glycoproteins isolated from plants have a strong antigenic effect in mammals. In most cases, animal organisms with glycosylation defects are not viable, since terminal glycan residues (e.g. of membraneous glycoproteins) mostly possess biological signal function and are indispensable for cell-cell-recognition during the course of embryogenesis. Mammalian cell lines with defined glycosylation defects already exist, the cultivation of which, however, is labour-intensive and expensive.
- For mammals, different glycosylation mutants have been described in detail at the cell culture level (ref. 7,8,9,10). Said mutants are either defective in biosynthesis of mature oligosaccharide chains attached to dolichol pyrophosphate or in glycan processing or show alterations in their terminal sugar residues, respectively. Some of these cell lines exhibit a conditional-lethal phenotype or are defective in intracellular protein transport. The consequences of said defects for the intact organism are difficult to estimate. It has been observed, that a modification in the pattern of complex glycans on the cell surfaces of mammals is accompanied by the formation of tumours and metastases, although a functional relationship could not yet unambiguously be demonstrated (ref. 9). Therefore, in mammals glycosylation mutants are very rare. These defects, summarized under HEMPAS (Hereditary Erythroblastic Multinuclearity with a Positive Acidified Serum lysis test) (ref. 10,11), are based either on a deficiency in mannosidase II and/or low levels of the enzyme N-acetyl glucosaminyl transferase II (GnTII), and have strongly limiting effects on the viability of the mutated organism. GntI knock-out mice, in which the gene for GnTI has been destroyed, already die in utero of multiple developmental defects (personal communication, H. Schachter, Toronto).
- Until recently, no comparable mutants were known for plants. By the-use of- an antiserum, which specifically recognizes complex modified glycan chains of plant glycoproteins and which predominantly is directed against the highly antigenic β1→2 linked xylose residues (ref. 12), the applicant was able to isolate several independant mutants from an EMS mutagenized F2 population of the genetic model plant Arabidopsis thaliana, which no longer showed complex glycoprotein modification (complex glycan, cgl mutants). After at least five backcrosses, each followed by intermittent selfings (to screen for the recessive defects), the glycoproteins were analyzed. These glycoproteins mainly carried glycans of the Man5GlcNAc2 type, indicating a defect in N-acetyl glucosaminyl transferase I (GnTI) (ref. 8). Indeed, the Arabidopsis cgl mutants lacked GnTI activity (ref. 13), which normally catalyzes the first reaction in the synthetic pathway to complex modified sugar chains (ref. 1). However, according to observations so far, the viability of the mutated plants is not affected. In recent publications, plants are suggested as a putative source for the production of pharmaceutically relevant glycoproteins or vaccines (ref. 14,15). There however, it was overlooked, that glycoproteins isolated from plants may cause severe immune reactions in mammals, which up to now obstructed the production of heterologous glycoproteins in cultivated plants.
- The applicant could demonstrate by way of example for the Arabidopsis cgl mutant, that plants can manage without complex modified glycoproteins to a great extent (ref. 13). Initially, secretory proteins are normally glycosylated in the ER of the mutant. In the Golgi apparatus of the cgl mutant, however, the oligomannosyl chains linked to the polypetide backbone via asparagine residues (N-glycosylation) then remain at the stage of Man 5GlcNAc2 residues, since N-acetyl glucosaminyl transferase I (GnTI) activity is missing (FIG. 1). By this biosynthesis block, the plant specific complex glycoprotein modification and in particular the attachment of α1→3 fucose and β1→2 xylose residues is prevented, whereby the strong antigenic effect on the mammalian organism is absent. However, Arabidopsis as a herb only has little utilizable biomass. Therefore, for the large scale production of biotechnologically relevant glycoproteins these cgl plants are less suitable. As an alternative, cultivars, especially Solanaceae, such as potato, tobacco, tomato or pepper and furthermore alfalfa, canola, beets, soybean, lettuce, corn, rice and grain, with missing or highly reduced GnTI activity, would be ideal for the production of heterologous glycoproteins in plants. For this purpose, the methods of homology-dependent gene silencing would be applicable (ref. 16, 17).
- As FIG. 3 demonstrates, the homology of the first determined plant GntI sequence from potato ( Solanum tuberosum L., St) is extraordinary low in comparison to the corresponding known sequences of animal organisms (only 30-40% identity at the protein level, cf. FIG. 3A). Therefore, by the use of heterologous GntI gene sequences an efficient reduction of endogenous complex glycoprotein modification in plants by means of antisense or sense suppression, respectively, (ref. 21), probably cannot be achieved.
- Thus, in medicine and research there is still the need for a cost-effective production in suitable organisms of recombinant glycoproteins with a minimum of uniform, i.e. defined sugar residues.
- Since the applicant for the first time has been able to isolate and elucidate plant GntI cDNA sequences, it is now possible i.a. to obtain and, in particular, to generate any plant having reduced or missing GnTI activity, and to detect the corresponding mutants, respectively, by means of reverse genetic approaches following transposon (ref. 18) or T-DNA insertion (ref. 19), respectively, so as to produce glycoproteins with low antigenic potential in said mutants.
- i) Enzymes
- Generally, the present invention comprises different N-acetyl glucosaminyl transferase I enzymes (EC 2.4.1.101) from plants, e.g. potato ( Solanum tuberosum L.), tobacco (Nicotiana tabacum L.) and Arabidopsis thaliana (L.). In particular, the present invention relates to enzymes, which exhibit or contain the amino acid sequences given in FIGS. 2 and 3B as well as in the accompanying sequence protocol.
- Further, the invention comprises enzymes, which are derived from amino acid sequences of the above mentioned enzymes by amino acid substitution, deletion, insertion, modification or by C-terminal and/or N-terminal truncation and/or extension, and which—if showing enzymatic activity—exhibit a specificity comparable to that of the starting enzyme,. i.e. N-acetyl glucosaminyl transferase I activity, and optionally a comparable activity.
- In the present context, by the term “comparable activity” an activity is understood, which is in the range of up to 100% above or below that of the starting enzyme. Accordingly, also comprised by the invention are derived enzymes or proteins with very low or completely lacking enzymatic activity, which is detectable by means of one or more of the tests mentioned as follows. The enzyme activity is determined by a standard assay, which is performed with microsomal fractions either under radioactive conditions, e.g. using UDP-[6- 3H]GlcNAc as a substrate (ref. 13) or non-radioactive conditions (HPLC method; ref 20). Plant GnTI activity can be detected on the subcellular level in Golgi fractions (ref. 21). On account of low yields, however, it is almost impossible to enrich the enzyme from plants.
- Alternatively, an enzyme derived according to the present invention, may optionally be defined as an enzyme, for which a DNA sequence encoding the enzyme can be determined or derived, which hybridizes to a DNA sequence encoding the starting enzyme or to a complementary sequence under stringent conditions, as defined as follows.
- For example, an enzyme derived in such a manner represents an isoform, which comprises the amino acids 74 to 446 of the amino acid sequence illustrated in FIG. 2 and in SEQ ID No:1 and 2. This isoform i.a. lacks the membrane anchor formed by
amino acids 10 to 29. As a result, this enzyme isoform may be located in the plant cytosol. - As examples for C- and/or N-terminally extended proteins, fusion proteins can be mentioned, comprising in addition to an amino acid sequence according to the invention a further protein, which e.g. exhibits a different enzymatic activity or which may be easily detected in another manner, such as by means of fluorescence or phosphorescence or on account of a reactivity with specific antibodies or by binding to suitable affinity matrices.
- Furthermore, the invention comprises fragments of said enzymes, which optionally no longer exhibit any enzymatic activity. Generally, these fragments show an antigenic effect in a host immunized with said fragments, and may accordingly be employed as an antigen for the production of monoclonal or polyclonal antibodies by immunization of a host with those fragments.
- Moreover, this invention also relates to N-acetyl glucosaminyl transferase I enzymes from other varieties and plant species, which are obtainable on account of hybridization of their genes or one or more regions of their genes:
- to one or more of the DNA sequences and/or DNA fragments of the present invention, as discussed below and/or
- to suitable hybridization probes according to the invention, which may be prepared on the basis of the amino acid sequences mentioned in the sequence protocol considering the degeneration of the genetic code.
- Further comprised by the invention in accordance with the above are enzymes or proteins derived from these N-acetyl glucosaminyl transferase I enzymes, including fusion proteins thereof, as well as fragments of all of these enzymes or proteins.
- ii) Antibodies
- Another aspect of the present invention relates to the use of the amino acid sequences mentioned above and of fragments thereof having antigenic effects, respectively, for the production of monoclonal or polyclonal antibodies or antisera by immunizing hosts with said amino acid sequences or fragments, respectively, as well as of antibodies or antisera, respectively, per se, which specifically recognize and bind to the enzymes and/or antigens described above. The general procedure and the corresponding techniques for the generation of polyclonal and monoclonal antibodies are all well-known to the persons skilled in the art.
- Exemplarily, by the use of a fragment of the GntI cDNA (nucleotides 275 to 1395) represented in FIG. 2 and SEQ ID NO: 1, the recombinant GnTI protein from Solanum tuberosum with 10 N-terminal histidine residues (His-tag) was overexpressed in E. coli, and, following affinity purification via a metal-chelate matrix, was employed as an antigen for the production of polyclonal antisera in rabbits (cf. Examples 5 and 6).
- One possible use of the antibodies of the invention resides in the screening of plants for the presence of N-acetyl glucosaminyl transferase I.
- Binding of the antibody according to the present invention to plant protein(s) indicates the presence of N-acetyl glucosaminyl transferase I enzyme detectable with said antibody. In general, this antibody may then be covalently bound to a carrier in a later step, and optionally be employed for the enrichment or purification of the enzyme by means of column chromatography.
- On the other hand, a negative binding result using the antibody of the present invention, i.e. lack of binding to the plant proteins, may suggest, that N-acetyl glucosaminyl transferase I enzyme is absent (or highly modified by mutation), and thus, that N-acetyl glucosaminyl transferase I activity of a plant investigated is missing or highly reduced.
- Techniques for the realization of the screening assays mentioned above or the enrichment or purification of enzymes by the use of antibody columns or other affinity matrices (cf. Examples 5 and 6) are well-known to those skilled in the art.
- iii) DNA Sequences
- The present invention further comprises DNA sequences encoding the amino acid sequences of the invention, including amino acid sequences derived therefrom according to the above provisions. In particular, the invention relates to the respective gene, which is the basis of the amino acid sequences described in the FIGS. 2 and-3B and the sequence protocol, and especially, to the cDNA sequences described in FIG. 2 and the sequence protocol, as well as to DNA sequences derived from these genes and DNA sequences.
- By the term “derived DNA sequences” are meant sequences, which are obtained by substitution, deletion and/or insertion of one or more and/or smaller groups of nucleotides of the sequences mentioned above and/or by truncation or extension at the 5′ and/or 3′ terminus. Modifications within the DNA sequence may lead to derived DNA sequences, which encode amino acid sequences being identical to the amino acid sequence encoded by the starting DNA sequence, or to such sequences, in which, compared to the amino acid sequence, which is encoded by the starting DNA sequence, single or a few amino acids are altered, i.e. substituted, deleted and/or inserted, as well as to such sequences, which—optionally in addition—are truncated and/or extended at the C-terminus and/or N-terminus.
- Furthermore, the present invention also extends to the complementary sequences of the genes and DNA sequences according to the invention, as well as the RNA transcription products thereof.
- Particularly comprised by the present invention are all sequences derived according to the above provisions, which over their entire length or only with one or more partial regions hybridize under stringent conditions to the starting sequences mentioned above or to the sequences complementary thereto or to parts thereof, as well as DNA sequences comprising such sequences.
- By the term “hybridization under stringent conditions” in the sense of the present invention is understood a hybridization procedure according to one or more of the methods described below. Hybridizing: up to 20 h in PEG buffer according to Church and Gilbert (0.25 M Na 2HPO4, 1 mM EDTA, 1% (w/v) BSA, 7% (w/v) SDS, pH 7.5 with phosphoric acid; ref. 22) at 42° C. or in standard hybridization buffers with formamide at 42° C. or without formamide at 68° C. (ref. 23). Washing: 3 times at 65° C. for 30 min in 3×SSC buffer (ref. 23), 0.1% SDS.
- In the sense of the present application, the term “hybridization” always means hybridization under stringent conditions, as mentioned above, even if this is not explicitely indicated in the individual case.
- Moreover, the invention relates to fragments of the DNA sequences mentioned above, including the DNA sequences derived in accordance with the above provisions, to fragments derived from such fragments by nucleic acid substitution, insertion and/or deletion as well as the corresponding fragments with sequences complementary thereto. Such fragments are i.a. suitable as sequencing or PCR primers, screening probes and/or for uses as discussed below. For the use as a screening or hybridizing probe, the DNA fragments according to the present invention are frequently employed as radio-labelled fragments. Fragments carrying sequences, which are derived from the starting sequences defined above by substitution, deletion and/or insertion of one or more nucleotides, and the sequences complementary thereto, respectively, are comprised by the invention to that extent, as said fragments hybridize under the above mentioned stringent conditions to the starting sequences, or to the sequences complementary thereto, respectively.
- On the basis of the DNA sequences mentioned in the sequence protocol and in FIG. 2, DNA fragments according to the invention may for example be obtained starting from plant DNA by means of restriction endonucleases using appropriate restriction sites or by employment of PCR by means of primers appropriately synthesized, or may, as an alternative, also be chemically synthesized. Such techniques are well-known to those skilled in the art.
- Moreover, the invention relates to any DNA sequences, which represent a gene or are a part of a gene encoding the enzyme N-acetyl glucosaminyl transferase I and, which in their entirety or in a partial region thereof hybridize under stringent conditions
- to one or more of the DNA sequences of the invention and/or
- to one or more of the DNA fragments of the invention and/or
- to a DNA sequence, which is derived from the amino acid sequences mentioned in the sequence protocol considering the degeneration of the genetic code.
- For this purpose, hybridization or screening probes are used as DNA fragments, which generally comprise at least 15 nucleotides, typically between 15 and 30 nucleotides, and, if necessary, substantially more nucleotides. As an example, the primers employed in Example 1 may be used. Alternatively, DNA sequences of appropriate length, derived from the DNA sequences mentioned in the sequence protocol, may be used. As a third possibility, appropriate hybridization probes according to the invention may be developed starting from the amino acid sequences mentioned in the sequence protocol considering the degeneration of the genetic code.
- In this respect, a subject-matter of the present invention are also genes encoding N-acetyl glucosaminyl transferase I, which may be detected from other varieties or plant species on account of the hybridization thereof to above mentioned hybridization probes, as well as DNA sequences, DNA fragments and constructs, which are derived therefrom in accordance with the above provisions.
- The isolation of the corresponding gene and sequencing thereof following detection by means of the hybridization probes of the invention are well within the skills of a specialist in this field, and are detailed by way of example with respect to N-acetyl glucosaminyl transferase I from Solanum tuberosum and to the corresponding enzymes from Nicotiana tabacum and Arabidopsis thaliana (partial sequence) in the examples.
- Finally, another subject matter of the present invention are antisense sequences with respect to any of the above DNA sequences.
- iv) Constructs
- Also comprised by the invention are constructs, which may optionally comprise besides additional 5′ and/or 3′ sequences, e.g. linkers and/or regulatory DNA sequences or other modifications, the DNA sequences of the invention, including the DNA sequences derived as detailed above.
- An example for this are hybridization or screening probes, which in addition to a DNA sequence of the invention also comprise a detection agent for the verification of hybridization products, which in this case typically is non-radioactive, e.g. fluorescent or phosphorescent molecules, biotin, biotin derivatives, digoxigenin and digoxigenin derivatives. In this respect, however, radioactive or non-radioactive detection agents may be considered, which may be attached to the DNA sequence according to the present invention e.g. by means of end labelling.
- A subject-matter of the invention are also antisense and sense constructs with respect to the DNA sequences and fragments according to the present invention, i.e. with respect to
- the DNA sequences mentioned in the sequence protocol and the corresponding genes;
- the DNA sequences derived therefrom in accordance with the above provisions;
- one or more regions of these DNA sequences;
- DNA sequences, especially from other varieties or plant species, which represent a gene or are a part of a gene, encoding the enzyme N-acetyl glucosaminyl transferase I; and which hybridize under stringent conditions
- to one or more of the above DNA sequences and/or
- to one or more of the above DNA fragments and/or
- to a DNA sequence, which is derived from the amino acid sequences mentioned in the sequence protocol considering the degeneration of the genetic code.
- Furthermore, the present invention extends to any DNA-transfer systems such as vectors, plasmids, viral and phage genomes or cosmids, which contain the DNA sequences according to the present invention, e.g. the GntI gene, cDNA and DNA regions according to the invention, as mentioned in the sequence protocol, fragments thereof, in particular antisense or sense constructs and/or cDNA sequences derived therefrom according to the above provisions.
- Various techniques for the production or synthesis of DNA, DNA fragments, constructs and transfer systems according to the invention, e.g. digestion by means of restriction endonucleases, PCR amplification using suitable primers, optionally followed by cloning and additional chemical or enzymatic modification starting from plant DNA are well-known to those skilled in the art.
- One possibility of application of the DNA hybridization probes according to the invention is the detection of N-acetyl glucosaminyl transferase I genes in plants other than those, from which the DNA sequences mentioned in the sequence protocol were obtained, or the detection of potential (other) isoforms of the N-acetyl glucosaminyl transferase I gene in the starting plants Solanum tuberosum, Nicotiana tabacum and Arabidopsis thaliana.
- If it is possible to make use of a plant genomic library or cDNA library for the hybridization experiment, a positive hybridization result of such screening of each library may indicate a clone or a few clones, which contain the desired sequence completely or in part, i.e. the N-acetyl glucosaminyl transferase I gene, combined with only a limited amount of other DNA from the genome of the target plant, which appropriately facilitates cloning and sequencing of the target gene. As an alternative, a PCR amplification of the gene or parts thereof may also be carried out starting from plant DNA and suitable constructs, so-called PCR primers, to facilitate cloning and sequencing.
- One use of sequencing primers of the invention, which are synthesized starting from suitable regions of the sequences according to the invention, e.g. enables genomic sequencing starting from the entire target plant-genomic DNA cleaved by restriction endonucleases, by means of the Church-Gilbert technique, as well as sequencing at the cDNA level following RT-PCR amplification of the total RNA of the target plant (cf. Expl. 1).
- An alternative possibility of application of the DNA hybridization probes according to the present invention derived from the DNA sequences mentioned in the sequence protocol, is the use thereof according to the invention for the detection of plants with reduced or lacking N-acetyl glucosaminyl transferase I activity. The hybridization experiment serves to detect the N-acetyl glucosaminyl transferase I (GntI) gene by which it may be concluded, e.g. owing to a negative hybridization result under stringent conditions, that the GntI gene, and thus, N-acetyl glucosaminyl transferase I activity in a plant investigated is lacking.
- Such hybridization techniques for the detection of proteins or genes particularly in plant material by means of DNA probes are also known to the persons skilled in the art. In this context, it is referred to the above statements under item iii) for possible hybridization conditions. Generally, suitable DNA hybridization probes comprise at least 15 nucleotides of a sequence, which for example is derived from the cDNA sequences mentioned in FIG. 2 and the sequence protocol or from the corresponding GntI genes.
- v) Transformed Microorganisms
- Furthermore, the invention relates to microorganisms, such as bacteria, bacteriophages, viruses, unicellular eukaryotic organisms, such as fungi, yeasts, protozoa, algae, and human, animal and plant cells, which have been transformed by one or more of the DNA sequences of the invention or one or more of the constructs of the invention, as illustrated above.
- Transformed microorganisms according to the present invention are used e.g. as expression systems for the transforming foreign DNA to obtain the corresponding expression products. For this purpose, typical microorganisms are bacteria, e.g. such as E. coli. Furthermore, transformed microorganisms according to the invention, in particular agrobacteria, may be employed e.g. for the transformation of plants by transmission of the transforming foreign DNA.
- Methods for the transformation of cells of microorganisms by (foreign) DNA are well-known to those skilled in the art.
- For this purpose, e.g. constructs referred to as expression vectors are used, which contain the DNA sequence of the invention under control of a constitutive or inducible promoter, which, if necessary, is additionally tissue specific, so as to enable the expression of the introduced DNA in the target or host cell.
- Therefore, a further aspect of the invention is a method for the production of the enzymes and proteins of the invention by using one or more of the transformed microorganisms of the present invention. The method comprises cultivating at least one microorganism transformed by the DNA of the invention, in particular by one of the cDNAs mentioned in the sequence protocol, under the control of an active promoter, as defined above, and isolating the enzyme of the invention from the microorganisms, and, if applicable, also from the culture medium. It is understood, that this method also relates to the production of enzymes and proteins, respectively, which are derived from the enzymes according to the present invention from Solanum tuberosum, Nicotiana tabacum and Arabidopsis thaliana, as defined under i) above.
- Methods for the cultivation of transformed microorganisms are well-known to those skilled in the art. For example, the isolation of the expressed enzyme may be employed according to the method described in Example 5 by means of metal-chelate chromatography or, alternatively, by chromatography via columns, which contain the antibodies against the enzyme bound to the packing material.
- vi) Transgenic Plants
- Furthermore, the invention comprises transgenic plants, which are transformed by means of a DNA sequence according to the invention or a corresponding construct, respectively. Accordingly, there may be obtained e.g. transgenic plants, in which a GnTI deficiency, for example on account of a missing or defectice GntI gene or due to defects in the regulatory regions of this gene, has been removed by complementation using a construct derived from the cDNA sequences mentioned in the sequence protocol, wherein the expression of said construct is under the control of an active constitutive or inducible promoter, which may be additionally tissue specific. In this case, the GnTI enzyme or protein expressed on account of the DNA of the invention contained in the construct and having GnTI activity complements the GnTI activity missing in the starting plant.
- Also considered are transgenic plants, in which the GnTI activity already present in the starting plant is increased by additional expression of the GntI transgene introduced by means of a construct according to the present invention. Up to now, the extremely low expression of the GntI gene in vivo accompanied by extremely low enzyme activity, which correspondingly was very difficult to detect, has been a main problem in the investigation of the enzyme N-acetyl glucosaminyl transferase I in plants. The problem of a too low GnTI enzyme activity in plants may be overcome by the coexpression of a DNA according to the present invention.
- In this case, it may be preferable for the transformation of plants to employ DNA according to the invention, additionally comprising a sequence region, which following expression enables a facilitated detection and/or enrichment and purification, respectively, of the protein product having GnTI activity. This is for example accomplished by the use of a specific DNA sequence for the expression of a recombinant GnTI enzyme, said sequence carrying a N-terminal or C-terminal sequence extension encoding an affinity marker. If it is additionally intended to provide an amino acid sequence portion between the GnTI enzyme and the affinity marker, which represents a recognition site for a specific protease, cleavage of the N-terminal or C-terminal sequence extension from the GnTI enzyme may be achieved by the subsequent use of this specific protease, and the GnTI enzyme thereby obtained in isolated form.
- An example for this is the use of a DNA sequence according to the present invention, which codes for the recombinant GnTI enzyme with a C-terminal sequence extension, encoding the affinity marker AWRHPQFGG (strep-tag; ref. 39), and an intervening protease recognition site IEGR. The expression of the DNA according to the present invention provides GnTI enzymes with the C-terminal sequence extension mentioned, by means of which the expressed protein molecules specifically bind to a streptavidin derivatized matrix, and may thus be isolated. Then, by means of the protease factor Xa specifically recognizing the amino acid sequence IEGR, the GnTI portion of the protein molecules may be released. As an alternative, the complete protein may be removed from the streptavidin derivatized matrix by means of biotin or biotin derivatives.
- A further example is represented by DNA sequences of the invention, encoding a protein which comprises multiple, e.g. 10, N-terminally added histidine residues (His-tag) in addition to a GnTI enzyme. Due to the N-terminal histidine residues, isolation or purification, respectively, of the proteins expressed may be easily conducted by metal-chelate affinity chromatography (e.g. Ni sepharose) (cf. also Example 5).
- Moreover, the invention comprises portions of such transgenic plants, adequately transformed plant cells, transgenic seeds and transgenic reproduction material.
- A further important aspect of the invention is the use of the sequence information discussed above for the production of plants having reduced or lacking N-acetyl glucosaminyl transferase I activity.
- The possibilities of identifying plants with reduced or lacking N-acetyl glucosaminyl transferase I activity due to a gene defect or a missing gene by means of antibodies of the invention or screening or hybridization probes of the invention have already been described above.
- Two additional possibilities reside in the use according to the invention of antisense or sense constructs, respectively, which are derived from the DNA sequence of a plant GntI gene, for the production of transgenic plants with reduced or lacking N-acetyl glucosaminyl transferase I activity by means of homology-dependent gene silencing (cf. ref. 16,17). The DNA sequence used as a starting sequence for the generation of the constructs, may be derived from the starting plant to be transformed itself but also from a different plant variety or species. In particular, antisense or sense constructs as discussed under items iii) and iv) above are of use. Generally, the constructs employed comprise at least 50 to 200 and more base pairs.
- In particular, the constructs employed for this purpose comprise at least 50 to 200 and more base pairs, with a sequence, which is derived on the basis of
- the cDNA sequences mentioned in the sequence protocol and/or the corresponding GntI genes and/or
- the derived DNA sequences discussed above and/or DNA fragments according to the present invention and/or
- the DNA sequences, in particular from other varieties and plant species,.which encode N-acetyl glucosaminyl transferase I and which may be identified due to a hybridization under stringent conditions to hybridization or screening probes, as defined under items iii) and iv) above.
- Generally, the constructs contain a strong constitutive or inducible promoter, which additionally may be tissue specific, by means of which the antisense or sense DNA sequence regions are controlled.
- In the production of transgenic plants by integration of antisense construct(s) into the plant genome or by viral infection of starting plants or plant cells by means of virus containing antisense construct(s) for an extrachomosomal propagation and transcription of the antisense construct or the antisense constructs in infected plant tissue, it is intended to achieve a hybridization of GntI-gene transcripts to transcripts of the antisense DNA region at the RNA level, which prevents translation of the GntI mRNA. The result is a transgenic plant with strongly decreased contents of N-acetyl glucosaminyl transferase I, and thus, a strongly decreased corresponding enzyme activity.
- For the transformation of plants according to the invention with antisense constructs, for example constructs may be employed, which hybridize to one of the complete cDNAs, mentioned in FIG. 2 and in the sequence protocol, or to corresponding regions thereof, generally comprising at least 50 to more than 200 base-pairs. Moreover, particularly preferred is the use of fragments, the transcripts of which additionally cause a hybridization to a portion of the 5′ untranslated region of the GntI mRNA, at which or in the proximity of which usually the attachment of ribosomes would occur. Examples of such constructs are shown in FIG. 4.
- In view of the occurence of an isoform in Solanum tuberosum, which probably is located in the cytoplasm due to lack of the membrane anchor (
aa 10 to 29) of yet unkown function, it may be desirable to target only the N-acetyl glucosaminyl transferase I enzyme located in the Golgi cisternae, i.e. only that enzyme comprising the membrane anchor. One reason for this desire may be the effort or, in the individual case, also the requirement, to affect as little as possible the cytoplasmatic metabolism of the plant cell, for which the cytoplasmatic N-acetyl glucosaminyl transferase I possibly is of importance. For this purpose, antisense constructs may be used according to the present invention, which themselves or the transcripts of which, respectively, hybridize to a DNA or RNA region of the GntI gene or the GntI mRNA, comprising a part of the 5′ untranslated region and the coding region including the membrane anchor. Generally, the extension of the region of hybridization up to position 266 of the cDNA in FIG. 2 and SEQ ID NO: 1 is considered harmless for the purpose mentioned above. - In the production of transgenic plants by integration of sense constructs into the plant genome or by viral infection of starting plants or plant cells by means of virus containing sense construct(s) for extrachromosomal propagation and expression of the construct or constructs in infected plant tissue, there are assumed hybridization phenomena in tobacco according to the work of Faske et al. (ref. 17), of said constructs to the endogenous GntI gene at a posttranscriptional or DNA level, respectively, which finally affect or prevent the translation of the GntI gene. Also in this case, the result are transgenic plants having reduced or-even lacking N-acetyl glucosaminyl transferase I activity.
- Methods for the stable integration of such antisense and sense constructs into the genome of plants, or for the viral infection of plants or plant cells, respectively, for an extrachromosomal propagation and transcription/expression of such constructs in infected plant tissue are well known to those skilled in the art. This includes the direct DNA transfer (e.g. into protoplasts by means of electroporation or by the addition of a high molecular osmotic agent as well as biolistic methods, by which DNA coated particles are shot into the plant tissue), such as the use of natural host/vector systems (e.g. agrobacteria or plant viruses). For viral infection of starting plants or plant cells by viruses containing appropriate constructs for extrachromosomal propagation and transcription/expression of the constructs in infected plant tissue, a variety of specific viruses, such as tobacco mosaic virus (TMV) or potato virus X, is available.
- Representative plants, which are suitable for such integration, comprise dicotyledonous as well as monocotyledonous cultivated plants, in particular Solanaceae such as potato, tobacco, tomato and pepper. Additionally, banana, alfalfa, canola, beets, soybean, lettuce, corn, rice and grain, would be suitable target plants for the use of homologous antisense constructs. For example, the sequence from Arabidopsis thaliana mentioned in the sequence protocol appears to be particularly suitable as a starting sequence for the transformation according to the invention of Brassicaceae, such as canola plants, by means of sense or antisense constructs. Further plants of interest are any plants, which express glycoproteins of interest for medicine and research.
- Generally, it should be noted, that the transformation according to the invention of plants, which in the corresponding region of the GntI gene exhibit a homology of ≧70% at the nucleotide level to the employed antisense or sense constructs according to the present invention, typically results in transgenic plants of the invention, which show the desired reduction of N-acetyl glucosaminyl transferase I activity.
- Further, another possibility is seen in the targeted destruction (knock-out) of the N-acetyl glucosaminyl transferase I gene via gene targeting by means of homologous recombination (ref. 24) in a target plant using a suitable DNA fragment derived from the cDNA sequence of the present invention, similar to the procedure established for yeast systems and mammals.
- Further, the present invention comprises transgenic plants, which have been transformed by the antisense or sense constructs mentioned above or the viruses containing the same, respectively, as well as parts of such transgenic plants, correspondingly transformed plant cells, transgenic seeds and transgenic reproduction material.
- Methods of the production of transgenic plants, e.g. by means of agrobacteria- or virus-mediated as well as direct DNA transfer are known to those skilled in the art. Concerning representative plants for such a transformation, the above mentioned applies.
- The plants of the invention and the plants obtained according to the invention, respectively, with reduced or lacking N-acetyl glucosaminyl transferase I activity, may be used according to the invention for the production of glycoproteins with minimal and uniform, i.e. defined, sugar residues. As discussed above, such glycoproteins are of great importance for medicine and research. As a reasonable source of raw material and food as well as due to their unproblematical disposal via composting, plants per se represent ideal bioreactors. According to the present invention, it is now possible to express biotechnologically or pharmaceutically relevant glycoproteins (e.g. therapeutics of low antigenic potential for mammals) in cultivated plants, in which GnTI activity is highly reduced or completely absent.
- Accordingly, the invention also comprises a method for the production of glycoproteins with minimal uniform and defined sugar residues, comprising cultivating a transgenic plant according to the invention, of parts of such plants or of plant cells transformed according to the invention, each expressing the desired glycoprotein, as well as isolating the desired glycoprotein from the cultivated material.
- In this context, representative cultivated plants are Solanaceae, in particular potato, tobacco, tomato and pepper. Furthermore possible are banana, alfalfa, canola, beets, soybean, lettuce, corn, rice and grain.
- The sequence of the enzymatically controlled and plant specific N-glycan modifications, which secretory glycoproteins are subjected to during passage through the Golgi apparatus of higher plants, is schematically shown in FIG. 1. The biosynthesis block due to lacking or insufficient N-acetyl glucosaminyl transferase I (GlcNAc transferase I) activity in a plant leads, instead of complex glycans, to the predominant formation of glycans of the Man 5GlcNAc2 type, i.e. glycoproteins with uniform and well-defined sugar residues, which are of extremely high importance for medicine and research.
- For this purpose, the genes encoding the desired glycoproteins may be expressed in their natural producing plants, which have been transformed according to the present invention e.g. by means of antisense or sense constructs to yield transgenic plants with reduced or missing N-acetyl glucosaminyl transferase I activity.
- There is also the possibility to use transgenic plants of the invention displaying reduced or lacking N-acetyl glucosaminyl transferase I activity, which additionally have been transformed by the gene encoding the desired glycoprotein. In order to achieve this, constructs may be employed, which contain the gene encoding the desired glycoprotein under the control of a strong constitutive or inducible promoter, which is optionally tissue specific as well, and lead to the integration of the gene into the plant genome. Alternatively, the transformation may also be conducted by viral infection by means of a virus containing the gene for the desired glycoprotein for extrachromosomal propagation and expression of the gene. The glycoprotein may then be expressed in the respective host plant and obtained therefrom.
- Naturally, as an alternative, the procedure may be such, that initially a transformation using an expression construct or virus containing the DNA encoding the glycoprotein is performed, and subsequently, another transformation with one or more of the antisense or sense constructs of the invention or with one or more viruses, containing the corresponding DNA, is performed. It is also possible to perform a simultaneous transformation using both constructs or using one virus containing the antisense or sense construct as well as the gene encoding the desired glycoprotein (piggyback version).
- Within the scope of the present invention, there is also considered a viral overinfection of the transgenic plants according to the invention, in which integration of an anti-sense/sense construct and/or the gene encoding the desired glycoprotein into the genome has already occured, by viruses containing the antisense/sense construct and/or the gene encoding the desired glycoprotein, for an additional extrachromosomal propagation and transcription or expression, respectively, of this DNA. As a result, the concentrations of antisense or sense DNA, respectively, or of the expressed glycoprotein may be increased in the transgenic plant cells.
- It may prove to be practical for the production according to the invention of glycoproteins with defined glycosylation, to use tissue specific promoters in such cases, where it is intended to obtain the desired glycoproteins specifically only from certain parts of a plant such as tubers or roots. Today, for a large variety of plant tissues, tissue specific promoters are available, which drive expression of foreign genes specifically only-in these tissues. By way of example, tuber specific promoters such as patatin class I (ref. 26) and proteinase inhibitor II promoters (ref. 27) may be mentioned. Under certain conditions, both promoters exhibit expression also in leaf tissue, i.e. they can be induced by high metabolite contents (for example sucrose) and in the case of the proteinase inhibitor II promoter also by mechanical lesion or by spraying with abscisic or jasmonic acid, respectively.
- The use of tissue specific promoters may also be indicated in cases, where the DNA sequence or the transcription products or translation products thereof according to the invention, respectively, which are employed for the transformation, turn out to be detrimental to certain plant parts, e.g. due to a negative influence on the metabolism of the corresponding plant cells.
- As a representative target glycoprotein, human glucocerebrosidase may be used for the therapy of the hereditary Gaucher's disease (ref. 25). In order to obtain human glucocerebrosidase (GC) with uniform and defined sugar residues, e.g. plants of the present invention which are transformed by means of-antisense DNA, may be transformed with the gene encoding human glucocerebrosidase. For this purpose, the human glucocerebrosidase cDNA sequence (ref. 38) is modified at the 3′ terminus by means of PCR using gene specific primers in a manner, that the recombinant enzyme carries a C-terminal sequence extension encoding an affinity marker (e.g. AWRHPQFGG, strep-tag; ref. 39) and, optionally, also a protease recognition site (e.g. IEGR) between the GnTI enzyme region and the affinity marker. The GC-cDNA sequence thus altered is expressed in GntI antisense plants of the present invention by using a strong and optionally tissue specific promoter (e.g. for potato under the control of the tuber specific B33 patatin promoter), so that the enzyme synthesized in these plants exclusively carries well defined N-glycans. The affinity marker is intended to facilitate-the enrichment of the recombinant enzyme from the transgenic plants. In this case, the expressed protein molecules (GC-strep molecules) bind to a streptavidin derivatized matrix via the affinity marker sequence and can be released therefrom by means of biotin or biotin derivatives. The removal from the strepatavidin derivatized matrix may also be carried out by means of catalytic amounts of a protease, which exhibits a specificity for the protease recognition site located between the GnTI enzyme region and the affinity marker. In this case, only the GnTI enzyme region is released from the matrix. This could be advantageous especially in that case, if the affinity marker sequence has a detrimental effect on the GnTI activity.
- Due to their terminal mannose residues, the Man 5GlcNAc2-glycans of the glucocerebrosidase obtained, from the plants of the present invention will be recognized by macrophages as an uptake signal, and can thus directly be employed for the therapy of hereditary Gaucher's disease. Currently, a therapy is only possible upon expensive isolation and deglycosylation of native glucocerebrosidase (ref. 25).
- Accordingly, the production of recombinant glycoproteins may be highly facilitated by the use of plant GntI sequences compared to conventional methods, e.g. the chemical deglycosylation of purified glycoproteins, which is technically demanding (ref. 25), or a difficult and expensive production in GnTI deficient animal cell lines (ref. 7,10).
- FIG. 1: Sequence of plant specific N-glycan modifications, which secretory glycoproteins are subject to during passage through the Golgi apparatus of higher plants (ref. 28). The biosythesis block to complex modified glycans is based on a deficiency in GnTI activity (which is either caused by a defective or missing GnTI enzyme or by effective reduction of the GntI gene expression) and is indicated by a cross. Meaning of the symbols: (F) fucose residues, (X) xylose residues, dues, () GlcNAc residues, (□) mannose residues.
- FIG. 2: Full length cDNA sequence of a plant GnTI from potato ( Solanum tuberosum L.) and amino acid sequence deduced therefrom. By way of example, the complete cDNA of the membrane anchor containing GntI isoform from potato leaf tissue (A1) is illustrated. The EcoRI/NotI linkers at the 5′ and 3′ ends of the cDNA are highlighted by bold letters, the binding sites of the degenerate oligonucleotides used for obtaining the RT-PCR probe are underlined. In contrast to already published animal GnTI sequences, the protein sequence derived from the potato cDNA clones contains a potential N-glycosylation site: Asn-X(without Pro)-Ser/Thr, which is indicated by an asterisk. The region of the membrane anchor is highlighted in italics (
aa 10 to 29). The start of the isoform (A8), which is potentially located in the cytosol, is indicated by an arrow. - FIG. 3: A, Degree of identity or similarity, respectively, of the amino acid sequence deduced from a complete GntI cDNA sequence from potato (A1) in comparison to other GnTI sequences of animal organisms, which have been selected from data bases. Identical amino acid positions (in %) are printed in bold letters, similar amino acid positions are given in brackets underneath. Meaning of the abbreviations: Hu, human; Ra, rat; Mo, mouse; Ce, Caenorhabditis elegans (round-worm); St, Solanum tuberosum (potato) B, Comparison of the derived amino acid sequences of different plant GntI-cDNA clones. A_Stb-A1, GnTI from potato leaf; B_Ntb-A9, GnTI from tobacco leaf (A9); C_Atb-Full, GnTI from Arabidopsis thaliana. Identical aa are highlighted in black, similar aa in light grey.
- FIG. 4: Cloning strategy of the GntI-antisense constructs used. Following fill-in of the ends, a NotI linker was introduced into the SalI restriction site of the polylinker region of the plant expression vector pA35 (=pA35N) (ref. 29), and the complete A1-GntI-cDNA was inserted into pA35N via NotI. The corresponding antisense construct (=pA35N-Alas) was inserted into binary vector pBin19 (ref. 30) via EcoRI and HindIII. Additionally, following PCR amplification, a 5′ fragment of the A1-GntI-cDNA comprising 270 bp was cloned into pA35N via XbaI and NotI restriction sites in antisense orientation (=pA35N-A1-short) and also inserted into pBin19. Abbreviations; Numerals in brackets, positions of the restriction sites in the A1-GntI-cDNA (in base pairs); pBSK, cloning vector (Stratagene): pGEM3Z, cloning vector (Promega); CaMVp35S, constitutive 35S promoter of cauliflower mosaic virus; OCSpA, polyadenylation signal of octopin synthase; PNOS, promoter of nopaline synthase; NEO, neomycin phosphotransferase (selection marker, confers kanamycin resistance); NOSpA, polyadenylation signal of nopaline synthase; LB/RB, left/right border of the T-DNA of the binary vector; arrow, translation initiation (ATG); A8, start ;of the GnTI isoform, which is potentially located in the cytosol (7 aa substitutions in comparison to A1).
- FIG. 5: Extent of suppression of complex glycoprotein modification in transgenic potato plants transformed with the long GntI antisense construct (cf. FIG. 4). A, Coomassie-stained SDS gel from leaf extracts; B, Western-blot analysis (Ref. 13,33) of parallel samples developed with a complex-glycan antiserum (Ref. 12,13). The lanes contain 30 μg each of total protein: cgl (Ara), Arabidopsis cgl mutant (Ref. 13); WT(Desi), wild-type potato; the numerals refer to individual transgenic potato plants; the arrows represent molecular weight standards of 66, 45, 36 and 29 kDa, respectively.
- FIG. 6: Detection of specificity of the generated GnTI antiserum following cell fractionation (Ref. 40) of tobacco callus material. For Western-blot analysis (Ref. 13,33) 30 μg of protein were applied per lane. The antiserum was used in 1:1000 dilution.
Lane 1, homogenate following separation of cellular debris;lane 2, vesicle fraction following column chromatography;lane 3, sucrose gradient fraction I (microsomes);lane 4, sucrose gradient fraction II (plastids);lane 5, antigen used for immunization (recombinant GnTI fusion protein); arrow, molecular weight of about 49 kDa. - Aa, amino acid(s); bp, base pair(s); EMS, Ethyl methane sulfonate (mutagenic agent); F2, second filial generation; Fuc, fucose; Glc, glucose; GlcNAc, N-acetyl glucosamine; GnTI, N-acetyl glucosaminyl transferase I (EC 2.4.1.101); GntI, gene for GnTI (nuclear encoded); kDa, kilodalton; Man, mannose; PCR, polymerase chain reaction; PAGE, polyacrylamide gel electrophoresis; ref., reference; RT-PCR, reverse transcription coupled polymerase chain reaction; SDS, sodium dodecyl sulfate; var., variety; Xyl, xylose.
- In the following, the invention will be described in more detail by means of examples, which are only intended to illustrate the invention and shall not limit the invention in any manner.
- Total RNA was isolated from potato and tobacco leaf tissue, and cDNA fragments of about 90 bp were amplified by means of RT-PCR in combination with degenerate primers (procedure analogous to ref. 31), which were derived from conserved amino acid regions of known GnTI sequences from animal organisms (
sense primer 1*, 5′-TG(CT) G(CT)I (AT)(GC)I GCI TGG (AC)A(CT) GA(CT) AA(CT)-3′;antisense primer 3*, 5′-CCA ICC IT(AG) ICC (ACGT)G(CG) (AG)AA (AG)AA (AG)TC-3′; 30 pmol of each primer per 50 μl PCR assay at an annealing temperature of 55° C. and 45 cycles). Following gel elution, the ends of the PCR products were repaired (i.e. blunt ended using DNA polymerase I and phosphorylated using T4 polynucleotide kinase) and cloned into the EcoRV restriction site of pBSK (Stratagene). By comparison with known GnTI sequences between the primers (arrows), the identity of the derived amino acid sequences from the potato and tobacco RT-PCR products could be confirmed as being homologous; Q(R/M)QFVQDP(D/Y)ALYRS (homologous aa are underlined). Of one clone each, radio-labelled probes were synthesized by means of PCR (standard PCR assay using degenerate primers as above, nucleotide mixture without dCTP, but instead with 50 μCi α-32P-dCTP [>3000 Ci/mMol]), and different cDNA libraries were screened for GntI containing clones using the corresponding homologous potato or tobacco probes, respectively (procedure analogous to ref. 31; the stringent hybridization conditions have already been described in the text above). The cDNA libraries were prepared from mRNA of young and still growing plant parts (sink tissues). Following cDNA synthesis and ligating EcoRI/NotI adaptors (cDNA synthesis kit, Pharmacia) EcoRI compatible lambda arms were ligated, those packaged and used to transfect E. coli XL1 Blue cells (Lambda ZAPII cloning and packaging system, Stratagene). Following amplification of the libraries, one full-length GntI clone each was isolated from a potato leaf sink library (Al according to FIG. 2 and SEQ ID NO: 1) and a tobacco leaf sink library (A9 according to SEQ ID NO: 3), as well as two additional clones from a tuber sink library (A6, A8). The deduced GnTI amino-acid sequences contain a potential N-glycosylation site, Asn-X(without Pro)-Ser/Thr, in contrast to those of animals. One of the tuber GntI cDNA sequences carries stop codons in all three reading frames in front of the first methionine (A8). The coding region shows high homology to the longer tuber clone (A6) (only 2 aa substitutions), but displays a completely different 5′ non-translated region. Furthermore, the membrane anchor characteristic for the Golgi enzyme is missing, so that this GnTI isoform might be located in the cytosol. Sequence comparisons carried out by means of the gap or pileup option, respectively, and the box option of the gcg software package (J. Devereux, P. Haeberli, O. Smithies (1984) Nucl. Acids Res. 12: 387-395) indicate, that the deduced plant GnTI amino-acid sequences exhibit only 30-40% identity and 57-59% similarity to those of animal organisms (FIG. 3A), while they are highly homologous among each other (75 - 90% identity, FIG. 3B). - The procedure in the case of Arabidopsis thaliana was analogous, wherein for the preparation of a specific probe first a partial GntI sequence was amplified by RT-PCR using GntI sense primer 4A (5′-ATCGGAAAGCTTGGATCC CCA GTG GC(AG) GCT GTA GTT GTT ATG GCT TGC-3′; HindIII restriction site underlined, BamHI printed in bold) and
antisense primer 3*, as defined above. First, a 5′-incomplete cDNA clone was isolated from a phage library (Lambda Uni-Zap) using this probe. By means of a vector insert PCR, the missing 5′-terminus was amplified from another library (via an unique SpeI restriction site in the 5′ region) and assembled to yield a full-length cDNA sequence. The nucleic acid sequence determined by means of sequencing is listed in SEQ ID NO: 5. - Approximately 4 weeks subsequent to sowing, protoplasts were isolated from leaves of cgl mutants cultivated under sterile conditions (nonstainer plants following 5 backcrosses, ref. 13), transformed with expression constructs of the complete GntI cDNA sequences (NotI cDNA fragments, cf. FIG. 4) in sense (pA35N-A1s or pA35N-A9s, respectively) or antisense orientation (pA35N-Alas or pA35N-A9as, respectively), and cultivated for 96 h at room temperature in the dark (50 μg of plasmid DNA each per 1 million protoplasts, PEG method according to ref. 32). Subsequent SDS-PAGE of the protoplast extracts and Western-blot analysis (analogous to ref. 13, 33) indicated functional complementation of the GnTI defect, i.e. complex glycosylation of numerous protein bands upon transient expression of the potato Al and tobacco A9 sense constructs, but not of the corresponding antisense constructs in protoplasts of the Arabidopsis cgl mutant (data not shown).
- Into the SalI restriction site of the polylinker region (corresponding to the one of pUC18) of plant expression vector pA35 (ref. 29), a NotI linker was introduced subsequently to the fill-in of the ends (=pA35N), and the complete A1-GntI-cDNA (nucleotides 9 to 1657; according to the cDNA in FIG. 2) was inserted into pA35N via NotI (sense construct pA35N-A1s and antisense construct pA35N-Alas, respectively). The expression cassettes of the sense and antisense constructs, respectively, were isolated via the terminal restriction sites (filled-in NcoI restriction site, partial post digestion with HindIII) as a fragment of about 2410 bp and inserted into the EcoRI (filled-in) and HindIII restriction sites of the binary vector pBin19 (Ref. 30) (=pBin-35-A1s and pBin-35-Alas, respectively). The EcoRI restriction site of the vector is restored by fusion with the equally filled-in NcoI restriction site of the fragment. By means of a standard PCR assay (sense primer: KS sequencing primer (Stratagene) extended for PCR, 5′-GGC CCC CCC TCG AGG TCG ACG GTA TCG-3′; antisense primer: 5′-GGGCC TCTAGACTCGAG AGC (CT)AC TAC TCT TCC TTG CTG CTG GCT AAT CTT G-3′, XbaI restriction site underlined, XhoI restriction site in italics), there was additionally amplified a 5′-fragment of the GntI cDNA at an annealing temperature of 50° C. (nucleotides 9 to 261, according to the cDNA in FIG. 2 and SEQ ID NO: 1). The PCR product was digested with XbaI (within the antisense primer) and NotI (within the 5′-linker of the cDNA), isolated as a fragment of about 260 bp and cloned into pA35N (=pA35N-A1-short). The expression cassette of the short antisense construct was also inserted into pBin19 (=pBin-35-A1-short) as a EcoRI/HindIII fragment (about 1020 bp).
- The binary antisense GntI constructs (pBin-35-Alas and pBin-35-A1-short) were transformed into the Agrobacterium strain GV2260 (ref. 34, 35). By way of example, sterile leaf discs of potato plants var. Désirée and of tobacco plants var.
Wisconsin 38 were infected with the recombinant agrobacterial lines (50 μl of a fresh overnight culture in 10 ml liquid 2MS medium: 2% sucrose in Murashige & Skoog salt/vitamin standard mediums pH 5.6; small pieces of leaf without midrip; co-cultivation for 2 days in the dark in phytotrons). Subsequent to washing of the infected leaf pieces in 2MS medium with 250 μg/ml claforan, transgenic plants were regenerated from said pieces in tissue culture under kanamycin selection (potato protocol ref. 26; tobacco protocol ref. 36) and analyzed for reduced GnTI activity (exemplary shown in FIG. 5 for transgenic potato plants). As apparent from FIG. 5, antisense suppression of complex glycoprotein modifiaction was successful in transgenicpotato plant # 439. The determined reduction of complex glycoprotein modification was stable in this transformant over the entire investigation period of several months and has been verified in three tests which were performed in an interval of about l month each. For the respective transgenic tobacco plants, analogous results were obtained. - Recombinant GnTI carrying 10 additional N-terminal histidine residues (His-tag) was produced in E. coli by means of the pET system (Novagen) and purified by metal-chelate affinity chromatography. A cDNA fragment comprising nucleotides 275-1395 of the potato GntI cDNA (corresp. to aa 75-446, FIG. 2 and SEQ ID NO: 1 and 2, respectively) was amplified by standard PCR (annealing temperature of 50° C., 30 cycles, ref. 31) (sense primer GntI-5′fus: 5′-CATGGATCC CTC GAG AAG CGT CAG GAC CAG GAG TGC CGG C-3′; antisense primer GntI-3′ stop: 5′-ATCCCGGGATCCG CTA CGT ATC TTC AAC TCC AAG TTG-3′; XhoI and BamHI restriction sites, respectively, are underlined, stop codon in italics), and inserted into vector pET16b (Novagen) (=pET-His-A1) via the restriction sites of the synthetic primer (5′-XhoI-GntI-BamHI-3′). Following propagation and analysis in E. coli XL1-Blue (Stratagene) the construct was stored as a glycerol culture. Competent E. coli BL21(DE3) pLysS cells (Novagen) were transformed with pET-His-A1 for overexpression. Addtition of IPTG (Isopropyl-1-thio-β-D-galactopyranoside, at 0.5-2 mM) to a BL21 culture in logarithmic growth phase, initially induces the expression of T7 RNA polymerase (from the bacterial chromosome), and thus, also the expression of the recombinant fusion protein under control of the T7 promoter in pET vectors (Novagen). By means of metal-chelate chromatography using TALON matrix (Clontech), recombinant potato GnTI was purified from induced BL21:pET-His-A1 cells under denaturating conditions via its His-tag (manufacturer's protocol, Novagen), and the preparation was verified with respect to homogeneity by means of SDS-PAGE.
- Recombinant potato GnTI (from Expl. 5) was used as an antigen. Following the harvest of some milliliters of pre-immune serum, the rabbits were subcutaneously injected with 300-500 μg of affinity-purified protein together with 25 μg of GMDP adjuvant (Gerbu) in intervals of three weeks. Subsequent to three basis injections, the- animals were bled from the ear vein 12 to 14 days after the respective successive injection (boost), the serum harvested (ref. 37) and tested for recognition of recombinant GnTI by Western-blot analyses (dilution 1:200 to 1:2000). The antiserum of the boosts resulting in the lowest background-to-signal ratio were mixed with 0.04% sodium azide, aliquoted and kept at +4° C. or for long-term storage at −20° C., respectively. As shown in FIG. 6, Western-blot analyses of tobacco callus cells (BY-2 suspension culture) revealed a t specific GnTI signal in enriched microsomal fractions, which indicates, that antibodies raised against the recombinant protein specifially recognize plant GnTI. The detection was carried out with enriched microsomal fractions (ER and Golgi vesicles), since—due to low amounts—it is not possible to detect GnTI protein in crude plant extracts by means of the employed Western-blot method.
- References:
- 1) R Kornfeld, S Kornfeld (1985) Assembly of asparagine-linked oligosaccharides. Annu Rev Biochem 54: 631-664
- 2) G P Kaushal, T Szumilo, A D Elbein (1988). Structure and biosynthesis of plant N-linked glycans. In J Preiss (editor) The Biochemistry of Plants, Vol 14: Carbohydrates. Academic Press, San Diego, Calif., pp 421-463
- 3) L Faye, M J Chrispeels (1989) Apparent inhibition of β-fructosidase secretion by tunicamycin may be explained by breakdown of the unglycosylated protein during secretion. Plant Physiol 89: 845-851
- 4) T W Rademacher, R B Parekh, R A Dwek (1988) Glycobiology. Annu Rev Biochem 57: 785-838
- 5) A Sturm (1991) Heterogeneity of the complex N-linked oligosaccharides at specific glycosylation sites of 2 secreted carrot glycoproteins. Eur J Biochem 199: 169-179
- 6) K Olden, B A Bernard, M J Humphries, T Yeo, S L White, S A Newton, H C Bower, J B Parent (1985) Function of glycoprotein glycans. Trends Biochem Sci 10: 78-82
- 7) P Stanley (1989) Chinese hamster ovary cell mutants with multiple glycosylation defects for production of glycoproteins with minimal carbohydrate heterogeneity. Mol Cell Biol 9: 377-383
- 8) R Kumar, J Yang, R D Larsen, P Stanley (1990) Cloning and expression of N-acetylglucosaminyltransferase I, the medial Golgi transferase that initiates complex N-linked carbohydrate formation. Proc Natl Acad Sci USA 87: 9948-9952
- 9) J W Dennis, S Laferte, C Waghorne, M L Breitman, R S Kerbel (1987) β→6 branching of Asn-linked oligosaccharides is directly associated with metastasis. Science 236: 582-585
- 10) M N Fukuda (1990) HEMPAS disease: genetic defect of glycosylation. Glycobiology 1: 9-15
- 11) M N Fukuda, K A Masri, A Dell, L Luzzatto, K W Moremen (1990) Incomplete synthesis of N-glycans in congenital dyserythropoetic anemia type-II caused by a defect in the gene encoding α-mannosidase II. Proc Natl Acad Sci USA 87: 7443-7447
- 12) M Laurière, C Lauriere, M J Chrispeels, K D Johnson, A Sturm (1989) Characterization of a xylose-specific anti-serum that reacts with the complex asparagine-linked glycans of extracellular and vacuolar glycoproteins. Plant Physiol 90: 1182-1188
- 13) A von Schaewen, A Sturm, J O'Neill, M J Chrispeels (1993) Isolation of a mutant Arabidopsis plant that lacks N-acetyl glucosaminyl transferase I and is unable to synthesize Golgi-modified complex N-linked glycans. Plant Physiol 102: 1109-1118
- 14) JK-C Ma, M B Hein (1995) Plant antibodies for immunotherapy. Plant Physiol 109: 341-346
- 15) A S Moffat (1995) Medical applications: Exploring transgenic plants as a new vaccine source. Science 268: 658-660 (summary of two original publications in the same issue)
- 16) C B Taylor (1997) Comprehending cosuppression. Plant Cell 9: 1245-1249 (summary of several original publications in the same issue)
- 17) M Faske, J E Backhausen, M Sendker, M Singer-Bayrle, R Scheibe, A von Schaewen (1997) Transgenic tobacco plants expressing pea chloroplast Nmdh cDNA in sense and antisense orientation: Effects on NADP-MDH level, stability of transformants, and plant growth. Plant Physiol 115: 705-715
- 18) R Koes, E Souer, A van Houwelingen, L Mur, C Spelt, F Quattrocchio, J Wing, B Oppedijk, S Ahmed, T Maes, T Gerats, P Hoogeveen, M Meesters, D Kloos, JNM Mol (1995) Targeted gene inactivation in petunia by PCR-based selection of transposon insertion mutants. Proc Acad Sci USA 92: 8149-8153
- 19) E C McKinney, N Ali, A Traut, K A Feldmann, D A Belostotsky, J M McDowell, R B Meagher (1995) Sequence-based identification of T-DNA insertion mutations in Arabidopsis: actin mutants act2-1 and act4-1. Plant J 8: 613-622
- 20) F Altmann, G Kornfeld, T Dalik, E Staudacher, J Glössl (1993) Processing of asparagine-linked oligosaccharides in insect cells. N-acetylglucosaminyl transferase I and II activities in cultured lepidopteran cells. Glycobiology 3: 619-625
- 21) A Sturm, K D Johnson, T Szumilo, A D Elbein, M J Chrispeels (1987) Subcellular localization of glycosidases and glycosyltransferases involved in the processing of N-linked oligosaccharides. Plant Physiol 85: 741-745
- 22) G M Church, W Gilbert (1984) Genomic sequencing. Proc Acad Sci USA 81: 1991-1995
- 23) J Sambrook, E F Fritsch, T Maniatis (1989) Molecular cloning: a laboratory manual (2nd edn), Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
- 24) H Puchta, B Hohn (1996) From centiMorgans to base pairs: homologous recombination in plants. Plant Sci 1: 340-348
- 25) N W Barton, F S Furbish, G J Murray, M Garfield, R O Brady (1990) Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease. Proc Natl Acad Sci USA 87: 1913-1916
- 26) M Rocha-Sosa, U Sonnewald, W-B Frommer, M Stratmann, J Schell, L Willmitzer (1989) Both developmental and metabolic signals activate the promoter of a class I patatin gene. EMBO J 8: 23-29
- 27) T Hildmann, M Ebneth, H Pena-Cortes, J J Sanchez-Serrano, L Willmitzer, S Prat (1992) General roles of abscisic and jasmonic acids in gene activation as a result of mechanical wounding. Plant Cell 4: 1157-1170
- 28) K D Johnson, M J Chrispeels (1987) Substrate specificities of N-acetylglucosaminyl-, fucosyl-, and xylosyltransferases that modify glycoproteins in the Golgi apparatus of bean cotyledons. Plant Physiol 84: 1301-1308
- 29) H Hofte, L Faye, C Dickinson, E M Herman, M J Chrispeels (1991) The protein-body proteins phytohemagglutinin and tonoplast intrinsic protein are targeted to vacuoles in leaves of transgenic tobacco. Planta 184: 431-437
- 30) M Bevan (1984) Binary Agrobacterium vectors for plant transformation. Nucl Acids Res 12: 8711-8721
- 31) K Graeve, A von Schaewen, R Scheibe (1994) Purification, characterization and cDNA sequence of glucose-6-phosphate dehydrogenase from potato ( Solanum tuberosum L.). Plant J 5: 353-361
- 32) B Damm, R Schmidt, L Willmitzer (.1989) Efficient transformation of Arabidopsis thaliana using direct gene transfer to protoplasts. Mol Gen Genet 213: 15-20
- 33) A von Schaewen, M Stitt, R Schmidt, L Willmitzer (1990) Expression of a yeast-derived invertase in the cell wall of tobacco and Arabidopsis plants leads to accumulation of carbohydrate, inhibition of photosynthesis and strongly influences growth and phenotype of transgenic tobacco plants. EMBO J. 9: 3033-3044
- 34) R Deblaere, B Bytebier, H De Greve, F Debroeck, J Schell, M van Montagu, J Leemans (1985) Efficient octopine Ti plasmid-derived vectors for Agrobacterium mediated gene transfer to plants. Nucl Acids Res 13: 4777-4788
- 35) R Höfgen, L Willmitzer (1988) Storage of competent cells for Agrobacterium transformation. Nucl Acids Res 16: 9877
- 36) T Voelker, A Sturm, M J Chrispeels (1987) Differences in expression between two seed lectin alleles obtained from normal and-lectin-deficient beans are maintained in transgenic tobacco. EMBO J 6: 3571-3577
- 37) E Harlow, D Lane (1988) Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
- 38) J Sorge, C West, B Westwood, E Beutler (1985) Molecular cloning and nucleotide sequence of human cerebrosidase cDNA. Proc Natl Acad Sci USA 82: 7289-7293
- 39) T G M Schmidt, A Skerra (1993) The random peptide library-assisted engineering of a C-terminal affinity peptide, useful for the detection and purification of a functional Ig Fv fragment. Prot Engineering 6: 109-122
- 40) M van der Wilden, N R Gilkes, M J Chrispeels (1980) The endoplasmic reticulum of mung bean cotyledons: role in the accumulation of hydrolases in protein bodies during seedling growth. Plant Physiol. 66: 390-394
-
1 14 1 1669 DNA Solanum tuberosum misc_feature (659)...(667) function Asn codon in this context is a potential glycosylation site; product N-glycosylation consensus sequence; phenotype N-glycans modulate protein properties; 1 gaattcgcgg ccgcctgaga aaccctcgaa ttcaatttcg catttggcag ag atg aga 58 Met Arg 1 ggg aac aag ttt tgc ttt gat tta cgg tac ctt ctc gtc gtg gct gct 106 Gly Asn Lys Phe Cys Phe Asp Leu Arg Tyr Leu Leu Val Val Ala Ala 5 10 15 ctc gcc ttc atc tac ata cag atg cgg ctt ttc gcg aca cag tca gaa 154 Leu Ala Phe Ile Tyr Ile Gln Met Arg Leu Phe Ala Thr Gln Ser Glu 20 25 30 tat gta gac cgc ctt gct gct gca att gaa gca gaa aat cat tgt aca 202 Tyr Val Asp Arg Leu Ala Ala Ala Ile Glu Ala Glu Asn His Cys Thr 35 40 45 50 agt cag acc aga ttg ctt att gac aag att agc cag cag caa gga aga 250 Ser Gln Thr Arg Leu Leu Ile Asp Lys Ile Ser Gln Gln Gln Gly Arg 55 60 65 gta gta gct ctt gaa gaa caa atg aag cat cag gac cag gag tgc cgg 298 Val Val Ala Leu Glu Glu Gln Met Lys His Gln Asp Gln Glu Cys Arg 70 75 80 caa tta agg gct ctt gtt cag gat ctt gaa agt aag ggc ata aaa aag 346 Gln Leu Arg Ala Leu Val Gln Asp Leu Glu Ser Lys Gly Ile Lys Lys 85 90 95 tta atc gga gat gtg cag atg cca gtg gca gct gta gtt gtt atg gct 394 Leu Ile Gly Asp Val Gln Met Pro Val Ala Ala Val Val Val Met Ala 100 105 110 tgc agt cgt act gac tac ctg gag agg act att aaa tcc atc tta aaa 442 Cys Ser Arg Thr Asp Tyr Leu Glu Arg Thr Ile Lys Ser Ile Leu Lys 115 120 125 130 tac caa aca tct gtt gca tca aaa tat cct ctt ttc ata tcc cag gat 490 Tyr Gln Thr Ser Val Ala Ser Lys Tyr Pro Leu Phe Ile Ser Gln Asp 135 140 145 gga tca aat cct gat gta aga aag ctt gct ttg agc tat ggt cag ctg 538 Gly Ser Asn Pro Asp Val Arg Lys Leu Ala Leu Ser Tyr Gly Gln Leu 150 155 160 acg tat atg cag cac ttg gat tat gaa cct gtg cat act gaa aga cca 586 Thr Tyr Met Gln His Leu Asp Tyr Glu Pro Val His Thr Glu Arg Pro 165 170 175 ggg gaa ctg gtt gca tac tac aag att gca cgt cat tac aag tgg gca 634 Gly Glu Leu Val Ala Tyr Tyr Lys Ile Ala Arg His Tyr Lys Trp Ala 180 185 190 ttg gat cag ctg ttt cac aag cat aat ttt agc cgt gtt atc ata cta 682 Leu Asp Gln Leu Phe His Lys His Asn Phe Ser Arg Val Ile Ile Leu 195 200 205 210 gaa gat gat atg gaa att gct gct gat ttt ttt gac tat ttt gag gct 730 Glu Asp Asp Met Glu Ile Ala Ala Asp Phe Phe Asp Tyr Phe Glu Ala 215 220 225 gga gct act ctt ctt gac aga gac aag tcg att atg gct att tct tct 778 Gly Ala Thr Leu Leu Asp Arg Asp Lys Ser Ile Met Ala Ile Ser Ser 230 235 240 tgg aat gac aat gga caa agg cag ttc gtc caa gat cct gat gct ctt 826 Trp Asn Asp Asn Gly Gln Arg Gln Phe Val Gln Asp Pro Asp Ala Leu 245 250 255 tac cgc tca gac ttt ttt cct ggt ctt gga tgg atg ctt tca aaa tca 874 Tyr Arg Ser Asp Phe Phe Pro Gly Leu Gly Trp Met Leu Ser Lys Ser 260 265 270 act tgg tcc gaa cta tct cca aag tgg cca aag gct tac tgg gat gac 922 Thr Trp Ser Glu Leu Ser Pro Lys Trp Pro Lys Ala Tyr Trp Asp Asp 275 280 285 290 tgg cta agg ctg aaa gaa aat cac aga ggt cga caa ttt att cgc cca 970 Trp Leu Arg Leu Lys Glu Asn His Arg Gly Arg Gln Phe Ile Arg Pro 295 300 305 gaa gtt tgc aga acg tac aat ttt ggt gag cat ggt tct agt ttg ggg 1018 Glu Val Cys Arg Thr Tyr Asn Phe Gly Glu His Gly Ser Ser Leu Gly 310 315 320 cag ttt ttt aag cag tat ctt gag cca att aag cta aat gat gtc cag 1066 Gln Phe Phe Lys Gln Tyr Leu Glu Pro Ile Lys Leu Asn Asp Val Gln 325 330 335 gtt gat tgg aag tca atg gac cta agt tac ctt ttg gag gac aac tat 1114 Val Asp Trp Lys Ser Met Asp Leu Ser Tyr Leu Leu Glu Asp Asn Tyr 340 345 350 gtg aaa cac ttt ggc gac ttg gtt aaa aag gct aag ccc atc cac gga 1162 Val Lys His Phe Gly Asp Leu Val Lys Lys Ala Lys Pro Ile His Gly 355 360 365 370 gct gat gct gtt ttg aaa gca ttt aac ata gat ggt gat gtg cgt att 1210 Ala Asp Ala Val Leu Lys Ala Phe Asn Ile Asp Gly Asp Val Arg Ile 375 380 385 cag tac aga gac caa cta gac ttt gaa gat atc gct cga cag ttt ggc 1258 Gln Tyr Arg Asp Gln Leu Asp Phe Glu Asp Ile Ala Arg Gln Phe Gly 390 395 400 att ttt gaa gaa tgg aag gat ggt gta cca cgg gca gca tat aaa ggg 1306 Ile Phe Glu Glu Trp Lys Asp Gly Val Pro Arg Ala Ala Tyr Lys Gly 405 410 415 ata gta gtt ttc cgg ttt caa aca tct aga cgt gtg ttc ctt gtt tcc 1354 Ile Val Val Phe Arg Phe Gln Thr Ser Arg Arg Val Phe Leu Val Ser 420 425 430 cct gat tct ctt cga caa ctt gga gtt gaa gat act tag cgaagatatg 1403 Pro Asp Ser Leu Arg Gln Leu Gly Val Glu Asp Thr * 435 440 445 attggagcct gagcaacaat ttagacttat ttggtaggat acatttgaaa gagctgacac 1463 gaaaagtatg actaccagta gctacatgca acattttaat gttaatggaa ggaacccact 1523 gcttattgtt ggaatggatg aatcatcacc acatcctatt attcaagttt acaaacataa 1583 agaggaaatg ttgccctata aaaacaaatt ttttgtttct aagaaggaac gttacgatta 1643 tgagcaactt tggcggccgc gaattc 1669 2 446 PRT Solanum tuberosum 2 Met Arg Gly Asn Lys Phe Cys Phe Asp Leu Arg Tyr Leu Leu Val Val 1 5 10 15 Ala Ala Leu Ala Phe Ile Tyr Ile Gln Met Arg Leu Phe Ala Thr Gln 20 25 30 Ser Glu Tyr Val Asp Arg Leu Ala Ala Ala Ile Glu Ala Glu Asn His 35 40 45 Cys Thr Ser Gln Thr Arg Leu Leu Ile Asp Lys Ile Ser Gln Gln Gln 50 55 60 Gly Arg Val Val Ala Leu Glu Glu Gln Met Lys His Gln Asp Gln Glu 65 70 75 80 Cys Arg Gln Leu Arg Ala Leu Val Gln Asp Leu Glu Ser Lys Gly Ile 85 90 95 Lys Lys Leu Ile Gly Asp Val Gln Met Pro Val Ala Ala Val Val Val 100 105 110 Met Ala Cys Ser Arg Thr Asp Tyr Leu Glu Arg Thr Ile Lys Ser Ile 115 120 125 Leu Lys Tyr Gln Thr Ser Val Ala Ser Lys Tyr Pro Leu Phe Ile Ser 130 135 140 Gln Asp Gly Ser Asn Pro Asp Val Arg Lys Leu Ala Leu Ser Tyr Gly 145 150 155 160 Gln Leu Thr Tyr Met Gln His Leu Asp Tyr Glu Pro Val His Thr Glu 165 170 175 Arg Pro Gly Glu Leu Val Ala Tyr Tyr Lys Ile Ala Arg His Tyr Lys 180 185 190 Trp Ala Leu Asp Gln Leu Phe His Lys His Asn Phe Ser Arg Val Ile 195 200 205 Ile Leu Glu Asp Asp Met Glu Ile Ala Ala Asp Phe Phe Asp Tyr Phe 210 215 220 Glu Ala Gly Ala Thr Leu Leu Asp Arg Asp Lys Ser Ile Met Ala Ile 225 230 235 240 Ser Ser Trp Asn Asp Asn Gly Gln Arg Gln Phe Val Gln Asp Pro Asp 245 250 255 Ala Leu Tyr Arg Ser Asp Phe Phe Pro Gly Leu Gly Trp Met Leu Ser 260 265 270 Lys Ser Thr Trp Ser Glu Leu Ser Pro Lys Trp Pro Lys Ala Tyr Trp 275 280 285 Asp Asp Trp Leu Arg Leu Lys Glu Asn His Arg Gly Arg Gln Phe Ile 290 295 300 Arg Pro Glu Val Cys Arg Thr Tyr Asn Phe Gly Glu His Gly Ser Ser 305 310 315 320 Leu Gly Gln Phe Phe Lys Gln Tyr Leu Glu Pro Ile Lys Leu Asn Asp 325 330 335 Val Gln Val Asp Trp Lys Ser Met Asp Leu Ser Tyr Leu Leu Glu Asp 340 345 350 Asn Tyr Val Lys His Phe Gly Asp Leu Val Lys Lys Ala Lys Pro Ile 355 360 365 His Gly Ala Asp Ala Val Leu Lys Ala Phe Asn Ile Asp Gly Asp Val 370 375 380 Arg Ile Gln Tyr Arg Asp Gln Leu Asp Phe Glu Asp Ile Ala Arg Gln 385 390 395 400 Phe Gly Ile Phe Glu Glu Trp Lys Asp Gly Val Pro Arg Ala Ala Tyr 405 410 415 Lys Gly Ile Val Val Phe Arg Phe Gln Thr Ser Arg Arg Val Phe Leu 420 425 430 Val Ser Pro Asp Ser Leu Arg Gln Leu Gly Val Glu Asp Thr 435 440 445 3 1737 DNA Nicotiana tabacum misc_feature (733)...(741) function Asn codon in this context is a potential glycosylation site; product N-glycosylation consensus sequence; phenotype N-glycans modulate protein properties; 3 gaattcgcgg ccgccattga cttgatccta actgaacagg caaagtaaat ccagcgatga 60 aacactcata actgaacact gagagactat tcgctttctc ctaaagcctt caatcgaatt 120 cgcacg atg aga ggg aac aag ttt tgc tgt gat ttc cgg tac ctc ctc 168 Met Arg Gly Asn Lys Phe Cys Cys Asp Phe Arg Tyr Leu Leu 1 5 10 atc ttg gct gct gtc gcc ttc atc tac aca cag atg cgg ctt ttt gcg 216 Ile Leu Ala Ala Val Ala Phe Ile Tyr Thr Gln Met Arg Leu Phe Ala 15 20 25 30 aca cag tca gaa tat gca gat cgc ctt gct gct gca att gaa gca gaa 264 Thr Gln Ser Glu Tyr Ala Asp Arg Leu Ala Ala Ala Ile Glu Ala Glu 35 40 45 aat cat tgt aca agc cag acc aga ttg ctt att gac cag att agc ctg 312 Asn His Cys Thr Ser Gln Thr Arg Leu Leu Ile Asp Gln Ile Ser Leu 50 55 60 cag caa gga aga ata gtt gct ctt gaa gaa caa atg aag cgt cag gac 360 Gln Gln Gly Arg Ile Val Ala Leu Glu Glu Gln Met Lys Arg Gln Asp 65 70 75 cag gag tgc cga caa tta agg gct ctt gtt cag gat ctt gaa agt aag 408 Gln Glu Cys Arg Gln Leu Arg Ala Leu Val Gln Asp Leu Glu Ser Lys 80 85 90 ggc ata aaa aag ttg atc gga aat gta cag atg cca gtg gct gct gta 456 Gly Ile Lys Lys Leu Ile Gly Asn Val Gln Met Pro Val Ala Ala Val 95 100 105 110 gtt gtt atg gct tgc aat cgg gct gat tac ctg gaa aag act att aaa 504 Val Val Met Ala Cys Asn Arg Ala Asp Tyr Leu Glu Lys Thr Ile Lys 115 120 125 tcc atc tta aaa tac caa ata tct gtt gcg tca aaa tat cct ctt ttc 552 Ser Ile Leu Lys Tyr Gln Ile Ser Val Ala Ser Lys Tyr Pro Leu Phe 130 135 140 ata tcc cag gat gga tca cat cct gat gtc agg aag ctt gct ttg agc 600 Ile Ser Gln Asp Gly Ser His Pro Asp Val Arg Lys Leu Ala Leu Ser 145 150 155 tat gat cag ctg acg tat atg cag cac ttg gat ttt gaa cct gtg cat 648 Tyr Asp Gln Leu Thr Tyr Met Gln His Leu Asp Phe Glu Pro Val His 160 165 170 act gaa aga cca ggg gag ctg att gca tac tac aaa att gca cgt cat 696 Thr Glu Arg Pro Gly Glu Leu Ile Ala Tyr Tyr Lys Ile Ala Arg His 175 180 185 190 tac aag tgg gca ttg gat cag ctg ttt tac aag cat aat ttt agc cgt 744 Tyr Lys Trp Ala Leu Asp Gln Leu Phe Tyr Lys His Asn Phe Ser Arg 195 200 205 gtt atc ata cta gaa gat gat atg gaa att gcc cct gat ttt ttt gac 792 Val Ile Ile Leu Glu Asp Asp Met Glu Ile Ala Pro Asp Phe Phe Asp 210 215 220 ttt ttt gag gct gga gct act ctt ctt gac aga gac aag tcg att atg 840 Phe Phe Glu Ala Gly Ala Thr Leu Leu Asp Arg Asp Lys Ser Ile Met 225 230 235 gct att tct tct tgg aat gac aat gga caa atg cag ttt gtc caa gat 888 Ala Ile Ser Ser Trp Asn Asp Asn Gly Gln Met Gln Phe Val Gln Asp 240 245 250 cct tat gct ctt tac cgc tca gat ttt ttt ccc ggt ctt gga tgg atg 936 Pro Tyr Ala Leu Tyr Arg Ser Asp Phe Phe Pro Gly Leu Gly Trp Met 255 260 265 270 ctt tca aaa tct act tgg gac gaa tta tct cca aag tgg cca aag gct 984 Leu Ser Lys Ser Thr Trp Asp Glu Leu Ser Pro Lys Trp Pro Lys Ala 275 280 285 tac tgg gac gac tgg cta aga ctc aaa gag aat cac aga ggt cga caa 1032 Tyr Trp Asp Asp Trp Leu Arg Leu Lys Glu Asn His Arg Gly Arg Gln 290 295 300 ttt att cgc cca gaa gtt tgc aga aca tat aat ttt ggt gag cat ggt 1080 Phe Ile Arg Pro Glu Val Cys Arg Thr Tyr Asn Phe Gly Glu His Gly 305 310 315 tct agt ttg ggg cag ttt ttc aag cag tat ctt gag cca att aaa cta 1128 Ser Ser Leu Gly Gln Phe Phe Lys Gln Tyr Leu Glu Pro Ile Lys Leu 320 325 330 aat gat gtc cag gtt gat tgg aag tca atg gac ctt agt tac ctt ttg 1176 Asn Asp Val Gln Val Asp Trp Lys Ser Met Asp Leu Ser Tyr Leu Leu 335 340 345 350 gag gac aat tac gtg aaa cac ttt ggt gac ttg gtt aaa aag gct aag 1224 Glu Asp Asn Tyr Val Lys His Phe Gly Asp Leu Val Lys Lys Ala Lys 355 360 365 ccc atc cat gga gct gat gct gtc ttg aaa gca ttt aac ata gat ggt 1272 Pro Ile His Gly Ala Asp Ala Val Leu Lys Ala Phe Asn Ile Asp Gly 370 375 380 gat gtg cgt att cag tac aga gat caa cta gac ttt gaa aat atc gca 1320 Asp Val Arg Ile Gln Tyr Arg Asp Gln Leu Asp Phe Glu Asn Ile Ala 385 390 395 cgg caa ttt ggc att ttt gaa gaa tgg aag gat ggt gta cca cgt gca 1368 Arg Gln Phe Gly Ile Phe Glu Glu Trp Lys Asp Gly Val Pro Arg Ala 400 405 410 gca tat aaa gga ata gta gtt ttc cgg tac caa acg tcc aga cgt gta 1416 Ala Tyr Lys Gly Ile Val Val Phe Arg Tyr Gln Thr Ser Arg Arg Val 415 420 425 430 ttc ctt gtt ggc cat gat tcg ctt caa caa ctc gga att gaa gat act 1464 Phe Leu Val Gly His Asp Ser Leu Gln Gln Leu Gly Ile Glu Asp Thr 435 440 445 taa caaagatatg attgcaggag cccgggcaaa atttttgact tattgggtag 1517 * gatgcatcga gctgacacta aaccatgatt ttaccagtta catacaacgt tttaatgtta 1577 tacggaggag ctcactgttc tagtgttgaa gggatatcgg cttcttagta ttggatgaat 1637 catcaacaca acctattatt ttaagtgttc agaacataaa gaggaaatgt agccctgtaa 1697 agactataca tgggaccatc ataatcgcgg ccgcgaattc 1737 4 446 PRT Nicotiana tabacum 4 Met Arg Gly Asn Lys Phe Cys Cys Asp Phe Arg Tyr Leu Leu Ile Leu 1 5 10 15 Ala Ala Val Ala Phe Ile Tyr Thr Gln Met Arg Leu Phe Ala Thr Gln 20 25 30 Ser Glu Tyr Ala Asp Arg Leu Ala Ala Ala Ile Glu Ala Glu Asn His 35 40 45 Cys Thr Ser Gln Thr Arg Leu Leu Ile Asp Gln Ile Ser Leu Gln Gln 50 55 60 Gly Arg Ile Val Ala Leu Glu Glu Gln Met Lys Arg Gln Asp Gln Glu 65 70 75 80 Cys Arg Gln Leu Arg Ala Leu Val Gln Asp Leu Glu Ser Lys Gly Ile 85 90 95 Lys Lys Leu Ile Gly Asn Val Gln Met Pro Val Ala Ala Val Val Val 100 105 110 Met Ala Cys Asn Arg Ala Asp Tyr Leu Glu Lys Thr Ile Lys Ser Ile 115 120 125 Leu Lys Tyr Gln Ile Ser Val Ala Ser Lys Tyr Pro Leu Phe Ile Ser 130 135 140 Gln Asp Gly Ser His Pro Asp Val Arg Lys Leu Ala Leu Ser Tyr Asp 145 150 155 160 Gln Leu Thr Tyr Met Gln His Leu Asp Phe Glu Pro Val His Thr Glu 165 170 175 Arg Pro Gly Glu Leu Ile Ala Tyr Tyr Lys Ile Ala Arg His Tyr Lys 180 185 190 Trp Ala Leu Asp Gln Leu Phe Tyr Lys His Asn Phe Ser Arg Val Ile 195 200 205 Ile Leu Glu Asp Asp Met Glu Ile Ala Pro Asp Phe Phe Asp Phe Phe 210 215 220 Glu Ala Gly Ala Thr Leu Leu Asp Arg Asp Lys Ser Ile Met Ala Ile 225 230 235 240 Ser Ser Trp Asn Asp Asn Gly Gln Met Gln Phe Val Gln Asp Pro Tyr 245 250 255 Ala Leu Tyr Arg Ser Asp Phe Phe Pro Gly Leu Gly Trp Met Leu Ser 260 265 270 Lys Ser Thr Trp Asp Glu Leu Ser Pro Lys Trp Pro Lys Ala Tyr Trp 275 280 285 Asp Asp Trp Leu Arg Leu Lys Glu Asn His Arg Gly Arg Gln Phe Ile 290 295 300 Arg Pro Glu Val Cys Arg Thr Tyr Asn Phe Gly Glu His Gly Ser Ser 305 310 315 320 Leu Gly Gln Phe Phe Lys Gln Tyr Leu Glu Pro Ile Lys Leu Asn Asp 325 330 335 Val Gln Val Asp Trp Lys Ser Met Asp Leu Ser Tyr Leu Leu Glu Asp 340 345 350 Asn Tyr Val Lys His Phe Gly Asp Leu Val Lys Lys Ala Lys Pro Ile 355 360 365 His Gly Ala Asp Ala Val Leu Lys Ala Phe Asn Ile Asp Gly Asp Val 370 375 380 Arg Ile Gln Tyr Arg Asp Gln Leu Asp Phe Glu Asn Ile Ala Arg Gln 385 390 395 400 Phe Gly Ile Phe Glu Glu Trp Lys Asp Gly Val Pro Arg Ala Ala Tyr 405 410 415 Lys Gly Ile Val Val Phe Arg Tyr Gln Thr Ser Arg Arg Val Phe Leu 420 425 430 Val Gly His Asp Ser Leu Gln Gln Leu Gly Ile Glu Asp Thr 435 440 445 5 1854 DNA Arabidopsis thaliana misc_feature (1185)...(1193) function Asn Codon is a potential glycosylation site; product Consensus sequence for N-glycosylation; phenotype N glycans modulate protein characteristics; standard name N glycosylation site; 5 ctcgaggcca cgaaggccac cgtttttgtt ataacgaacg acaccgtttc aaacaacttc 60 cttattagct agctccctcc cggcggcaaa caccagaaga tccaccgctt ttgatctggt 120 tgtttgtcgt cgat atg gcg agg atc tcg tgt gac ttg aga ttt ctt ctc 170 Met Ala Arg Ile Ser Cys Asp Leu Arg Phe Leu Leu 1 5 10 atc ccg gca gct ttc atg ttc atc tac atc cag atg agg ctt ttc cag 218 Ile Pro Ala Ala Phe Met Phe Ile Tyr Ile Gln Met Arg Leu Phe Gln 15 20 25 acg caa tca cag tat gca gat cgc ctc agt tcc gct atc gaa tct gag 266 Thr Gln Ser Gln Tyr Ala Asp Arg Leu Ser Ser Ala Ile Glu Ser Glu 30 35 40 aac cat tgc act agt caa atg cga ggc ctc ata gat gaa gtt agc atc 314 Asn His Cys Thr Ser Gln Met Arg Gly Leu Ile Asp Glu Val Ser Ile 45 50 55 60 aaa cag tcg cgg att gtt gcc ctc gaa gat atg aag aac cgc cag gac 362 Lys Gln Ser Arg Ile Val Ala Leu Glu Asp Met Lys Asn Arg Gln Asp 65 70 75 gaa gaa ctt gtg cag ctt aag gat cta atc cag acg ttt gaa aaa aaa 410 Glu Glu Leu Val Gln Leu Lys Asp Leu Ile Gln Thr Phe Glu Lys Lys 80 85 90 gga ata gca aaa ctc act caa ggt gga cag atg cct gtg gct gct gta 458 Gly Ile Ala Lys Leu Thr Gln Gly Gly Gln Met Pro Val Ala Ala Val 95 100 105 gtg gtt atg gcc tgc agt cgt gca gac tat ctt gaa agg act gtt aaa 506 Val Val Met Ala Cys Ser Arg Ala Asp Tyr Leu Glu Arg Thr Val Lys 110 115 120 tca gtt tta aca tat caa act ccc gtt gct tca aaa tat cct cta ttt 554 Ser Val Leu Thr Tyr Gln Thr Pro Val Ala Ser Lys Tyr Pro Leu Phe 125 130 135 140 ata tct cag gat gga tct gat caa gct gtc aag agc aag tca ttg agc 602 Ile Ser Gln Asp Gly Ser Asp Gln Ala Val Lys Ser Lys Ser Leu Ser 145 150 155 tat aat caa tta aca tat atg cag cac ttg gat ttt gaa cca gtg gtc 650 Tyr Asn Gln Leu Thr Tyr Met Gln His Leu Asp Phe Glu Pro Val Val 160 165 170 act gaa agg cct ggt gaa ctg act gcg tac tac aag att gca cgt cac 698 Thr Glu Arg Pro Gly Glu Leu Thr Ala Tyr Tyr Lys Ile Ala Arg His 175 180 185 tac aag tgg gca ctg gac cag ttg ttt tac aaa cac aaa ttt agt cga 746 Tyr Lys Trp Ala Leu Asp Gln Leu Phe Tyr Lys His Lys Phe Ser Arg 190 195 200 gtg att ata cta gaa gac gat atg gaa att gct cca gac ttc ttt gat 794 Val Ile Ile Leu Glu Asp Asp Met Glu Ile Ala Pro Asp Phe Phe Asp 205 210 215 220 tac ttt gag gct gca gct agt ctc atg gat agg gat aaa acc att atg 842 Tyr Phe Glu Ala Ala Ala Ser Leu Met Asp Arg Asp Lys Thr Ile Met 225 230 235 gct gct tca tca tgg aat gat aat gga cag aag cag ttt gtg cat gat 890 Ala Ala Ser Ser Trp Asn Asp Asn Gly Gln Lys Gln Phe Val His Asp 240 245 250 ccc tat gcg cta tac cga tca gat ttt ttt cct ggc ctt ggg tgg atg 938 Pro Tyr Ala Leu Tyr Arg Ser Asp Phe Phe Pro Gly Leu Gly Trp Met 255 260 265 ctc aag aga tcg act tgg gat gag tta tca cca aag tgg cca aag gct 986 Leu Lys Arg Ser Thr Trp Asp Glu Leu Ser Pro Lys Trp Pro Lys Ala 270 275 280 tac tgg gat gat tgg ctg aga cta aag gaa aac cat aaa ggc cgc caa 1034 Tyr Trp Asp Asp Trp Leu Arg Leu Lys Glu Asn His Lys Gly Arg Gln 285 290 295 300 ttc att gca ccg gaa gtc tgt aga aca tac aat ttt ggt gaa cat ggg 1082 Phe Ile Ala Pro Glu Val Cys Arg Thr Tyr Asn Phe Gly Glu His Gly 305 310 315 tct agt ttg gga cag ttt ttc agt cag tat ctg gaa cct ata aag cta 1130 Ser Ser Leu Gly Gln Phe Phe Ser Gln Tyr Leu Glu Pro Ile Lys Leu 320 325 330 aac gat gtg acg gtt gac tgg aaa gca aag gac ctg gga tac ctg aca 1178 Asn Asp Val Thr Val Asp Trp Lys Ala Lys Asp Leu Gly Tyr Leu Thr 335 340 345 gag gga aac tat acc aag tac ttt tct ggc tta gtg aga caa gca cga 1226 Glu Gly Asn Tyr Thr Lys Tyr Phe Ser Gly Leu Val Arg Gln Ala Arg 350 355 360 cca att caa ggt tct gac ctt gtc tta aag gct caa aac ata aag gat 1274 Pro Ile Gln Gly Ser Asp Leu Val Leu Lys Ala Gln Asn Ile Lys Asp 365 370 375 380 gat gat cgt atc cgg tat aaa gac caa gta gag ttt gaa cgc att gca 1322 Asp Asp Arg Ile Arg Tyr Lys Asp Gln Val Glu Phe Glu Arg Ile Ala 385 390 395 ggg gaa ttt ggt ata ttt gaa gaa tgg aag gat ggt gtg cca cga aca 1370 Gly Glu Phe Gly Ile Phe Glu Glu Trp Lys Asp Gly Val Pro Arg Thr 400 405 410 gca tat aaa gga gta gtg gtg ttt cga atc cag aca aca aga cgt gta 1418 Ala Tyr Lys Gly Val Val Val Phe Arg Ile Gln Thr Thr Arg Arg Val 415 420 425 ttc ctg gtt ggg cca gat tct gta atg cag ctt gga att cga aat tcc 1466 Phe Leu Val Gly Pro Asp Ser Val Met Gln Leu Gly Ile Arg Asn Ser 430 435 440 tga tgcaaaacat atgaaaggaa aagaagattt tggaccgcat gcagcctcct 1519 * tctagcagct gttaggttgt attgttattt atggatgagt ttgtagagcg gtggggttaa 1579 ctttaacagc aaggaagctc tggtgaccag gctgattggc ttagaagtta tgggaacccc 1639 ttgaaagggt cagggttaaa tatatttcag ttgttttatt agtgattatc ttgtgggtaa 1699 cttatacgaa tgcaaatcat tctatgcagt ttttcttcgt cccacttgtt ttggcttctc 1759 tattgctagt gtacatatct cttcaaacat gtactaaata atgcgtgttg cttcaaagaa 1819 gtaactttta ttaaaaaaaa aaaaaaaaac tcgag 1854 6 444 PRT Arabidopsis thaliana 6 Met Ala Arg Ile Ser Cys Asp Leu Arg Phe Leu Leu Ile Pro Ala Ala 1 5 10 15 Phe Met Phe Ile Tyr Ile Gln Met Arg Leu Phe Gln Thr Gln Ser Gln 20 25 30 Tyr Ala Asp Arg Leu Ser Ser Ala Ile Glu Ser Glu Asn His Cys Thr 35 40 45 Ser Gln Met Arg Gly Leu Ile Asp Glu Val Ser Ile Lys Gln Ser Arg 50 55 60 Ile Val Ala Leu Glu Asp Met Lys Asn Arg Gln Asp Glu Glu Leu Val 65 70 75 80 Gln Leu Lys Asp Leu Ile Gln Thr Phe Glu Lys Lys Gly Ile Ala Lys 85 90 95 Leu Thr Gln Gly Gly Gln Met Pro Val Ala Ala Val Val Val Met Ala 100 105 110 Cys Ser Arg Ala Asp Tyr Leu Glu Arg Thr Val Lys Ser Val Leu Thr 115 120 125 Tyr Gln Thr Pro Val Ala Ser Lys Tyr Pro Leu Phe Ile Ser Gln Asp 130 135 140 Gly Ser Asp Gln Ala Val Lys Ser Lys Ser Leu Ser Tyr Asn Gln Leu 145 150 155 160 Thr Tyr Met Gln His Leu Asp Phe Glu Pro Val Val Thr Glu Arg Pro 165 170 175 Gly Glu Leu Thr Ala Tyr Tyr Lys Ile Ala Arg His Tyr Lys Trp Ala 180 185 190 Leu Asp Gln Leu Phe Tyr Lys His Lys Phe Ser Arg Val Ile Ile Leu 195 200 205 Glu Asp Asp Met Glu Ile Ala Pro Asp Phe Phe Asp Tyr Phe Glu Ala 210 215 220 Ala Ala Ser Leu Met Asp Arg Asp Lys Thr Ile Met Ala Ala Ser Ser 225 230 235 240 Trp Asn Asp Asn Gly Gln Lys Gln Phe Val His Asp Pro Tyr Ala Leu 245 250 255 Tyr Arg Ser Asp Phe Phe Pro Gly Leu Gly Trp Met Leu Lys Arg Ser 260 265 270 Thr Trp Asp Glu Leu Ser Pro Lys Trp Pro Lys Ala Tyr Trp Asp Asp 275 280 285 Trp Leu Arg Leu Lys Glu Asn His Lys Gly Arg Gln Phe Ile Ala Pro 290 295 300 Glu Val Cys Arg Thr Tyr Asn Phe Gly Glu His Gly Ser Ser Leu Gly 305 310 315 320 Gln Phe Phe Ser Gln Tyr Leu Glu Pro Ile Lys Leu Asn Asp Val Thr 325 330 335 Val Asp Trp Lys Ala Lys Asp Leu Gly Tyr Leu Thr Glu Gly Asn Tyr 340 345 350 Thr Lys Tyr Phe Ser Gly Leu Val Arg Gln Ala Arg Pro Ile Gln Gly 355 360 365 Ser Asp Leu Val Leu Lys Ala Gln Asn Ile Lys Asp Asp Asp Arg Ile 370 375 380 Arg Tyr Lys Asp Gln Val Glu Phe Glu Arg Ile Ala Gly Glu Phe Gly 385 390 395 400 Ile Phe Glu Glu Trp Lys Asp Gly Val Pro Arg Thr Ala Tyr Lys Gly 405 410 415 Val Val Val Phe Arg Ile Gln Thr Thr Arg Arg Val Phe Leu Val Gly 420 425 430 Pro Asp Ser Val Met Gln Leu Gly Ile Arg Asn Ser 435 440 7 24 DNA Artificial Sequence Primer for cloning plant genes 7 tgygynwsng cntggmayga yaay 24 8 24 DNA Artificial Sequence Primer for cloning plant genes 8 ccanccntrn ccngsraara artc 24 9 14 PRT Artificial Sequence Primer for cloning plant genes 9 Gln Xaa Gln Phe Val Gln Asp Pro Xaa Ala Leu Tyr Arg Ser 1 5 10 10 48 DNA Artificial Sequence Primer for cloning plant genes 10 atcggaaagc ttggatcccc agtggcrgct gtagttgtta tggcttgc 48 11 27 DNA Artificial Sequence Primer for cloning plant genes 11 ggccccccct cgaggtcgac ggtatcg 27 12 51 DNA Artificial Sequence Primer for cloning plant genes 12 gggcctctag actccagagc yactactctt ccttgctgct ggctaatctt g 51 13 40 DNA Artificial Sequence Primer for cloning plant genes 13 catggatccc tcgagaagcg tcaggaccag gagtgccggc 40 14 37 DNA Artificial Sequence Primer for cloning plant genes 14 atcccgggat ccgctacgta tcttcaactc caagttg 37
Claims (30)
1. Method for the production of glycoproteins displaying minimal, uniform and defined sugar residues, comprising cultivating a transgenic plant, parts of transgenic plants or transformed plant cells, and isolating the desired glycoprotein from the material cultivated, characterized in that the transgenic plant, parts of transgenic plants or transformed plant cells, respectively, is/are transformed with an antisense construct or a sense construct, comprising an antisense DNA or a sense DNA with respect to the DNA sequence for a gene or a cDNA for plant N-acetyl glucosaminyl transferase I or a part thereof, for elimination or reduction of the activity of said N-acetyl glucosaminyl transferase, wherein the antisense or sense construct optionally contains additional regulatory sequences for the transcription of the respective antisense or sense DNA.
2. Method according to claim 1 , characterized in that for transformation an antisense or sense construct with respect to one of the cDNAs encoding N-acetyl glucosaminyl transferase I from Solanum tuberosum, Nicotiana tabacum or Arabidopsis thaliana is used.
3. Method according to claim 2 , characterized in that for transformation an antisense or sense construct with respect to one of the DNA sequences given in SEQ ID NO: 1, 3 or 5 is used.
4. Method according to any of the claims 1 to 3 , characterized in that the transgenic plant used is additionally transformed with the gene encoding the desired glycoprotein.
5. DNA, characterized in that it encodes N-acetyl glucosaminyl transferase I from Solanum tuberosum.
6. DNA according to claim 5 , characterized in that it comprises the nucleotide sequence given in SEQ ID NO: 1 or a part thereof.
7. DNA, characterized in that it encodes N-acetyl glucosaminyl transferase I from Nicotiana tabacum.
8. DNA according to claim 7 , characterized in that it comprises the nucleotide sequence given in SEQ ID NO: 3 or a part thereof.
9. DNA encoding N-acetyl glucosaminyl transferase I from Arabidopsis thaliana, characterized in that said DNA encodes the amino-acid sequence given in SEQ ID NO: 6 or the nucleotide sequence given in SEQ ID NO: 5 or a part thereof.
10. DNA, characterized in that it comprises the nucleotide sequence complementary to the DNA according to claim 6 , 8 or 9.
11. DNA, characterized in that it may be obtained by substitution, deletion and/or insertion of one or more nucleotides and/or truncation at the 5′ and/or 3′ end of one of the DNAs according to any of the claims 5 to 10 , with the proviso, that said DNA hybridizes at least in a partial region with the starting DNA or its complementary sequence or parts thereof under stringent conditions.
12. DNA, characterized in that it represents a gene or is part of a gene, which encodes the enzyme N-acetyl glucosaminyl transferase I, and which in its entirety or in a partial region thereof hybridizes under stringent conditions
to one of the DNA sequences or fragments according to any of the claims 5 to 11 and/or
to a DNA sequence, which has been derived from the amino acid sequences given in SEQ ID NO: 1, 3 and/or 5, considering the degeneration of the genetic code.
13. DNA construct,
characterized in that it comprises one or more of the DNAs according to any of the claims 5 to 14 .
14. DNA construct according to claim 13 ,
characterized in that it comprises an antisense or sense DNA with respect to the DNA sequence according to any of the claims 5 to 12 and optionally regulatory sequences for the transcription of the antisense or sense DNA, respectively.
15. Vector, plasmid, cosmid, virus or phage genome, characterized in that it contains at least a DNA and/or construct according to any of the claims 5 to 14 .
16. N-acetyl glucosaminyl transferase I from Solanum tuberosum.
17. N-acetyl glucosaminyl transferase I from Nicotiana tabacum.
18. N-acetyl glucosaminyl transferase I from Arabidopsis thaliana, characterized in that the enzyme comprises the amino acid sequence set forth in SEQ ID NO: 6.
19. N-acetyl glucosaminyl transferase I, characterized in that the enzyme comprises the amino acid sequence set forth in SEQ ID NO: 2.
20. N-acetyl glucosaminyl transferase I, characterized in that the enzyme comprises amino acids 74 to 446 of the amino acid sequence set forth in SEQ ID NO: 2.
21. N-acetyl glucosaminyl transferase I, characterized in that the enzyme comprises the amino acid sequence set forth in SEQ ID NO: 4.
22. N-acetyl glucosaminyl transferase I, available due to hybridization of its gene or one or more of the portions of its gene to one or more of the DNAs and/or DNA fragments according to any of the claims 5 to 12 .
23. Enzymes or proteins derived from the enzymes according to any of the claims 16 to 22 by substitution, deletion, insertion and/or modification of individual amino acids and/or smaller groups of amino acids and/or by N- and/or C-terminal truncation and/or extension.
24. Protein or peptide, comprising one or more portions of the amino acid sequence(s) of one or more of the enzymes defined in any of the claims 16 to 23 .
25. Protein or peptide, encoded by one of the DNAs according to any of the claims 5 to 12 .
26. Antigen, characterized in that it comprises:
the amino acid sequence given in SEQ ID NO: 2, SEQ ID NO: 4 or SEQ ID NO: 6, or
amino acids 74 to 446 of the amino acid sequence given in FIG. 2, or
an amino acid sequence derived from the amino acid sequences given in SEQ ID NO: 2, 4 or 6 by substitution, deletion, insertion and/or modification of individual amino acids and/or smaller groups of amino acids, or
one or more parts of said sequences, with the proviso, that upon immunization of a host with the antigen, said antigen may raise an immunological reaction, including the production of antibodies directed against the antigen.
27. Monoclonal or polyclonal antibody, characterized in that it specifically recognizes and binds one or more of the enzymes or antigens according to any of the claims 16 to 26 .
28. Microorganism,
characterized in that it is transformed by at least one of the nucleotide sequences selected from the DNAs, constructs, vectors, plasmids, cosmids, virus or phage genomes according to one or more of the claims 5 to 15 .
29. Transgenic plant, transgenic seed, transgenic reproduction material, parts of transgenic plants or transformed plant cell, obtainable by integration of one or more DNA sequence(s) or construct(s) according to any of the claims 5 to 13 under the control of a promoter effective in plants, into the genome of a plant, or via infection by means of a virus containing one or more DNA sequence(s) or construct(s) according to any of the claims 5 to 13 , for an extrachromosomal propagation and expression of the DNA sequence(s) or construct(s) in the plant tissue infected.
30. Transgenic plant, transgenic seed, transgenic reproduction material, parts of transgenic plants or transformed plant cell with missing or reduced N-acetyl glucosaminyl transferase I activity, obtainable by integration of one or more antisense or sense construct(s) according to claim 14 under the control of a promoter effective in plants, into the genome of a plant, or by viral infection by means of a virus containing one or more antisense or sense construct(s) according to claim 14 , for an extrachromosomal propagation and transcription of the antisense construct(s) in the plant tissue infected.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/615,144 US20040181827A1 (en) | 1997-12-09 | 2003-07-09 | Plant Gntl sequences and the use thereof for the production of plants having reduced or lacking N-acetyl glucosaminyl transferase I (GnTI) activity |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19754622.6 | 1997-12-09 | ||
| DE19754622A DE19754622A1 (en) | 1997-12-09 | 1997-12-09 | Plant GntI sequences and the use thereof for obtaining plants with reduced or missing N-acetylglucosaminyltransferase I (GnTI) activity |
| PCT/EP1998/008001 WO1999029879A1 (en) | 1997-12-09 | 1998-12-09 | VEGETABLE GntI SEQUENCES AND THE USE THEREOF TO OBTAIN PLANTS WITH A REDUCED OR LACK OF N-ACETYLGLUCOSAMINYLTRANSFERASE I (GnTI) ACTIVITY |
| US09/591,466 US6653459B1 (en) | 1997-12-09 | 2000-06-09 | Plant GntI sequences and the use thereof for the production of plants having reduced or lacking N-acetyl glucosaminyl transferase I(GnTI) activity |
| US10/615,144 US20040181827A1 (en) | 1997-12-09 | 2003-07-09 | Plant Gntl sequences and the use thereof for the production of plants having reduced or lacking N-acetyl glucosaminyl transferase I (GnTI) activity |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US09/591,466 Continuation US6653459B1 (en) | 1997-12-09 | 2000-06-09 | Plant GntI sequences and the use thereof for the production of plants having reduced or lacking N-acetyl glucosaminyl transferase I(GnTI) activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US20040181827A1 true US20040181827A1 (en) | 2004-09-16 |
Family
ID=7851259
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US09/591,466 Expired - Fee Related US6653459B1 (en) | 1997-12-09 | 2000-06-09 | Plant GntI sequences and the use thereof for the production of plants having reduced or lacking N-acetyl glucosaminyl transferase I(GnTI) activity |
| US10/615,144 Abandoned US20040181827A1 (en) | 1997-12-09 | 2003-07-09 | Plant Gntl sequences and the use thereof for the production of plants having reduced or lacking N-acetyl glucosaminyl transferase I (GnTI) activity |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US09/591,466 Expired - Fee Related US6653459B1 (en) | 1997-12-09 | 2000-06-09 | Plant GntI sequences and the use thereof for the production of plants having reduced or lacking N-acetyl glucosaminyl transferase I(GnTI) activity |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US6653459B1 (en) |
| EP (1) | EP1038014B1 (en) |
| JP (1) | JP2002509696A (en) |
| AT (1) | ATE302853T1 (en) |
| AU (1) | AU760394B2 (en) |
| CA (1) | CA2312734A1 (en) |
| DE (2) | DE19754622A1 (en) |
| WO (1) | WO1999029879A1 (en) |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040214273A1 (en) * | 2001-01-19 | 2004-10-28 | Kazuhito Fujiyama | Method for secretory production of glycoprotein having human-type sugar chain using plant cell |
| US20050143564A1 (en) * | 1998-12-09 | 2005-06-30 | Tatsuji Seki | Method for manufacturing glycoproteins having human-type glycosylation |
| US20050223430A1 (en) * | 2002-03-19 | 2005-10-06 | Bakker Hendrikus A C | Gntiii expression in plants |
| US20070089201A1 (en) * | 2002-11-27 | 2007-04-19 | Kristen Briggs | Plant production of immunoglobulins with reduced fucosylation |
| US20070214519A1 (en) * | 2001-03-06 | 2007-09-13 | Kazuhito Fujiyama | Plant cell having animal-type sugar chain adding function |
| US20080003680A1 (en) * | 1999-10-26 | 2008-01-03 | Bakker Hendrikus A C | Mammalian-type glycosylation in plants |
| US7601891B2 (en) | 2002-03-19 | 2009-10-13 | Plant Research International B.V. | Optimizing glycan processing plants |
| US20110067146A1 (en) * | 2007-04-17 | 2011-03-17 | Plant Research International B.V. | Mammalian-type glycosylation in plants by expression of non-mammalian glycosyltransferases |
| US8332398B2 (en) | 2003-01-31 | 2012-12-11 | Minolta Co., Ltd. | Database system in which logical principles for a data retrieval process can evolve based upon learning |
| US20140273163A1 (en) * | 2013-03-14 | 2014-09-18 | Glycobia, Inc. | Oligosaccharide compositions, glycoproteins and methods to produce the same in prokaryotes |
| WO2020190031A1 (en) * | 2019-03-18 | 2020-09-24 | (주)지플러스 생명과학 | Transgenic plant with suppressed expression of cgl1 and cgl2 and method for producing target protein using same |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1294631A (en) | 1998-03-20 | 2001-05-09 | 贝尼泰克澳大利亚有限公司 | control gene expression |
| AUPP249298A0 (en) | 1998-03-20 | 1998-04-23 | Ag-Gene Australia Limited | Synthetic genes and genetic constructs comprising same I |
| US20040214330A1 (en) | 1999-04-07 | 2004-10-28 | Waterhouse Peter Michael | Methods and means for obtaining modified phenotypes |
| US8598332B1 (en) | 1998-04-08 | 2013-12-03 | Bayer Cropscience N.V. | Methods and means for obtaining modified phenotypes |
| US6423885B1 (en) | 1999-08-13 | 2002-07-23 | Commonwealth Scientific And Industrial Research Organization (Csiro) | Methods for obtaining modified phenotypes in plant cells |
| AU1573601A (en) * | 1999-10-21 | 2001-04-30 | Monsanto Company | Post-translational modification of recombinant proteins produced in plants |
| ES2349427T3 (en) * | 1999-10-26 | 2011-01-03 | Stichting Dienst Landbouwkundig Onderzoek | GLAMMOSILATION OF MAMMAL TYPE IN PLANTS. |
| DE10003573A1 (en) * | 2000-01-27 | 2001-08-09 | Mpb Cologne Gmbh Molecular Pla | Inhibition of carbohydrate-modifying enzymes in host organisms |
| AT409381B (en) * | 2000-03-03 | 2002-07-25 | Gloessl Josef Dr | Xylosyltransferase-GEN |
| FR2808286B1 (en) * | 2000-04-26 | 2004-12-17 | Agronomique Inst Nat Rech | NOVEL PLANT GLUCOSIDASE I AND ITS APPLICATION TO THE PRODUCTION OF RECOMBINANT PROTEINS WITH MODIFIED GLYCOSYLATION |
| WO2006119627A1 (en) * | 2005-05-09 | 2006-11-16 | Simon Fraser University | Enhancing vegetative protein production in transgenic plants using seed specific promoters |
| CN101203612B (en) | 2005-06-24 | 2013-03-20 | 拜尔作物科学公司 | Methods for altering the reactivity of plant cell walls |
| EP1995312A1 (en) * | 2007-05-23 | 2008-11-26 | Plant Research International B.V. | Alg3 mutant |
| JP5158639B2 (en) | 2008-04-11 | 2013-03-06 | 独立行政法人農業生物資源研究所 | Genes specifically expressed in the endosperm of plants, promoters of the genes, and use thereof |
| MX338560B (en) | 2010-11-24 | 2016-04-20 | Glykos Finland Oy | Fusion enzymes having n-acetylglucosaminyltransferase activity. |
| CA2821660A1 (en) * | 2010-12-23 | 2012-06-28 | Philip Morris Products S.A. | Alpha-mannosidases from plants and methods for using the same |
| US9695454B2 (en) | 2012-05-23 | 2017-07-04 | Glykos Finland Oy | Production of fucosylated glycoproteins |
| PL3016970T3 (en) | 2013-07-04 | 2019-09-30 | Glykos Finland Oy | O-mannosyltransferase deficient filamentous fungal cells and methods of use thereof |
| DK3019621T3 (en) | 2013-07-10 | 2019-03-04 | Glykos Finland Oy | PREPARATION OF GLYCOPROTEINES WITH INCREASED N-GLYCOLYZING LOCATION USE |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5702933A (en) * | 1990-12-26 | 1997-12-30 | Monsanto Company | Control of fruit ripening and senescence in plants |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU8941191A (en) * | 1990-11-30 | 1992-06-25 | Hsc Research And Development Limited Partnership | Cloning of udp-n-acetylglucosamine:alpha-3-d-mannoside beta -1,2-n-acetylglucosaminyltransferase i |
| US5834251A (en) * | 1994-12-30 | 1998-11-10 | Alko Group Ltd. | Methods of modifying carbohydrate moieties |
-
1997
- 1997-12-09 DE DE19754622A patent/DE19754622A1/en not_active Ceased
-
1998
- 1998-12-09 JP JP2000524450A patent/JP2002509696A/en active Pending
- 1998-12-09 DE DE59813024T patent/DE59813024D1/en not_active Expired - Fee Related
- 1998-12-09 WO PCT/EP1998/008001 patent/WO1999029879A1/en not_active Ceased
- 1998-12-09 CA CA002312734A patent/CA2312734A1/en not_active Abandoned
- 1998-12-09 AT AT98966266T patent/ATE302853T1/en not_active IP Right Cessation
- 1998-12-09 AU AU22688/99A patent/AU760394B2/en not_active Ceased
- 1998-12-09 EP EP98966266A patent/EP1038014B1/en not_active Expired - Lifetime
-
2000
- 2000-06-09 US US09/591,466 patent/US6653459B1/en not_active Expired - Fee Related
-
2003
- 2003-07-09 US US10/615,144 patent/US20040181827A1/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5702933A (en) * | 1990-12-26 | 1997-12-30 | Monsanto Company | Control of fruit ripening and senescence in plants |
Cited By (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080124798A1 (en) * | 1998-12-09 | 2008-05-29 | Dfb Biotech, Inc. | Method for manufacturing glycoproteins having human-type glycosylation |
| US20050143564A1 (en) * | 1998-12-09 | 2005-06-30 | Tatsuji Seki | Method for manufacturing glycoproteins having human-type glycosylation |
| US8241909B2 (en) | 1998-12-09 | 2012-08-14 | Phyton Holdings, Llc | Method for manufacturing glycoproteins having human-type glycosylation |
| US8853370B2 (en) | 1998-12-09 | 2014-10-07 | Phyton Holdings, Llc | Plant-produced glycoprotein comprising human-type sugar chain |
| US7388081B2 (en) | 1998-12-09 | 2008-06-17 | Dfb Biotech, Inc. | Method for manufacturing glycoproteins having human-type glycosylation |
| US20110030108A1 (en) * | 1999-10-26 | 2011-02-03 | Stichting Dienst Landbouwkundig Onderzoek | Mammalian-type glycosylation in plants |
| US20080003680A1 (en) * | 1999-10-26 | 2008-01-03 | Bakker Hendrikus A C | Mammalian-type glycosylation in plants |
| US8907163B2 (en) | 1999-10-26 | 2014-12-09 | Stichting Dienst Landbouwkundig Onderzoek | Transgenic plants expressing galactosyltransferase and sialyl transferase |
| US7781647B2 (en) | 1999-10-26 | 2010-08-24 | Stichting Dienst Landbouwkundig Onderzoek | Mammalian-type glycosylation in transgenic plants expressing mammalian β1,4-galactosyltransferase |
| US8193415B2 (en) | 1999-10-26 | 2012-06-05 | Stichting Dienst Landbouwkundig Onderzock | Plant expressing mammalian β1,4-galactosyltransferase and β1,3-glucuronyltransferase |
| US20040214273A1 (en) * | 2001-01-19 | 2004-10-28 | Kazuhito Fujiyama | Method for secretory production of glycoprotein having human-type sugar chain using plant cell |
| US8735656B2 (en) | 2001-01-19 | 2014-05-27 | Phyton Holdings, Llc | Method of expressing galactosyltransferase and inhibiting xylosyltransferase or fucosyltransferase in a transgenic plant cell for secretory production of glycoproteins having human-type sugar chains |
| US9574218B2 (en) | 2001-01-19 | 2017-02-21 | Phyton Holdings, Llc | Method of co-expressing galactosyltransferase and a glycoprotein in a transgenic plant cell and sialylating the glycoprotein for production of glycoprotein having human-type sugar chain |
| US8309795B2 (en) | 2001-01-19 | 2012-11-13 | Phyton Holdings, Llc | Method for secretory production of glycoprotein having human-type sugar chain using plant cell |
| US20080034456A1 (en) * | 2001-01-19 | 2008-02-07 | Kazuhito Fujiyama | Method for secretory production of glycoprotein having human-type sugar chain using plant cell |
| US20070214519A1 (en) * | 2001-03-06 | 2007-09-13 | Kazuhito Fujiyama | Plant cell having animal-type sugar chain adding function |
| US9255277B2 (en) | 2002-03-19 | 2016-02-09 | Stichting Dienst Landbouwkundig Onderzoek | GNTIII expression in plants |
| US8058508B2 (en) | 2002-03-19 | 2011-11-15 | Stichting Dienst Landbouwkundig Onderzoek | Optimizing glycan processing in plants |
| US20050223430A1 (en) * | 2002-03-19 | 2005-10-06 | Bakker Hendrikus A C | Gntiii expression in plants |
| US7897842B2 (en) | 2002-03-19 | 2011-03-01 | Plant Research International B.V. | GnTIII expression in plants |
| US8927810B2 (en) | 2002-03-19 | 2015-01-06 | Stichting Dienst Landbouwkundig Onderzoek | Optimizing glycan processing in plants |
| US8492613B2 (en) | 2002-03-19 | 2013-07-23 | Stichting Dienst Landbouwkundig Onderzoek | GNTIII expression in plants |
| US20100122365A1 (en) * | 2002-03-19 | 2010-05-13 | Plant Research International B.V. | Optimizing glycan processing in plants |
| US7601891B2 (en) | 2002-03-19 | 2009-10-13 | Plant Research International B.V. | Optimizing glycan processing plants |
| US8106169B2 (en) | 2002-11-27 | 2012-01-31 | Phyton Holdings, Llc | Plant production of immunoglobulins with reduced fucosylation |
| US20070089201A1 (en) * | 2002-11-27 | 2007-04-19 | Kristen Briggs | Plant production of immunoglobulins with reduced fucosylation |
| US8332398B2 (en) | 2003-01-31 | 2012-12-11 | Minolta Co., Ltd. | Database system in which logical principles for a data retrieval process can evolve based upon learning |
| US8829276B2 (en) | 2007-04-17 | 2014-09-09 | Stichting Dienst Landbouwkundig Onderzoek | Mammalian-type glycosylation in plants by expression of non-mammalian glycosyltransferases |
| US20110067146A1 (en) * | 2007-04-17 | 2011-03-17 | Plant Research International B.V. | Mammalian-type glycosylation in plants by expression of non-mammalian glycosyltransferases |
| US9745594B2 (en) | 2007-04-17 | 2017-08-29 | Stichting Dienst Landbouwkundig Onderzoek | Mammalian-type glycosylation in plants by expression of a zebrafish glycosyltransferase |
| US20140273163A1 (en) * | 2013-03-14 | 2014-09-18 | Glycobia, Inc. | Oligosaccharide compositions, glycoproteins and methods to produce the same in prokaryotes |
| WO2014152137A3 (en) * | 2013-03-14 | 2014-12-11 | Glycobia, Inc. | Oligosaccharide compositions, glycoproteins and methods to produce the same in prokaryotes |
| WO2020190031A1 (en) * | 2019-03-18 | 2020-09-24 | (주)지플러스 생명과학 | Transgenic plant with suppressed expression of cgl1 and cgl2 and method for producing target protein using same |
Also Published As
| Publication number | Publication date |
|---|---|
| US6653459B1 (en) | 2003-11-25 |
| DE19754622A1 (en) | 1999-06-10 |
| WO1999029879A1 (en) | 1999-06-17 |
| DE59813024D1 (en) | 2005-09-29 |
| CA2312734A1 (en) | 1999-06-17 |
| ATE302853T1 (en) | 2005-09-15 |
| EP1038014B1 (en) | 2005-08-24 |
| AU760394B2 (en) | 2003-05-15 |
| JP2002509696A (en) | 2002-04-02 |
| AU2268899A (en) | 1999-06-28 |
| EP1038014A1 (en) | 2000-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6653459B1 (en) | Plant GntI sequences and the use thereof for the production of plants having reduced or lacking N-acetyl glucosaminyl transferase I(GnTI) activity | |
| JP5105257B2 (en) | Optimization of glycan processing in plants | |
| KR101426576B1 (en) | Mammalian-type glycosylation in plants by expression of non-mammalian glycosyltransferases | |
| WO2001029242A2 (en) | Post-translational modification of recombinant proteins produced in plants | |
| KR100859919B1 (en) | Beta 1,2-xylosyltransferase-gene from arabidopsis | |
| US20100227363A1 (en) | Alg3 mutant | |
| AU2013205260B2 (en) | Optimizing glycan processing in plants | |
| CH | OH y—CHACONINE | |
| AU2016203395A1 (en) | Optimizing glycan processing in plants | |
| HK1124364B (en) | Optimizing glycan processing in plants |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |